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 Depression is the most common comorbid psychiatric disorder in patients with 
Parkinson’s disease (PD) and imposes a significant negative impact on PD. Studies have shown 
that antidepressants (ADs) may both treat depression and ameliorate its negative effects on PD. 
However, little has been reported regarding how improved adherence to antidepressants affects 
the outcomes among PD patients with depression. The purpose of this study was to examine 
antidepressant use patterns (adherence, persistence, switching, and combination therapy) and 
evaluate the associated healthcare utilization and costs in PD patients with comorbid depression. 
 A retrospective cohort analysis using claims data from the Humana healthcare insurance 
plan (2007-2010) was conducted. Medicare Advantage with Prescription Drug (MAPD) Plan 
insured patients with ADs and a diagnosis of both depression and PD were identified and 
followed for one year. Healthcare resource utilization and costs were compared between 
 v 
adherent and non-adherent AD users while adjusting for demographic and clinical covariates. 
Adherence was defined as having at least 80 percent of AD coverage for the year, using 
proportion of days covered (PDC) calculations. A total of 856 PD patients initiating AD 
treatment were included. Less than half (N= 355 (41.5%) were considered adherent. The mean 
PDC (±SD) for antidepressants was 0.63 (± 0.31).  The mean persistence (using a 30-day gap 
period) for antidepressants was 194 days. Having a regimen modification, (11% of patients had 
switching or combination therapy) was associated with a greater likelihood of being adherent 
(odds ratio = 2.97, 95% CI = [1.88, 4.68], p < 0.001) and a lower likelihood of discontinuation 
(hazard ratio = 0.63, 95% CI = [0.47, 0.84], p = 0.0016). After adjusting for covariates, adherent 
AD users had fewer all-cause and PD-related inpatient visits (all p < 0.05). Adherent AD users 
also had lower all-cause nursing facility, inpatient, emergency room (ER), and total costs (all p < 
0.05) than non-adherent AD users. However, the results were no longer significant when 
assessing PD-related costs. In conclusion, regimen modification (switching, or combination 
therapy) to antidepressants was associated with better adherence and persistence in depressed PD 
patients. Adherent AD users had some lower healthcare utilization and costs than non-adherent 
AD users among depressed PD patients. 
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 1 
CHAPTER 1: LITERATURE REVIEW 
This chapter will review the literature on 1) Parkinson’s disease (PD); 2) depression as a 
common comorbidity in PD; 3) the importance of management of depression in PD. The 
following contents will be described: 
 Epidemiology of PD 
 Humanistic and economic burden of PD 
 Symptoms, diagnosis, and management of PD 
 Link between PD and depression 
 Epidemiology of depression in PD 
 Diagnosis and management of depression in PD 
 Impact of depression on PD 
1.1 Section 1: Parkinson’s Disease (PD) 
1.1.1 Definition, Etiology, and Epidemiology of PD 
 Parkinson’s disease (PD) is one of the most common progressive neurologic disorders 
typically characterized by movement deficits, affecting more than seven million people 
worldwide.
1,2
 PD is associated with both motor and non-motor symptoms.
3
 Motor symptoms 
such as tremor, bradykinesia, rigidity, and postural instability are cardinal clinical features of 
PD.
1
 Non-motor symptoms include sleep, emotional, cognitive, sensory, and autonomic 
disorders. Both motor and non-motor symptoms may become more prominent as PD progresses 




 To date, the cause of PD remains unknown. It is hypothesized that both genetics and 
environmental factors contribute to the development of PD.
1
 The identified environmental 
factors associated with risk of developing PD include: pesticide exposure, prior head injury, rural 
living, beta-blocker use, agricultural occupation, and well water drinking.
1
 Family history is 
another important risk factor for PD and several studies have revealed the association between 
dozens of gene loci and PD.
1
   
 The worldwide prevalence of PD is estimated to be approximately 320 per 100,000 
population among individuals aged 40 years or older.
5
 By 2030, it is estimated that the number of 
people with PD will be between 8.7 to 9.3 million.
6
 One meta-analysis conducted by Pringsheim 
et al. has observed a lower prevalence of PD in Asia than in North America, Europe, and 
Australia.
5
 However, it has been questioned whether the geographic variation in PD prevalence 
was in fact due to the methodological differences rather than ethnic differences.
7
 Both prevalence 
and incidence of PD are age-dependent.
5
 The reported prevalence increases with age: 41 for the 
40-49 age group; 107 in the 50-59 age group; 173 in the 55-64 age group; 428 in the 60-69 age 
group; 425 in the 65-74 age group; 1,087 in the 70-79 age group; and 1,903 in the ≥80 age group, 
all per 100,000 population.
5
 A review by de Lau and Breteler demonstrated that the standardized 
incidence rates ranged  from 8 to 18 cases per 100,000 person-years.
8
 The age of onset of PD is 
relatively late, most often in those aged 60 years or older.
8
 
In the United States, there are approximately one million individuals living with PD, with 
60,000 new cases diagnosed annually.
9
 Van Den Eeden et al. estimated the incidence of PD 
among commercially insured individuals from a large health maintenance organization and 
reported an age- and gender-adjusted incidence rate of 13.4 per 100,000 population.
10
 Using a 
 3 
passive surveillance PD registry with a great proportion of elderly people in Nebraska, Strickland 
and Bertoni found a prevalence of 329.3 per 100,000 population.
11
 A more recent study 
investigated Medicare beneficiaries (≥ 65 years old), which revealed higher prevalence and 
incidence rate of PD in the US than those reported from the Van Den Eeden study and the 
Strickland study.
12
 Wright-Willis et al. used Medicare research-identifiable files and observed 
that the mean prevalence of PD was approximately 1,588 cases and the mean annual incidence 




The prevalence and incidence rate of PD have been found to vary by gender and ethnicity. 
Some studies reported that men had a greater susceptibility to PD than women. In 2014, a meta-
analysis of 47 studies demonstrated that the prevalence of PD was significantly higher in men 
than women (134 vs. 41, per 100,000 population) among individuals between 50 to 59 years 
old.
5
 A review from Gillies et al. examined the gender differences in PD and found the male-to-
female ratios for incidence rates ranged from 1.37 to 3.7.
13
 Although no firm conclusions can be 
drawn, several studies have suggested that the differences in PD susceptibility by gender may be 
attributable to estrogenic neuroprotection.
13
 With regard to differences by race, Wright-Willis et 
al. examined Medicare beneficiaries (≥ 65 years old) and found that the prevalence of PD was 
higher in Whites than Hispanics, Asians, and Blacks (approximate cases in Whites: 2,168; 
Hispanics: 1,544; Asians: 1,139; Blacks: 1,036, all per 100,000 population). In the same study, 
the reported annual incidence of PD was higher in Hispanics than White, Blacks, and Asians 
(approximate annual new cases in Hispanics: 476; White: 452; Black: 362; Asian: 339, all per 
100,000 population). Wright-Willis et al. also observed higher prevalence and incidence in the 
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Midwest and Northeast regions of the United States. Possible explanations for the regional 
difference may involve pathophysiologic risk factors such as byproducts of industrialization or 
environmental risk factors such as pesticide and herbicide use.
12
  
Many studies have shown that people with PD had a lower life expectancy than the general 
population.
14-16
 One meta-analysis of eight studies suggested that people with PD were 
approximately two times more likely to die compared to the general population.
14
 Macleod et al. 
conducted another meta-analysis of 88 studies and showed that the mortality ratios for people 
with PD relative to those without PD range from 0.9 to 3.8. Authors also reported that the pooled 
estimate of the mortality ratio was approximately 1.5 among studies with participants recruited 
either at PD diagnosis or shortly afterwards.
15
 Commonly reported factors associated with 
increased mortality in patients with PD include: increasing age, dementia, male gender, disease 




1.1.2 Humanistic and Economic Burden of PD 
Because PD is a progressive disease, the motor and non-motor symptoms may become more 
severe as PD progresses over time. These symptoms of PD adversely affect patients’ health-
related quality of life (HRQoL) and pose significant burden on patients and society.
17
 
Several studies have assessed HRQoL in PD patients by using either generic or disease-
specific questionnaires. The results have shown that PD is associated with HRQoL 
deterioration.
4
 Reuther et al. conducted a prospective longitudinal study and assessed the HRQoL 
in PD patients. They found a lower HRQoL among patients with PD relative to the general 
population by using the EuroQOL five dimensions questionnaire (EQ-5D).
18
 In another cross-
 5 
sectional study, the World Health Organization Disability Assessment Schedule (WHO-DAS II) 
and the 36-Item Short-Form Health Survey (SF-36) PD patient scores were also lower than the 
normative values.
19
 Among those with disabling motor symptoms, gait impairments and 
complications due to medications were independent predictors of impaired HRQoL. Studies in 
recent years have also suggested that non-motor symptoms such as depression, fatigue, and sleep 
problems were stronger determinants of lower HRQoL than motor symptoms.
4,20
   
 PD has been described as a disease associated with significant economic burden.
21
 
Because of the expected continuing increase in the portion of elderly in the population, 
escalating costs associated with PD in the future are predicted. Kowal et al. evaluated excess 
healthcare use, medical, and non-medical costs in PD compared to those without PD using 
combined national representative surveys in the United States.
22
 The researchers projected costs 
based on the U.S. Census Bureau’s 2010 to 2050 demographic data. The estimated medical costs 
attributed to PD were predicted to increase from approximately $8 billion in 2010 to $18.5 
billion in 2050.  
Many studies have reported high direct and indirect costs associated with PD. The 
reported total direct costs for the population with PD in the United States were about $14 billion 
in 2010.
22
 The estimated annual direct cost among PD patients ranged from $5,176 to $80,904 
per patient depending on the patients’ disease severity, disease progression, complications, and 
compliance.
21
 Huse et al. assessed costs for PD using Medstat's MarketScan Research Database, 
which included medical and pharmacy claims data among enrollees under an employer-funded 
health plan or Medicaid. They found that the total annual direct costs for patients with PD were 




 Noyes et al. analyzed Medicare Current Beneficiary Survey data and reported 
annual health care expenses of $18,528 for PD patients and $10,818 for the beneficiaries without 
PD.
24
 Based on resource use and cost profiles from statewide hospital discharge data, O’Brien 
and colleagues reported an annual PD-related direct cost of $12,491.
25
 
Several studies have also shown that direct costs of PD were significantly associated with 
the level of disease disability and increased progressively over time.
21
 Kaltenboeck et al. used 
samples from Medicare to estimate direct medical costs among PD patients aged 65 and older.
26
 
Compared to the matched controls without PD, patients with PD had excess costs of $28,422 
($61,622 vs. $33,200) from the year prior to the quarter with first PD diagnosis to the end of 5-
year follow-up. The authors also analyzed the difference in direct medical costs between 
matched controls without PD and PD patients at different levels of disability. Relative to the 
matched controls without PD, the excess cumulative costs in the same observation period among 
patients with PD who received an ambulatory assistance device (a walker or wheelchair) or were 
in a skilled nursing facility were $50,923 ($78,042 vs. $27,119) and $102,750 ($142,008 vs. 
$39,258), respectively. Another study used a commercially insured claims database to calculate 
direct and indirect costs of PD patients under the age of 65 years.
27
 Compared to the matched 
controls without PD, after one-year follow-up, the excess mean direct PD-related costs were 
$4,072 ($9,175 vs. $5,103) for the newly diagnosed PD patients, $26,467 ($31,800 vs. $5,333) 
for those PD patients with an ambulatory assistance device, and $37,410 ($43,506 vs. $6,096) for 
the institutionalized PD patients.  
The identified main contributors to direct costs of PD included medications, 
hospitalization, nursing home, and outpatient costs. The study conducted by Kowal et al. showed 
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that the total direct costs were $22,129 per PD patient in 2010.
22
 They found that nursing home 
expenses accounted for the greatest percentage (37.4%) of direct costs ($8,272), followed by 
costs of hospitalization (29.1%, $6,444), and medications (17.1%, $3,780).  Richy et al. assessed 
healthcare costs incurred by PD patients using the PharMetrics claims database.
28
 The reported 
total direct costs were $80,905 per PD patient. Approximately 27% of the direct costs were from 
outpatient costs ($21,851), 25% were from medications ($20,336), 22% were from 
hospitalization ($17,743), and 18.6% were from emergency room visits ($15,038). The total 
direct costs in the Richy study were much higher than the costs in the Kowal study ($80,905 vs. 
$22,129). This may due to the difference in methodology and data source: Kowal et al. used 
combined nationally representative surveys and integrated the US Census Bureau’s population 
data, while Richy et al. retrospectively analyzed a nationally representative claims database for 
the commercially insured population in the US.  
Studies regarding indirect costs of PD due to productivity loss, early retirement, and 
reduced employment have been published. By integrating data from a claims database and 
simulation of lifetime earnings loss, Johnson et al. demonstrated that newly diagnosed PD 
patients and PD patients with ambulatory assistance devices (AAD) were more likely retire 
early.
29
 They reported that the earnings loss for newly diagnosed PD patients was $43,928 over 3 
years after PD diagnosis and $205,832 over 3 years after AAD use. Another study analyzed 
commercially insured claims data and found that the newly diagnosed PD patients’ indirect costs 
were $3,311 higher than matched controls without PD after one year follow-up. Among the 
newly diagnosed PD patients, the costs associated with absenteeism and disability were $2,315 
and $2,055 after one year, respectively. Kowal et al. revealed that patients with PD were less 
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likely to be employed than those without PD, which translated into $1.7 billion in loss of national 
productivity in 2010.
22
 The reported annual indirect costs were $10,046 per PD patient. Among 
those employed PD patients, they had eight more medically related absenteeism days per year 
relative to those without PD and generated a loss of $823 million.  
In addition to the humanistic and economic burden to patients who suffered from PD, 
several studies reported the burden to informal caregivers of PD patients.
21
 Most PD patients 
receive informal care performed by their spouse or child. Many informal caregivers take work 
leaves or quit their jobs to take care of their loved ones.
30
 A study conducted by Bhimani 
revealed that taking care of PD patients poses a significant burden on informal caregivers’ 
physical, psychological, and socioeconomic domains.
30
  
In summary, PD was associated with significant burden to patients, their families, and 
society. PD patients have impaired HRQoL and the economic burden of PD rises progressively 
over time. Previous studies have also demonstrated that both direct and indirect costs contribute 
substantially to the economic burden of PD. 
 
1.1.3 Symptoms and Disease Progression of PD 
Clinical features of PD can be categorized into motor and non-motor symptoms. Motor 
symptoms are caused by deficiency of dopamine in the striatum which degenerate patients’ 
movement abilities. Motor symptoms usually begin on one side of the body and extend gradually 
to the other side as the disease progresses. The core features of motor symptoms are tremor, 
bradykinesia, rigidity, and postural instability. Tremor is the shaking movement that is most 
noticeable when PD patients are at rest, occurring in approximately 70% of the PD patients. 
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Bradykinesia (slow movement) makes PD patients difficult to initiate movement. This is the 
most debilitating feature of motor symptoms which limits patients’ ability to perform daily living 
tasks, such as buttoning clothes, brushing teeth, and bathing. Rigidity, characterized by stiffness 
of limbs, neck, or trunk, is caused by failure of reciprocal relaxation of antagonist muscles. 
Postural instability refers to the motor symptom where patients lose the automatic reflexes 
required to retain balance, resulting in difficulty in walking and an increase the risk of falling. 
The term “parkinsonism” is used to describe the motor symptom complex such as tremor, 
rigidity, bradykinesia, and postural instability. Although PD causes the majority of cases of 
parkinsonism, many diseases can present with signs and symptoms of parkinsonism as well.
31
 
 A wide spectrum of non-motor symptoms have been reported: cognitive problems and 
dementia, psychosis and hallucinations, mood disorders, sleep disorders, daytime sleepiness, 
autonomic dysfunction, loss of sense of smell, and pain. Non-motor symptoms are common and 
nearly all PD patients have experienced non-motor symptoms.
32,33
 The neurochemical changes 
associated with non-motor symptoms have not been fully understood to date. Although motor 
symptoms are more noticeable, previous studies have shown that non-motor symptoms have a 
greater impact on PD patients’ quality of life than motor symptoms.
34-36
  
The symptoms and progression of PD vary from patient to patient. Non-motor symptoms 
usually present before the onset of motor symptoms and progress during the course of PD (See 
Figure 1.1).
37
 As the disease progresses, both motor and non-motor symptoms may become more 
severe and increase the degree of functional disability. In the late phase of PD, many patients 
develop complications due to long-term symptomatic treatment such as psychosis, fluctuations in 
response, and dyskinesia. For motor symptoms, the majority of the advanced PD patients 
 10 
experienced freezing of gait and falls. As for the non-motor symptoms, autonomic dysfunction 
and dementia are common in advanced PD patients. 
Figure 1.1 Clinical symptoms and time course of Parkinson’s disease progression 
 
EDS=excessive daytime sleepiness. MCI=mild cognitive impairment. RBD= REM (rapid eye movement) sleep behavior 
disorder. 
Source: Kalia LV, Lang AE. Parkinson's disease. Lancet (London, England). Aug 29 2015;386(9996):896-912. 
 
1.1.4 Diagnosis of PD  
 Currently, there is no definitive test available to specifically assess PD. The diagnosis of 
PD can be confirmed by histopathological examination of neuronal loss with Lewy bodies at 
autopsy. However, in clinical practice, the diagnosis of PD is usually based on different 
symptoms and findings from the patient’s history and a physical examination. Both the 
International Parkinson and Movement Disorder Society’s (MDS) Task Force and the UK 
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Parkinson’s Disease Society Brain Bank have published diagnostic criteria of PD (See Table 1.1 
and Table 1.2).
38-40
 In general, the diagnosis of PD involves identification of parkinsonism 
(bradykinesia, rigidity, 4-6 Hz rest tremor, and postural instability), exclusion of other diseases 
that manifest in a similar fashion, and assessment of response to dopaminergic therapy. The 
clinicians often review the patient’s history such as onset of the symptoms, whether symptoms 
are unilateral, changes in mood, sleeping habits, or autonomic dysfunction, recent injury/falls, 
medication use, etc. A series of physical and neurologic examinations are performed to assess the 
patient’s ability to regain balance and coordination. When the diagnosis of PD is uncertain or the 
symptoms become incapacitating for a patient’s everyday life, a medication challenge test (i.e., 
giving dopaminergic therapy to patients for diagnostic purpose) may be conducted to support the 
diagnosis of PD. If the patient’s symptoms significantly improve after the medication challenge 




Table 1.1 Movement Disorder Society’s (MDS) diagnostic criteria for Parkinson’s disease (PD) 
The first essential criterion is parkinsonism, which is defined as bradykinesia, in combination 
with at least 1 of rest tremor or rigidity. Examination of all cardinal manifestations should be 
carried out as described in the MDS–Unified Parkinson Disease Rating Scale. Once parkinsonism 
has been diagnosed: 
 
Diagnosis of Clinically Established PD requires: 
1. Absence of absolute exclusion criteria 
2. At least two supportive criteria, and 
3. No red flags 
 
Diagnosis of Clinically Probable PD requires: 
1. Absence of absolute exclusion criteria 
2. Presence of red flags counterbalanced by supportive criteria 
If 1 red flag is present, there must also be at least 1 supportive criterion 
If 2 red flags, at least 2 supportive criteria are needed 




(Check box if criteria met) 
 1. Clear and dramatic beneficial response to dopaminergic therapy. During initial treatment, 
patient returned to normal or near-normal level of function. In the absence of clear 
documentation of initial response a dramatic response can be classified as: 
a) Marked improvement with dose increases or marked worsening with dose decreases. 
Mild changes do not qualify. Document this either objectively (>30% in UPDRS III with 
change in treatment), or subjectively (clearly-documented history of marked changes 
from a reliable patient or caregiver). 
b) Unequivocal and marked on/off fluctuations, which must have at some point included 
predictable end-of-dose wearing off. 
 2. Presence of levodopa-induced dyskinesia 
 3. Rest tremor of a limb, documented on clinical examination (in past, or on current 
examination) 
 4. The presence of either olfactory loss or cardiac sympathetic denervation on MIBG 
scintigraphy 
 
Absolute exclusion criteria: The presence of any of these features rules out PD: 
 1. Unequivocal cerebellar abnormalities, such as cerebellar gait, limb ataxia, or cerebellar 
oculomotor abnormalities (e.g., sustained gaze evoked nystagmus, macro square wave jerks, 
hypermetric saccades) 
 2. Downward vertical supranuclear gaze palsy, or selective slowing of downward vertical 
saccades 
 3. Diagnosis of probable behavioral variant frontotemporal dementia or primary progressive 
aphasia, defined according to consensus criteria within the first 5 y of disease 
 4. Parkinsonian features restricted to the lower limbs for more than 3 y 
 5. Treatment with a dopamine receptor blocker or a dopamine-depleting agent in a dose and 
time-course consistent with drug-induced parkinsonism 
 6. Absence of observable response to high-dose levodopa despite at least moderate severity of 
disease 
 7. Unequivocal cortical sensory loss (i.e., graphesthesia, stereognosis with intact primary 
sensory modalities), clear limb ideomotor apraxia, or progressive aphasia 
 8. Normal functional neuroimaging of the presynaptic dopaminergic system 
 9. Documentation of an alternative condition known to produce parkinsonism and plausibly 
connected to the patient’s symptoms, or, the expert evaluating physician, based on the full 
diagnostic assessment feels that an alternative syndrome is more likely than PD 
 
Red flags 
 1. Rapid progression of gait impairment requiring regular use of wheelchair within 5 y of onset 
 2. A complete absence of progression of motor symptoms or signs over 5 or more y unless 
stability is related to treatment 
 3. Early bulbar dysfunction: severe dysphonia or dysarthria (speech unintelligible most of the 
time) or severe dysphagia (requiring soft food, NG tube, or gastrostomy feeding) within first 
5 y 
 4. Inspiratory respiratory dysfunction: either diurnal or nocturnal inspiratory stridor or frequent 
inspiratory sighs 
 5. Severe autonomic failure in the first 5 y of disease. This can include: 
a) Orthostatic hypotension32—orthostatic decrease of blood pressure within 3 min of 
Table 1.1 Movement Disorder Society’s (MDS) diagnostic criteria for PD (continued) 
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standing by at least 30 mm Hg systolic or 15 mm Hg diastolic, in the absence of 
dehydration, medication, or other diseases that could plausibly explain autonomic 
dysfunction, or 
b) Severe urinary retention or urinary incontinence in the first 5 y of disease (excluding 
long-standing or small amount stress incontinence in women), that is not simply functional 
incontinence. In men, urinary retention must not be attributable to prostate disease, and must 
be associated with erectile dysfunction 
 6. Recurrent (>1/y) falls because of impaired balance within 3 y of onset 
 7. Disproportionate anterocollis (dystonic) or contractures of hand or feet within the first 10 y 
 8. Absence of any of the common nonmotor features of disease despite 5 y disease duration. 
These include sleep dysfunction (sleep-maintenance insomnia, excessive daytime 
somnolence, symptoms of REM sleep behavior disorder), autonomic dysfunction 
(constipation, daytime urinary urgency, symptomatic orthostasis), hyposmia, or psychiatric 
dysfunction (depression, anxiety, or hallucinations) 
 9. Otherwise-unexplained pyramidal tract signs, defined as pyramidal weakness or clear 
pathologic hyperreflexia (excluding mild reflex asymmetry and isolated extensor plantar 
response) 
 10. Bilateral symmetric parkinsonism. The patient or caregiver reports bilateral symptom onset 
with no side predominance, and no side predominance is observed on objective examination 
 
Criteria Application: 
1. Does the patient have parkinsonism, as defined by the MDS criteria? Yes  No  
If no, neither probable PD nor clinically established PD can be diagnosed. If yes: 
2. Are any absolute exclusion criteria present? Yes  No  
If “yes,” neither probable PD nor clinically established PD can be diagnosed. If no: 
3. Number of red flags present ____ 
4. Number of supportive criteria present ____ 
5. Are there at least 2 supportive criteria and no red flags? Yes  No  
If yes, patient meets criteria for clinically established PD. If no: 
6. Are there more than 2 red flags? Yes  No  
If “yes,” probable PD cannot be diagnosed. If no: 
7. Is the number of red flags equal to, or less than, the number of supportive criteria?  
Yes  No   
If yes, patient meets criteria for probable PD 
 
Source: Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Movement disorders : 
official journal of the Movement Disorder Society. Oct 2015;30(12):1591-1601. 
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Table 1.2 UK Parkinson’s Disease Society Brain Bank (UKPDSBB) clinical diagnostic criteria 
for idiopathic Parkinson’s disease 
Step 1 Diagnosis of Parkinsonian syndrome 
- Bradykinesia (slowness of initiation of voluntary movement with progressive 
reduction in speed and amplitude of repetitive actions)  
- and at least one of the following:  
 muscular rigidity  
 4-6 Hz rest tremor  
 postural instability not caused by primary visual, vestibular, cerebellar, or 
proprioceptive dysfunction  
 
Step 2 Exclusion criteria for idiopathic Parkinson’s disease  
- Repeated strokes with stepwise progression of parkinsonian features  
- Repeated head injury  
- History of definite encephalitis  
- Oculogyric crises  
- Neuroleptic treatment at onset of symptoms  
- More than one affected relative  
- Sustained remission  
- Strictly unilateral features after 3 years  
- Supranuclear gaze palsy  
- Cerebellar signs  
- Early severe autonomic involvement  
- Early severe dementia with disturbances of memory, language, and praxis  
- Babinski sign  
- Presence of cerebral tumor or communicating hydrocephalus on computed 
tomography scan  
- Negative response to large doses of levodopa (if malabsorption excluded)  
- MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) exposure  
 
Step 3 Supportive prospective positive criteria for idiopathic Parkinson’s disease 
(Three or more required for diagnosis of definite Parkinson's disease)  
- Unilateral onset  
- Rest tremor present  
- Progressive disorder  
- Persistent asymmetry affecting side of onset most  
- Excellent response (70-100%) to levodopa  
- Severe levodopa-induced chorea  
- Levodopa response for 5 years or more  
- Clinical course of 10 years or more  
Source: National Institute for Health and Care Excellence (NICE). Parkinson's disease in over 20s: diagnosis and management. 
NICE Guidelines.  https://www.nice.org.uk/guidance/cg35/chapter/1-Guidance#diagnosing-parkinsons-disease. Accessed April 
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3, 2016. (Adapted from Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's 
disease: a clinico-pathological study of 100 cases. Journal of neurology, neurosurgery, and psychiatry. Mar 1992;55(3):181-
184.) 
 
Ruling out diseases that mimic PD is an essential step in diagnosis of PD. However, 
distinguishing PD from other neurodegenerative disorders that also share similar symptoms and 
signs of parkinsonism is challenging.
42
 PD may be confused with other diseases such as essential 
tremor, dementia with Lewy bodies (DLB), corticobasal degeneration (CBD), multiple system 
atrophy, and progressive supranuclear palsy (PSP), or other conditions such as secondary 
parkinsonism (See Table 1.3).
43
 The American Academy of Neurology (AAN) suggests the 
following clinical features to identify alternative diagnoses other than PD:  “Falls at presentation 
or early in the disease course, poor response to levodopa, symmetry of motor signs, rapid 
progression, lack of tremor, and early dysautonomia”.
41
  Although imaging tests cannot help the 
confirmation of PD diagnosis, they may be used to distinguish PD from other diseases. These 
include magnetic resonance imaging (MRI), 123I-FP-CIT single photon emission tomography 
(also known as DaTscan), positron-emission tomography (PET), and brain parenchyma 
sonography.
41
 In addition to the imaging tests, olfactory screening may help in the differential 







Table 1.3 Disorders that can mimic Parkinson’s disease 
Neurodegenerative causes: 
- Alzheimer disease 
- Corticobasal degeneration 
- Dementia with Lewy bodies 
- Frontotemporal dementia 
- Huntington disease 
- Multiple system atrophy 
- Parkinsonism-dementia-ALS complex of Guam 
- Progressive supranuclear palsy 
- Spinocerebellar ataxias 
 
Symptomatic: 
- Drug-induced (neuroleptics, other dopamine receptor antagonists) 
- Infectious (post-encephalitic, Creutzfeldt-Jakob disease) 
- Metabolic (Wilson disease, neurodegeneration with brain iron accumulation, 
hepatocerebral degeneration, parathyroid disorders) 
- Neoplastic 
- Post-traumatic 




- Essential tremor 
- Normal pressure hydrocephalus 
- SWEDD (Scans Without Evidence of Dopaminergic Deficit): patients with 
relatively isolated upper extremity tremor resembling early Parkinson disease who 
lack evidence of nigrostriatal dopamine deficiency on dopamine transporter 
imaging 
 
Source: Chou K, Hurtig HI, Dashe JF. Diagnosis of Parkinson Disease. 2015; http://www.uptodate.com/contents/diagnosis-of-
parkinson-disease?source=search_result&search=parkinson&selectedTitle=3~150#H13. Accessed Dec 6, 2015. 
 
1.1.5 Management of PD  
PD is associated with both motor and non-motor complications. For non-motor complications 
management (e.g., anxiety, depression, impulse-control disorders, psychosis, cardiovascular or 




 The following section will focus on motor 
complications management in PD. 
Currently, there is no cure for PD, and the current treatment goal is symptom control. There 
are a variety of management techniques that attempt to restore balance, reduce motor inhibitory 
control, and improve health-related quality of life (HRQoL) for PD patients. The management of 
PD can be divided into 3 categories — non-pharmacologic, pharmacologic, and surgical 
interventions. 
 
1.1.5.1 Non-pharmacologic Management of PD 
Although non-pharmacologic interventions cannot resolve the cardinal symptoms of PD, 
they may help maintain the overall functioning of PD patients. Exercise and physical therapy 
may help alleviate the pain due to muscular rigidity or flexed posture and improve balance and 
gait speed.
45
 Because PD patients commonly experience speech and voice disorders, speech 
therapy may help them restore communication abilities.
46
 Although no specific diet restrictions 
are required for PD patients, a high fiber diet is advised to prevent constipation while high-fat 
foods should be avoided as they may interfere with levodopa absorption by delaying gastric 
emptying.
47,48
 In patients in an advanced phase of PD, dietary protein restriction may be 
considered since dietary neutral amino acids may compete with levodopa for intestinal 





1.1.5.2 Pharmacologic Treatment of PD 
Pharmacotherapy remains the mainstream treatment for the management of PD. The current 
pharmacologic treatment of PD focuses on symptomatic therapy and cannot modify the disease 
progression. Because the medication treatment effect may diminish over time as the disease 
advances, how to optimize and implement medication treatment is critically important. Optimal 
control of PD with pharmacotherapy requires an individually tailored strategy, as well as 
monitoring the balance between continued efficacy and side effects.
50
 The major PD medications 
for motor symptoms treatment can be categorized into the following classes according to 
different mechanisms: levodopa, dopamine agonists (DAs), monoamine oxidase B (MAO-B) 





(1) Levodopa  
Levodopa, also known as L-dopa, is a prodrug of dopamine. It is metabolized by L-
aromatic amino acid decarboxylate to dopamine after crossing the blood-brain barrier (BBB), 
and hence replaces the neurotransmitter deficiency.
50
 Because levodopa can be extensively 
absorbed in the gastrointestinal tract and cause premature conversion of levodopa to dopamine 
outside of the brain, this may lead to nausea, vomiting, and orthostatic hypotension.  To prevent 
the above symptoms, levodopa is usually administered in combination with a peripheral 
decarboxylase inhibitor — carbidopa.
50
 The current available carbidopa-levodopa products in the 
United States include Sinemet®, Sinemet CR®, and Parcopa®. Although levodopa is an 
effective medication for PD management, patients may develop motor complications (e.g., motor 
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fluctuations, dyskinesia, and dystonia) after prolonged levodopa use.
50
 Other common adverse 
effects associated with levodopa include nausea, vomiting, postural hypotension, somnolence, 
sleep attacks, dizziness, sedation, confusion, and a range of mental disorders (e.g., isolated 




(2) Dopamine agonists  
 Dopamine agonists (DAs) bind and activate the post-synaptic dopamine receptors directly 
without metabolic conversion from other compounds.
50
 DAs can be further divided into two 
groups — ergot and nonergot derivatives. Ergot derivatives used to treat PD include 
bromocriptine, lisuride (not available in the United States), and pergolide.
50,54
 Though it is 
uncommon, ergot derivatives may have potential side effects such as fibrosis due to its affinity to 
both serotonin (5-HT2B) and dopamine receptors.
50
 In March 2007, pergolide was withdrawn 
from the market because of cardiac valvular fibrosis concerns.
55
 Unlike ergot derivatives, 
nonergot derivatives have relatively safe profiles compared to ergot derivatives because of their 
low affinity to serotonin (5- hydroxytryptamine 2B receptor or 5-HT2B) receptors.
50
 Nonergot 
derivatives for PD treatment include ropinirole, and pramipexole, injectable apomorphine, and 
rotigotine transdermal patch. Because of a delivery mechanism problem, rotigotine patches were 
recalled in 2008, and were released back to the market after approval of the new formulation in 
2012.
56,57
 In general, DAs tend to cause similar side effects as levodopa. These include nausea, 
vomiting, somnolence, orthostatic hypotension, and psychiatric disorders (e.g., confusion, 
cognitive changes, hallucination, and delusion). Other side effects associated with DAs are 




Pramipexole, ropinirole, and rotigotine have been implicated in causing sleep attacks, which may 
result in dangerous consequences if patients are driving.
50
 The ICDs in PD patients are 
hypothesized to be linked to dysfunction in the mesocorticolimbic dopaminergic pathway, and 





(3) Monoamine oxidase B (MAO-B) inhibitors 
Monoamine oxidase B (MAO-B) inhibitors prolong dopamine activation by blocking 
MAO-B, the major enzyme of dopamine degradation.
58
 These medications include selegiline and 
rasagiline. Both selegiline and rasagiline can be used as monotherapy for patients with mild-to-
moderate motor features in order to delay the use of carbidopa/levodopa or DAs.
58
 MAO-B 
inhibitors can also be used as adjunctive treatment to boost the effect of carbidopa/levodopa or 
DAs for patients with advanced PD.
58
 Some studies suggest that selegiline and rasagiline may 
have a neuroprotective effect against PD, yet more research is needed before this can be 
concluded.
58-62
 MAO-B inhibitors are generally well tolerated with minor adverse reactions such 
as nausea, vomiting, dizziness, orthostatic hypotension, and dyskinesias.
63
 There are also 
reported cases of impulse control disorders induced by rasagiline.
64,65
 Because MAO-B inhibitors 
can also inhibit serotonin breakdown and activate 5HT receptors, co-administration with 
serotonergic agents should be avoided.
58,63
      
 
(4) Catechol-O-methyltransferase (COMT) inhibitors 
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Catechol-O-methyltransferase (COMT) inhibitors, such as entacapone and tolcapone, 
indirectly increase dopamine availability by blocking methylation of levodopa.
58
 The COMT 
inhibitors are usually used as adjunctive treatment with carbidopa/levodopa among PD patients 
who experience motor fluctuations.
58
 The adverse events associated with COMT inhibitors are 
similar to those with increased dopaminergic stimulation, such as nausea and vomiting. Delayed-
onset diarrhea has also been reported in COMT inhibitors use.
58
 In addition, the use of tolcapone 




(5) Anticholinergic agents 
Anticholinergic agents were first introduced to PD treatment in the 1960s based on the 
concept that dopamine deficiency may cause subsequent imbalance between dopaminergic and 
cholinergic activity and result in PD symptoms.
58
 Anticholinergic agents act by blocking the 
action of acetylcholine and have shown effective control of tremor in patients younger than 60 
years.
58
 Currently available anticholinergics for PD treatment include benztropine, biperiden, 
trihexyphenidyl, and procyclidine. The side effects of anticholinergics have limited their use in 
elderly patients. These include CNS-related adverse events (e.g., confusion, memory loss, and 
hallucinations) and peripheral antimuscarinic adverse events (e.g., dry mouth, constipation, and 
urinary retention).
58
 Anticholinergics should be used with caution for PD patients with comorbid 






Although the mechanism of amantadine in PD treatment has not been fully elucidated, it 
appears that N-methyl-D-aspartate (NMDA) receptor blockade is involved and thus increases 
dopamine release.
58
 Amantadine has shown its effectiveness in improving motor symptoms and 
carbidopa/levodopa-induced dyskinesia.
58
 Amantadine may cause peripheral side effects (e.g., 
mottled skin, ankle edema), CNS effect (e.g., confusion, hallucinations), gastrointestinal 
symptoms, or corneal edema.
58
 Because amantadine also has anticholinergic properties, caution 





1.1.5.3 Surgery and Other Treatments for PD 
Surgical procedures may be advised for certain advanced PD patients with troublesome 
motor symptoms which cannot be controlled by the medications.
58
 Currently, the main surgical 
practice for PD is deep brain stimulation (DBS) — a surgery that implants an electrode into the 
brain. The implanted electrode can control the motor symptoms and reduce dyskinesia by 
sending electrical impulses to certain parts of the brain, such as subthalamic nucleus, the globus 
pallidus, and the thalamus.
58
 DBS is not recommended for PD patients who have comorbid 
psychiatric and cognitive problems.
58
 Other treatments such as transplantation of stem cells and 




1.1.6 Guidelines for the Management of PD 
Several clinical practice guidelines have been developed for the management of PD. These 
include guidelines published by the American Academy of Neurology (AAN), the European 
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Federation of Neurological Societies/the Movement Disorders Society (EFNS/MDS), the UK’s 
National Institute for Health and Clinical Excellence (NICE), the  Canadian Neurological Sciences 
Federation (CNSF), and the Scottish Intercollegiate Guidelines Network (SIGN). In general, the 
management of PD can be divided into two phases — early stage and late stage therapy. There is 
no universal first choice medication for these two phases.
45,66,67
 Instead, the medications for PD 
management should be tailored for individuals, and are based on several factors such as the 
clinical characteristics, disease progression, lifestyle, and patient preference.
45,66,67
 
Early stage therapy is for PD patients who have not developed motor complications due to 




 year after the PD diagnosis. The 
recommended main medications at this stage include DAs and levodopa. The choice of using a 
DA or levodopa depends on the age and symptom severity of the patient. DA monotherapy is 
usually advised for PD patients who are younger than 70 years old and have mild to moderate 
PD. Although levodopa is the most effective medication to control motor symptoms, the long-
term use of levodopa may cause motor complications. Therefore, the delayed use of levodopa 
has been proposed, and thus levodopa is more often recommended for those aged older than 70 
years with moderate to severe PD. Anticholinergics, MAO-B inhibitors, and amantadine are 
second-line treatment choices for PD management during the early stage.
45,66-68
  
Late stage therapy is for patients who have developed motor complications after long-term 
use of levodopa. These patients usually have had a PD diagnosis for more than five years. At this 
stage, many patients experience a wearing-off effect (shorter duration of parkinsonian symptoms 
control), an on-off effect (unpredictable and abrupt fluctuation between controlled and worsen 
parkinsonian symptoms), or dyskinesia. In addition to levodopa, MAO-B inhibitors, COMT 
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inhibitors, or DAs can be added as the combination therapy to reduce motor fluctuations. 
Amantadine may be considered as an adjunct therapy with levodopa to reduce dyskinesia. For 
those PD patients with severe motor complications, apomorphine may be used to alleviate “off” 
time (parkinsonian symptoms worsen period). If pharmacotherapy still cannot control the motor 
symptoms and complex fluctuations, a surgical procedure can be considered.
45,66,67,69
 








Source: Appendix: Treatment Algorithm for Parkinson's Disease. International Neurology: Wiley-Blackwell; 2010:681-682. 
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1.1.7 Antiparkinson Medication Taking Behavior in PD Patients 
1.1.7.1 Antiparkinson Medication Adherence  
The term, adherence (or compliance), refers to “the extent to which a patient acts in 
accordance with the prescribed interval and dose of a dosing regimen.”
71
 Another term, 
persistence, can be defined as “the duration of time from initiation to discontinuation of 
therapy.”
71
 Adherence and persistence are two constructs used to describe a patient’s medication 
taking behavior. Many factors may be associated with low medication adherence. These include 
forgetfulness, ineffectiveness of the medications, complexity of the treatment, side effects of 
medications, higher costs of the medications, polypharmacy, cognitive diseases, mental 
disorders, socioeconomics, and others.
72
  
The identified factors associated with poor adherence include age greater than 65 years old, 
more comorbid diseases, PD regimen modifications and complexity, disease progression, 
cognitive impairment, and a lower level of family support. As PD progresses, patients may need 
more than one medication to control motor symptoms. Also, advanced PD patients may need to 
take dopaminergic agents more frequently than early PD patients (e.g., 3-4 times/day in early 
PD; 6-10 times/day in advanced PD). In addition, physicians modify PD regimens often to 
optimize treatment effect. All of these contribute to suboptimal adherence to PD medications.
73
  
The reported non-adherence rate to PD medications ranged between 0 and 70 percent upon 
the methodology employed.
73
 Leopold et al. used a computerized medication event monitoring 
system to measure adherence and found that 20.5% of the PD patients missed ≥ 3 doses per 
week.
74
 For those studies using electronic monitoring bottles, 20% of PD patients were non-
adherent (less than 80% of prescribed doses) in a single-center observational study, while a 
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lower non-adherence rate was observed (12.5%) in a multi-center observational study.
75,76
 
Valldeoriola et al. administered the Morisky-Green Test (MGT) questionnaire to capture 
adherence and reported a non-adherence rate of 40%.
77
 Elm et al. compared adherence results 
measured by using a patient self-reported questionnaire versus using pill counts from two clinical 
trials. They observed a lower non-adherence rate using the pill count method compared to the 
MGT questionnaire (10% vs. 44%) among these PD patients.
78
 Although the authors did not 
discuss the possible explanation of the different results generated by these two adherence 
measure approaches, they pointed out that the wording of the MGT questionnaire may be 
somewhat ambiguous and less reliable. Some other studies measured adherence by calculating 
the medication possession ratio (MPR) and defined non-adherence as having an MPR < 80%. 
Davis et al. reported a non-adherence (MPR < 80%) rate of 61% by assessing MPR from a 
claims database with 30 managed care plans in the US.
79
 Kulkarni et al. tracked the MPR for PD 
medications in a Medicare population over five years and revealed that 67% of patients were 
non-adherent (MPR < 80%).
80
 Tarrants et al. compared medication adherence across PD 
medications and reported an average non-adherence (MPR < 80%) rate of 46.5%.
81
 Wei et al. 
calculated a 37.3% rate of non-adherence (MPR < 80%) using a 5% random sample of Medicare 
beneficiaries.
82
 Richy et al. performed a retrospective database analysis and found 45.7% of the 
PD patients were non-adherent (MPR < 80%).
28
 Persistence, or duration of therapy, was also 
reported in some studies. Tarrants et al. used a gap of 45 days and obtained a mean persistence of 
133 days across all PD medications.
81





Several studies have reported that suboptimal adherence to PD medications is associated 
with higher healthcare resource utilization and costs as well as reduced quality of life in PD 
patients.
28,79,83
 Using the USA PharMetrics claims database, Richy et al. observed a higher mean 
healthcare cost in non-adherent PD patients than those who were adherent ($84,949 vs. $77,499, 
p < 0.0001).
28
 Davis et al. found similar patterns - non-adherent patients had extra mean medical 
(+$3,451, P < 0.0001) and total healthcare costs (+$2,383, P = 0.0053).
79
 The retrospective study 
conducted by Wei et al. revealed that compared with non-adherent PD patients, adherent PD 
patients had lower rates of hospitalization (RR = 0.86), emergency room visits (RR = 0.91), 
skilled nursing facility episodes (RR = 0.67), home health agency episodes (RR = 0.83), and 
physician visits (RR = 0.93). The authors also found lower total health care expenditures in 
adherent PD patients than those who were non-adherent (-$2242, p < 0.001).
83
    
 
1.1.7.2 Antiparkinson Medication Switch and Augmentation 
In order to optimize the therapeutic effect, regimen modifications such as dose escalation, 
switching, or augmentation are common in PD treatment.
66
 The regimen modification could 
result from ineffective dose, poor tolerance, or side effects of the PD treatment. However, 
previous studies also revealed that poor adherence may result in regimen modifications in PD 
treatment.
73
 Physicians may not be aware that this ineffective treatment is due to non-adherence, 
and thus may prescribe unnecessary regimen modifications. One study demonstrated that prior 





Two studies examined PD regimen modification patterns. Huse et al. analyzed the initial PD 
medication use among patients in employer-funded health insurance plans and Medicaid. Among 
the PD patients, 14.1% had augmentation of their initial PD therapy, while 2.7% switched their 
initial PD therapy — together, this accounted regimen modifications in 16.8% of PD patients. 
For PD patients who initiated monotherapy, levodopa users had the lowest rate of augmentation 
or switching compared to other medication users.
85
 Wei et al. examined patterns of antiparkinson 
medication use in Medicare beneficiaries. The authors reported that 21.1% of the PD patients had 
augmentation and 16.4% had switches during the 19-month follow-up. In line with the Huse 
study, Wei et al. also found that PD patients who used levodopa had the lowest rates of switching 




1.1.7.3 Link between PD, Depression, and Antidepressants Use 
Depression has been found to be more prevalent in PD patients than the general 
population.
86
 Because depression and PD both involve neurobiological changes in the brain, 
several studies have been conducted to find the link between the two diseases. So far, the 
evidence has supported the hypothesis that depression may be a pre-symptom of PD.
7,87-89
 
Studies have also found that adequate depression treatment may not only control depression 
itself but may also reverse the negative impact brought about by depression in PD. Paumier et al. 
conducted a patient-level meta-analysis and reported that tri-cyclic antidepressants (TCAs) were 
associated with a delayed need of dopaminergic therapy among PD patients.
90
 In addition, the 
Ricci study found that depressed PD patients receiving selective serotonin reuptake inhibitor 




Kulisevsky et al. examined the motor changes among depressed PD patients using sertraline and 
found a similar result.
92
 One randomized controlled double-blind trial also suggested that longer-




1.1.7.4 Summary of Section 
PD is a prevalent neurodegenerative disorder in elderly people. It has been associated with a 
substantial humanistic and economic burden for PD patients. The symptoms of PD include 
motor- and non-motor symptoms, and both largely affect patients’ daily function and quality of 
life. The main management of PD is pharmacologic treatment. However, due to the complexity 
of the regimen and the need for lifelong treatment, among other issues, suboptimal adherence to 
antiparkinson medications has been observed. Depression could be a pre-symptom of PD. A 
detailed discussion of depression in PD patients is presented in the next section. 
 
1.2 Section 2: Depression in PD 
1.2.1 Epidemiology and Pathophysiology of Depression in PD 
Depression is a common non-motor symptom of PD, affecting roughly 20 to 50% of PD 
patients.
94
 The wide range of reported prevalence and incidence rates is due to the methodology 
to identify depression and the patient population. Generally, higher prevalence rates were 
observed when using depression rating scales than using diagnostic criteria (the Diagnostic and 
Statistical Manual for Mental Disorders (DSM) or the International Classification of Diseases 
(ICD) codes) to capture depression in PD patients. Lower prevalence rates were found in studies 
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analyzing a general ambulatory population compared with outpatient or inpatient settings. The 
reported prevalence of depression also varied according to the severity of depression. A 
systematic review concluded that the weighted mean prevalence of depression in PD patients 
was 17% for major depressive disorder, 22% for minor depression, and 13% for dysthymia. 
Those who had clinically relevant-depressive symptoms accounted for 35% of the PD patients.
86
 
Similarly, other recent studies have shown the prevalence rate ranged between 30 to 35% for 
clinically-relevant depression in PD patients.
95
 One study also observed that among PD patients, 
36.3% were diagnosed with minor depression while 12.9% were diagnosed with major 
depression.
96
 Another factor associated with some dissimilarity in the  reported prevalence of 
depression may be attributed to method used to identify depression. The studies with structured 
interviews for DSM criteria reported higher prevalence in major depressive disorders than those 
without structured interviews (19% vs. 7%).
86
 Factors associated with depression prevalence 
among PD patients included autonomic symptoms, motor fluctuations, severity and frequency of 
symptoms, staging of the disease, as well as PD onset and duration.
97
 Some studies investigated 
the incidence rate of depression in PD patients. Aarsland et al. reviewed articles before 2011 and 
found the annual incidence rates for the two largest studies were 2.6 and 13.0%. Both older age 
and longer duration of PD were reported to be risk factors associated with a higher incidence of 
depression in PD. 
95
   
Although the etiology of depression in PD remains uncertain, research suggests that both 
psychosocial and neurobiological factors may be involved.
98,99
 Receiving the diagnosis of PD 
can be a stressful life event to patients. They may proceed through different emotional reactions 
such as sadness, anger, fear, and demoralization when coping with a PD diagnosis as well as its 
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associated disability and symptoms, which may contribute to the development of depression.
99,100
 
However, one study compared depression symptom severity between PD patients and non-PD 
patients with other chronic disabling diseases not involving loss of endogenous 
neurotransmitters. The result showed PD patients had more severe depression symptoms than the 
non-PD patients with other functional disabilities, which might indicate that disability is not the 
sole factor that accounts for depression in PD.
101
  
In addition to the psychosocial aspects, neurobiological factors may also play a role in 
depression in PD. The onset of depression is not parallel with the onset of motor disturbance in 
PD. In fact, depression usually occurs years before a PD diagnosis and has been considered as 
either a risk factor or a prodromal symptom.
102
 Besides the degeneration of midbrain 
dopaminergic neurons, PD may affect noradrenergic and serotonergic neurons, which in turn 
regulate reward and mood.
98
 Some studies showed that PD patients with depression had greater 
loss of striatal dopamine transporters and white matter within the cortical-limbic network than 
non-depressed counterparts. Different cerebral glucose metabolic and frontal perfusion features 
were also found between PD patients with and without depression.
95
 These findings suggest a 
correlation between neurodegeneration and depression in PD.
98
  
Mood changes leading to suicide attempts, mania, aggression, and depression are reported 
complications after deep brain stimulation (DBS) treatment. Post-DBS mood changes were more 
likely to be observed after subthalamic nucleus (STN) DBS, but not after thalamic and pallidal 
DBS. Researchers have suggested that mood changes may result from serotonin inhibition in 
neuronal circuits caused by STN stimulation. However, mood changes could also be due to the 
stimulation spreading to adjacent pathways mediating non-motor functions as well as improper 
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electrode placement or contact. Alternatively, depression could exist before DBS and occur when 
reducing dopaminergic medication dose after DBS.
98,99
 
   Genetic susceptibility to depression has been postulated because a higher rate of depression 
was observed in non-PD first-degree relatives of PD patients with depression.
89
 The reported 
genes that may be associated with depression in PD include SLC6A4 and n LRRK G2019S 
mutations.
103-105
 Nonetheless, further research is needed to verify the relationship between 
genetic determinants and depression in PD.
98
   
 
 
1.2.2 Diagnosis of Depression in PD  
 The main clinical features of depression are depressed mood and loss of interest. 
Depressed patients may also present somatic or vegetative symptoms (e.g., psychomotor 
retardation, poor appetite, decreased energy or fatigue, sleep disturbance, pain, trouble 
concentrating, decreased memory, and loss of libido). However, many of these features may 
overlap with PD symptoms, and thus make it challenging to differentiate depressed from non-
depressed PD patients.
94
 The Diagnostic and Statistical Manual of Mental Disorders (DSM) 
criteria have been widely used to diagnose depression. But due to the overlapping symptoms of 
depression and PD, the National Institute of Neurological Disease and Stroke (NINDS)/National 
Institute of Mental Health provide following recommendations of diagnosing depression in PD: 
1) All symptoms should be counted toward the assessment of depression regardless of the 
presumed causality of the symptoms (i.e., inclusive approach). 2) Generally, the diagnosis of 
depression requires patients fulfilling the core criterion of depression—depressed mood or 
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anhedonia. But only depressed mood should be considered as the core feature when evaluating 
depression in PD because apathy or anhedonia may also occur in PD. 3) Practitioners should 
evaluate patients during “on-state” since drug-related motor fluctuations are associated with 
mood changes. 4) To avoid the unreliable results reported by PD patients with cognitive 
impairment, information from caregivers or individuals who know the patient well should be 
included.
106
 In addition to the recommendations above, routine laboratory tests should be 




 Psychiatric rating scales should also be used to assist in the diagnosis of depression.
107,108
 
However, because these rating instruments were not specifically designed for PD patients and the 
overlapping symptoms, the cutoff points might need to be adjusted.
94
 Also, the American 
Academy of Neurology and the Movement Disorders Society Task Force both examined the 
validity of using these instruments in PD patients and concluded that the Beck Depression 
Inventory (BDI) and the Hamilton Depression Rating Scale (HAM-D) were valid when 
screening for depression in PD.
107,108
 A recent study reviewed thirteen rating scales used in 
depression assessment for PD patients. The HAM-D and the Geriatric Depression Scales (GDS) 
were suitable for screening and evaluating the severity of depression in PD. The Cornell Scale 
for Depression in Dementia (CSDD) could be considered for patients with comorbid dementia. 
Several instruments had also shown valid and reliable psychometric properties in PD patients 
with depression, including the Hospital and Anxiety Depression Scale-Depression subscale 
(HADS-D), Hamilton Depression Inventory (HDI), the BDI, and the Montgomery–Asberg 





1.2.3 Management of Depression in PD 
 Before treating depression in PD, practitioners should review all medications that a PD 
patient is taking, then identify and eliminate any adverse influence on mood caused by current 
medication use.
99
 Practitioners should confirm that the antiparkinson medications have been 
optimized because depressive symptoms may result from the motor “off-and-on” fluctuations.
99
 
The management of depression in PD depends on the severity of depression. Counseling and 
cognitive behavioral therapy (CBT) are recommended for PD patients with mild depression 
while pharmacologic treatment is appropriate for those with moderate to severe depression. 
Electroconvulsive therapy (ECT) may also be considered when PD patients have severe and 
medication-resistant depression.
94,99
 One meta-analysis examined both pharmacologic and non-
pharmacologic intervention to treat depression in PD. The authors concluded that both selective 
serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy (CBT) have shown their 
efficacy in improving depression among PD patients.
110
 The general strategy for treating 





 The timing of starting TCAs is different between the two proposed management 
algorithms. Although there is more evidence for supporting the efficacy of TCAs than SSRIs, 
TCAs are associated with less tolerability and more side effects. It could be possible that the 
algorithm from the book — “Principles and Practice of Geriatric Psychiatry”
111
 provides more 
general recommendations based on the common comorbid conditions and potential adverse 
effects of TCAs for this population, while the algorithm proposed by Chen and Marsh
99
 focuses 
more on the efficacy data based on their reviewed evidence-based medicine (EBM) studies.  
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*For mild or subsyndromal depression, treatment can be deferred with watchful w iting and going follow-up for symptom worsening. ECT: electroconvulsive therapy; SNRI: s r ton n-norepineph ine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor; TCA: tricyclic antidepressant. 
PD: Parkinson’s disease; GDS: Geriatric Depression Scales; CBT: cognitive behavioral therapy; ECT: 
electroconvulsive therapy; SNRI: serotonin-norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake 
inhibitor; NaSSA: noradrenergic and specific serotonergic antidepressants; TCA: tricyclic antidepressant; rTMS: 
repetitive transcranial magnetic stimulation. 
Source:  Abou-Saleh MT, Katona C, Kumar A. Principles and practice of geriatric psychiatry. John Wiley & 
Sons; 2011. 
 




*For mild or subsyndromal depression, treatment can be deferred with watchful w iting and going follow-up for symptom worsening. ECT: electroconvulsive therapy; SNRI: s r ton n-norepineph ine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor; TCA: tricyclic antidepressant. 
*For mild or subsyndromal depression, treatment can be deferred with watchful waiting and ongoing follow-up for 
symptom worsening. ECT: electroconvulsive therapy; SNRI: serotonin-norepinephrine reuptake inhibitor; SSRI: 
selective serotonin reuptake inhibitor; TCA: tricyclic antidepressant. 





Figure 1.4 Management of depression in Parkinson’s Disease 
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1.2.3.1 Pharmacologic Treatment 
 A considerable amount of information regarding efficacy and safety of antidepressants 
can be found in the literature. However, only a few studies examined the efficacy of 
antidepressants in PD patients with depression. Results from these studies were inconclusive and 
most of them suffered from methodological difficulties, such as small sample sizes and using 
open-label trials.
107,112,113
 Tricyclic antidepressants (TCAs) and selective serotonin reuptake 
inhibitors (SSRIs) are commonly used in treating depression in PD patients. Other 
antidepressants commonly used for treating depression in PD include serotonin norepinephrine 
reuptake inhibitors (SNRIs), pramipexole, bupropion, nefazodone, and trazodone.
94,99
 
Amitriptyline is recommended by the American Academy of Neurology for treating depression 
in PD, while pramipexole, nortriptyline, and desipramine are recognized as efficacious or likely 




(1) Selective Serotonin Reuptake Inhibitors (SSRIs) 
 The SSRIs block the reuptake of serotonin (5-HT), resulting in a sustained level of 
serotonin at the synapse. The SSRIs are commonly prescribed to PD patients because they are 
well tolerated and have lower side effect profiles. Medications in this class for depression in PD 
include citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline.
99
 
Inconsistent results have been published with respect to the efficacy of antidepressants in treating 
depression in PD. Escitalopram, fluoxetine, fluvoxamine, sertraline, citalopram, and paroxetine 
have shown efficacy in reducing depressive symptoms in PD patients.
98,99
 However, two meta-
analysis studies compared the efficacy of SSRIs to placebo and reported that SSRIs might be no 
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more effective than placebo. But after removing one controversial article due to its dosage and 
definition of major depression, the meta-analysis conducted by Rocha et al. found SSRIs were 
superior to placebo.
116,117
 Despite the lack of consistent empirical evidence regarding their 
efficacy, SSRIs were still the most commonly prescribed medication for treating depression in 
PD.
118
 This may be because SSRIs are less likely to have adverse events such as drowsiness, 
constipation, urinary retention, and hypotension compared to other antidepressants.
99
 Currently, 
no one SSRI agent has demonstrated superior efficacy to another.
94,119
 But fluoxetine, 
fluvoxamine, and paroxetine are more likely to cause potential drug interactions through the 
inhibition of cytochrome P450.
99
 There is concern that SSRIs may worsen motor symptoms of 
PD. Nevertheless, previous studies failed to establish the association between SSRIs and 
worsening motor function in PD patients.
99,119-121
 Although the drug interaction between SSRIs 





(2) Tricyclic antidepressants (TCAs) 
 The TCAs inhibit the reuptake of both norepinephrine and serotonin at the synaptic cleft. 
Despite their potency of blocking muscarinic, α1 adrenergic, and histamine receptors, TCAs may 
be prescribed to treat depression in PD patients.
99,118
 Several TCAs have shown the efficacy of 
treating depression in PD, including amitriptyline, imipramine, desipramine, and nortriptyline. 
The meta-analysis conducted by Rocha et al. concluded that TCAs were more efficacious than 
SSRIs in depression treatment among PD patients.
116
 However, TCAs are not usually 
recommended as the first-line option for depression in PD because of their unfavorable side 
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effect profiles. TCAs are associated with the potential risk of exacerbating the pre-existing non-
motor symptoms such as orthostatic hypotension, cognitive dysfunction, constipation, and 
urinary retention. Monitoring of serum levels and electrocardiograms should be  performed for 
patients taking TCAs, due to associated cardiac conduction problems.
99
 Currently, there is no 
evidence suggesting that the efficacy of one TCA agent is superior to another. But tertiary amine 
TCAs (e.g., amitriptyline and imipramine) are associated with more potent antimuscarinic side 




(3) Other antidepressants 
 Bupropion is an antidepressant that inhibits both dopaminergic and norepinephrine 
reuptake. The efficacy of using bupropion to treat depression in PD has not been confirmed. 
Serotonin norepinephrine reuptake inhibitors (SNRIs) can also be used for depression in PD. 
These include desvenlafaxine, duloxetine, milnacipran, and venlafaxine. Previous studies 
showed that duloxetine and venlafaxine were well tolerated and ameliorated depressive 
symptoms among PD patients.
123,124
 Rocha et al. also concluded that SSRIs and SNRIs might be 
similarly efficacious in treating depression in PD.
116
 Other antidepressants that have been used 
for treating depression in PD are mirtazapine, moclobemide, selegiline, atomoxetine, reboxetine, 
nefazodone, trazodone, and vilazodone. Some of these antidepressants have limited evidence of 





(4) Dopamine Agonists 
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 Several studies examined the antidepressant properties of dopamine agonists in PD 
patients and mixed results were reported.
125-128
 Some studies found that pramipexole improved 
depressive symptoms and was efficacious in treating depression among PD patients.
125,126,128
 One 
RCT even concluded that pramipexole may be an alternative option for treating depression in 
PD.
127
 Another study also reported that a rotigotine transdermal system may improve depressive 
symptoms in PD.
129
 However, some of the efficacy studies did not use DSM or ICD criteria to 
capture depression diagnosis and the actual improvement of depressive symptoms might not be 
clinically significant.
127,128
 Additionally, other studies did not find the improvement in 
depression symptoms among PD patients using pramipexole.
130,131
   
 
1.2.3.2 Non-pharmacologic Treatment 
 Cognitive behavioral therapy (CBT) is a psychosocial intervention that can be used to 
treat depression in PD patients. A CBT package includes the structural training of behavioral 
activation, exercise, sleep hygiene, relaxation techniques, cognitive restructuring, and caregiver 
support.
98
 CBT can be used as an adjunctive treatment to pharmacotherapy in treating mild-to-
moderate depression in PD, and several studies have shown its efficacy in improving depressive 
symptoms.
132,133
 Electroconvulsive therapy (ECT) is thought to stimulate various 
neurotransmitters and has shown its efficacy in treating depression among PD patients.
98,99,134
 
However, due to its main side effect — cognitive impairment and occasional delirium — ECT is 
usually reserved for patients with severe and medication-resistant depression.
99
 Another less 
invasive intervention than ECT is the repetitive transcranial magnetic stimulation (rTMS). 
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However, further studies are still needed to evaluate and confirm its efficacy in treating 
depression in PD.
99
     
 
1.2.4 Impact of Depression on PD 
 Several studies have reported that depression may adversely affect the course of PD as it 
may have a negative influence on motor function, cognitive performance, daily functioning, 
medication compliance, quality of life, healthcare resource utilization, and costs among PD 
patients.
135-139
 Using the Unified Parkinson's Disease Rating Scale (UPDRS), Papapetropoulos et 
al. observed that depressed PD patients had greater disease severity and poorer motor function 
than non-depressed counterparts.
135
 A subsequent longitudinal study conducted by Ng et al. 
found similar results. The authors reported that depression might be associated with worse motor 
and cognitive functions.
138
 Pontone et al. examined the impact of depression on disability in PD 




 Depression can affect medication taking behavior in PD patients. Several studies have 
identified depression as a predictor of non-compliance to antiparkinson medications. Richy et al. 
used the US PharMetrics claims database to examine non-compliance (defined as without PD-
related medication for > 20% of the follow-up period) among commercially insured population. 
The authors found that depression was significantly associated with non-compliance in PD 
patients (No depression diagnosis [reference=depression diagnosed]: OR = 0.79, 95% CI = 0.74-
0.85, p < 0.001)
28
 Another UK observational study defined compliance as the percentage of dose 
taken compared to the total dose prescribed, and also reported similar results.
75
 In addition, one 
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previous study using  a 5% sample of the 2006-2007 Medicare database revealed that depressed 
PD patients were more likely to have regimen modifications (defined as switching and/or 
augmentation) of their antiparkinson medications.
84
   
 Depression has also been linked with lower health-related quality of life (HRQoL) among 
PD patients. Duncan et al. conducted a prospective longitudinal study and used the Parkinson’s 
Disease Quality of Life Questionnaire (PDQ-39) to measure HRQoL. The authors found 
depression was associated with lower HRQoL, and among other non-motor symptoms, 
depression had the greatest negative impact on HRQoL in PD patients.
139
 Using the Health 
Utilities Index Mark 3 (HUI3), Jones reported that the overall HUI3 scores among respondents 
with depression were lower than those without depression (0.20 vs. 0.49, p < 0.05).
141
 Shearer et 
al. analyzed the data from a community-based prospective study and captured HRQoL using the 
EQ-5D. They observed the health state value among PD patients with depression was reduced by 
0.12 (on a scale of 0 to 1), which indicated that depression had a negative impact on HRQoL.
142
  
 Only a few studies investigated healthcare resource utilization among depressed PD 
patients in the literature. Chen et al. conducted a cross-sectional study that assessed utilization by 
male veterans with PD during fiscal year 2002 using the Department of Veterans Affairs (VA) 
national databases. The authors found that compared with non-depressed PD patients, depressed 
PD patients had more frequent medical (OR = 1.34, 95% CI = 1.25-1.44, p < 0.001) and 
psychiatric hospitalizations (OR = 2.14, 95% CI = 1.83-2.51, p < 0.001), as well as more total 
outpatient visits (mean number of visits: 27.0 vs. 15.9, p < 0.001).
136
 Qureshi et al. also used the 
VA national databases and retrospectively assessed utilization by male PD patients for 12 years. 
They reported that depressed PD patients were more likely to have outpatient medical/surgical 
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visits (7.7 vs. 5.0, p = 0.004), mental health visits (1.2 vs. 0.2, p = 0.006), and neurology visits 
(8.3 vs. 6.1, p = 0.08) than those non-depressed PD patients.
143
 In addition, depression has been 
recognized as one of the cost-driving factors in PD patients. Winter et al. conducted a 
longitudinal study in Germany. During the 12-month follow-up period, they found that 
depression was significantly associated with higher out-of-pocket costs among PD patients (b = 
€420, 95% CI = €34-€1,208, p < 0.05).
144
 Another British study evaluated costs among 
community PD patients and their regression model revealed that depression was a significant 
predictor of higher costs (b = £257, 90% CI = £33-£482 for each unit increase in the geriatric 
depression score, p <0.05]).
145
 When examining the costs difference between depressed and non-
depressed PD patients, one German study analyzed the PD-related medication costs and found 
that depressed PD patients had lower PD-related medication costs than those who were non-
depressed (€6.6/day vs. €7.6/day, p < 0.05).
146
 However, the authors did not discuss a possible 
explanation for the observed lower PD medication costs among depressed PD patients. 
 
1.2.5 Antidepressants Use in PD Patients with Comorbid Depression 
 There is little information regarding antidepressant use in treating depression among PD 
patients in “real-world” settings. One early study used a questionnaire to capture antidepressant 
use in PD and found that 26% of the PD patients received medications for depression.
147
 Gony et 
al. analyzed the data from the French Pharmacovigilance Database and reported that 21.7% of 
the PD patients received antidepressants.
120
 Previous studies also revealed that the majority of 
depressed PD patients did not receive any antidepressant. Weintraub et al. examined 100 patients 




 Using a French cross-sectional survey, Nègre-Pagès et al. found 
among the PD patients with possible/probable depressive symptoms, only 19% of them used 
antidepressants.
149
 Another cross-sectional study also reported that the proportions of PD patients 
not receiving any antidepressants but having mild or moderate-to-severe depressive symptoms 
were 83.3% and 75%, respectively.
150
 SSRIs were found to be more commonly used than TCAs 
in treating depression among PD patients. The Gony study found that SSRIs were used most 
often (51% of the time), followed by TCAs (41% of the time) in France. Chen et al. used VA 
data in the US to examine the antidepressants use between patients with and without PD. Their 
results showed that among PD patients with depression, a high proportion of patients received 
SSRIs (62.9%) while only 7.4% of the patients received TCAs. The most commonly prescribed 
antidepressant was sertraline (25.9%), followed by citalopram (19.8%) and paroxetine 
(12.6%).
118
 Another study published only in abstract form analyzed the data from the UK 
General Practice Research Database. The authors reported that among PD patients with 
depression, 21% of them used amitriptyline, 19% used fluoxetine, 14% used citalopram, 7% 




1.2.5.1 Summary of Section 
The prevalence of depression in PD remains high. Depression is a common non-motor symptom 
in PD caused by both psychosocial and neurobiological factors. Depression affects not only 
quality of life and the daily functioning among PD patients, but also the course of PD (motor and 
cognitive functions) and healthcare resource utilization.  TCAs and SSRIs are two main 
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medications for depression in PD, but little has been reported regarding antidepressant taking 
behaviors among PD patients. 
 
1.3 Section 3: Study Rationale, Objectives, and Hypotheses 
1.3.1 Study Rationale 
 As mentioned earlier in Section 1 and Section 2, PD is a prevalent neuropsychiatric 
disease associated with a significant humanistic and economic burden. Depression is a common 
non-motor symptom in PD. The evidence has shown that psychosocial factors may not be the 
main determinant in comorbid depression. Neurobiological factors may also play a role. 
Depression greatly impacts PD. Previous studies have revealed that compared to the non-
depressed PD patients, depressed PD patients are more likely to have worse motor function, 
cognitive impairment, disability, reduced quality of life, and higher healthcare resource 
utilization and costs. Because of the potential correlation between depression in PD and 
noradrenergic and serotonergic neuron degeneration, antidepressant use in depressed PD patients 
is an important consideration due to its potential disease-modifying effects in PD. Several studies 
have revealed that use of antidepressants can help control depression in PD and even ameliorate 
motor and cognitive dysfunction in depressed PD patients.
90-93
 Adherence to antidepressants may 
also be associated with the outcomes of the comorbid disease. One previous study reported that 
depressed patients who were adherent to antidepressants had lower medical costs associated with 
their other comorbid diseases such as coronary artery disease, dyslipidemia, and diabetes 
mellitus.
152
 Previous studies provide some information regarding the impact of depression on 
 49 
PD. However, studies on the effects of better adherence to antidepressants and better control of 
depression on healthcare resource utilization and costs among PD patients are lacking. In 
addition, there is a gap in the literature concerning antidepressant utilization patterns such as 
adherence, persistence, as well as regimen modifications, such as switching, and changing to 
combination therapy, of antidepressants in depressed PD patients.   
 
1.3.2 Purpose of Study 
This study aimed to examine antidepressant use patterns (adherence, persistence, regimen 
modifications — switching and changing to combination therapy) and evaluate the associated 
healthcare resource utilization and costs in PD patients with comorbid depression. 
 
1.3.3 Objectives and Hypotheses  
The study objectives and hypotheses are: 
1) To describe baseline demographic and clinical characteristics among PD patients with 
antidepressant treatment 
2) To describe antidepressant use patterns (index antidepressant type, adherence, persistence, 
switching, combination therapy) among PD patients with depression 
3) To identify the factors associated with being adherent to antidepressant (dichotomous 
variable, Yes/No) among PD patients with depression 
H3a: Age is not associated with being adherent to antidepressants after controlling for other 
covariates 
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H3b: Being female is not associated with being adherent to antidepressants after controlling 
for other covariates 
H3c: Geographic region is not associated with being adherent to antidepressants after 
controlling for other covariates 
H3d: Having anxiety is not associated with being adherent to antidepressants after controlling 
for other covariates 
H3e: Having psychosis is not associated with being adherent to antidepressants after 
controlling for other covariates 
H3f: Having dementia is not associated with being adherent to antidepressants after 
controlling for other covariates 
H3g: The CCI score is not associated with being adherent to antidepressants after controlling 
for other covariates 
H3h: Having regimen modification (switching or combination therapy) of the index 
antidepressant is not associated with being adherent to antidepressants after controlling 
for other covariates  
H3i: Pre-index PD-related total costs are not associated with being adherent to 
antidepressants after controlling for other covariates 
4) To identify the factors associated with antidepressant persistence among PD patients with 
depression 
H4a: Younger age is not associated with persistence after controlling for other covariates  
H4b: Being female is not associated with persistence after controlling for other covariates 
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H04c: Geographic region is not associated with persistence after controlling for other 
covariates 
H4d: Having anxiety is not associated with persistence after controlling for other covariates 
H4e: Having psychosis is not associated with persistence after controlling for other 
covariates 
H4f: Having dementia is not associated with persistence after controlling for other covariates 
H4g: The CCI scores is not associated with persistence after controlling for other covariates 
H4h: Having regimen modification of the index antidepressant is not associated with 
persistence after controlling for other covariates 
H4i: The pre-index PD-related total cost is not associated with persistence after controlling 
for other covariates 
5) To determine if all-cause healthcare resource utilization differs significantly between 
adherent and non-adherent antidepressants users while controlling for covariates. 
H05a: There is no significant difference in number of outpatient visits between adherent and 
non-adherent antidepressants users while controlling for covariates 
H05b: There is no significant difference in number of nursing facility days billed between 
adherent and non-adherent antidepressants users while controlling for covariates 
H05c: There is no significant difference in number of inpatient visits between adherent and 
non-adherent antidepressants users while controlling for covariates 
H05d: There is no significant difference in number of emergency room (ER) visits between 
adherent and non-adherent antidepressants users while controlling for covariates 
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6) To determine if PD-related healthcare resource utilization rates differs significantly between 
adherent and non-adherent antidepressants users while controlling for covariates. 
H06a: There is no significant difference in number of PD-related outpatient visits between 
adherent and non-adherent antidepressants users while controlling for covariates 
H06b: There is no significant difference in PD-related number of nursing facility days 
billed between adherent and non-adherent antidepressants users while controlling for 
covariates 
H06c: There is no significant difference in number of PD-related inpatient visits between 
adherent and non-adherent antidepressants users while controlling for covariates 
H06d: There is no significant difference in number of PD-related ER visits between 
adherent and non-adherent antidepressants users while controlling for covariates 
7) To determine if all-cause healthcare costs differ significantly between adherent and non-
adherent antidepressants users while controlling for covariates. 
H07a: There is no significant difference in all-cause outpatient costs between adherent and 
non-adherent antidepressants users while controlling for covariates 
H07b: There is no significant difference in all-cause nursing facility costs between adherent 
and non-adherent antidepressants users while controlling for covariates 
H07c: There is no significant difference in all-cause inpatient costs between adherent and 
non-adherent antidepressants users while controlling for covariates 
H07d: There is no significant difference in all-cause ER costs between adherent and non-
adherent antidepressants users while controlling for covariates 
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H07e: There is no significant difference in all-cause pharmacy costs between adherent and 
non-adherent antidepressants users while controlling for covariates 
H07f: There is no significant difference in all-cause total costs between adherent and non-
adherent antidepressants users while controlling for covariates 
8) To determine if PD-related healthcare costs differ significantly between adherent and non-
adherent antidepressant users while controlling for covariates. 
H08a: There is no significant difference in PD-related outpatient costs between adherent and 
non-adherent antidepressants users while controlling for covariates 
H08b: There is no significant difference in PD-related nursing facility costs between 
adherent and non-adherent antidepressants users while controlling for covariates 
H08c: There is no significant difference in PD-related inpatient costs between adherent and 
non-adherent antidepressants users while controlling for covariates 
H08d: There is no significant difference in PD-related ER costs between adherent and non-
adherent antidepressants users while controlling for covariates 
H08e: There is no significant difference in PD-related pharmacy costs between adherent and 
non-adherent antidepressants users while controlling for covariates 
H08f: There is no significant difference in PD-related total costs between adherent and non-






CHAPTER 2: METHODOLOGY 
2.1 Institutional Review Board (IRB) Approval  
 The study was submitted and reviewed by the Institutional Review Board (IRB) Board of 
The University of Texas at Austin. An exempt study with a waiver of informed consent was 
granted because this study only involved de-identified patient-level data (IRB protocol number: 
2016-06-0013). 
 
2.2 Study Design and Data Source 
 This study was a retrospective cohort study using administrative claims data from the 
Humana database, for years 2007 to 2010. This database contains medical, pharmacy, 
enrollment, and partial laboratory results data for fully insured patients with commercial and 
Medicare health plans. Detailed demographic and enrollment data were available. Information 
regarding physician office visits, outpatient visits, hospital admissions, procedures, and diagnosis 
codes were captured from the medical claims database. Information regarding outpatient 
prescription fills such as quantity of the medication fill, dispense date, and the National Drug 
Codes (NDCs) was extracted from the pharmacy database. The Humana database includes over 
12 million individuals and more than 5 million Medicare Advantage Plan members in the US. It 
covers all census regions in the US, with predominance in the Midwestern and Southern regions. 
These data are de-identified and are fully compliant with the Health Insurance Portability and 
Accountability Act (HIPAA) regulations. 
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2.3 Inclusion Criteria 
Patients who met the following criteria were included in the present study:  
 
 




b) Had a diagnosis of depression at any time in the medical claims during the study period. In 
order to be consistent with previous research, the following ICD-9-CM codes were used: 
mood disorder resulting from a general medical condition (293.83); major depressive 
disorder (296.2x and 296.3x); mood disorder, not otherwise specified (296.90); dysthymia 




c) Had either 1) at least 2 diagnoses of PD (International Classification of Disease, Ninth 
Revision, Clinical Modification [ICD-9-CM] Code 332.0) on different dates from the 6-
month pre-index period to 6 months after the index date, or 2) had one PD-related 
prescription (i.e., levodopa, carbidopa, dopamine agonist, monoamine oxidase type B 
inhibitor, or catechol-O-methyltransferase inhibitor, see Table 2.2) plus a diagnosis of PD 
within the 6-month pre-index period to 6 months after the index date
154
; 
d) Had continuous enrollment for at least 6 months before and 12 months after the index date;  
e) Were covered by a Medicare Advantage plan; and 




Table 2.1 List of antidepressants for depression in Parkinson’s disease 
Drug Class Generic Names 
Tricyclic Antidepressants 
(TCAs) 
amitriptyline, imipramine, desipramine, nortriptyline, 
trimipramine, clomipramine, doxepin 
Selective Serotonin Reuptake 
Inhibitors (SSRIs) 
citalopram, escitalopram, fluoxetine, fluvoxamine, 
paroxetine, sertraline 
Serotonin Norepinephrine 
Reuptake Inhibitors (SNRIs) 
desvenlafaxine, duloxetine, milnacipran, venlafaxine 




Table 2.2 List of antiparkinson medications 
Drug Class Generic Names 






Dopamine Agonists (DAs) bromocriptine, cabergoline, pramipexole, ropinirole 
Levodopa levodopa/ carbidopa, levodopa/carbidopa/entacapone 




2.4 Data Collection and Index Date 
 The Humana data from January 1, 2007 to December 31, 2010 were extracted for the 
present study. The index date was the date the patient was newly initiated on an antidepressant 
(AD) prescription (no AD 6 months prior) with a confirmatory diagnosis of depression during 
the identification period (July 1, 2007 to December 31, 2009; See Figure 2.1). Figure 2.1 










2.5 Study Variables 
2.5.1 Dependent Variables 
 The dependent variables in the present study were: 1) Treatment patterns (i.e., adherence 
and persistence), and 2) Healthcare resource utilization and direct medical costs. A detailed 
description and operational definitions are provided below: 
 
1) Treatment patterns 
Medication Adherence to Antidepressants 
 Medication adherence was evaluated using proportion of days covered (PDC) during the 
12-month follow-up period. PDC was defined as ‘‘the number of days with drug on hand divided 
by the number of days in the specified time interval,’’ which generated a PDC value that falls 
between 0 and 1.
155




Identification period (30 months) 
Index date 
Post-index period (12 months) Pre-index period (6 months) 
Figure 2.1 Data extraction and patient identification period 
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Figure 2.2 Formula of proportion of days covered (PDC) 
PDC =  
Total days all drug(s) available
Days in the follow − up period
 
 
 In our present study, PDC was used to measure adherence to antidepressants and was 
calculated as the number of days with any antidepressant on hand divided by the number of days 
in the follow-up period (365 days). Because PD patients might start with only one antidepressant 
for the comorbid depression (monotherapy) then switch to or add another antidepressant 
(combination therapy), patients were allowed to switch to or add other antidepressants other than 
the index antidepressant. For objectives 5 to 8, patients were further categorized into adherent 
and non-adherent antidepressant users using 0.8 as the cut-off point for PDC as recommended in 
the literature.
157
 PD patients with PDCs ≥ 0.8 were considered as adherent, while those with 
PDCs < 0.8 were considered as non-adherent. Sensitivity analyses using PDC = 0.7 and 0.9 were 
also performed. 
 
Medication Persistence and Discontinuation of Antidepressants 
 Medication persistence refers to “the duration of time from initiation to discontinuation of 
therapy.”
71
 A permissible gap between an expected next refill and an actual refill is usually 
assigned. In line with previous studies examining antidepressant persistence, the allowable gap 
used in the present study was 30 days
158-160
 (Sensitivity analyses were also conducted for gaps of 
45, 60, and 90 days).
161
 Hence, the operational definition of medication persistence was the 
number of days from the first day any antidepressant was initiated (i.e., the index date) to the 
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discontinuation of all antidepressants without any 30-day gap. The operational definition of 
medication discontinuation was a refill gap of more than 30 days following a prescription.  
 
2) Healthcare Resource Utilization (HCRU) and Direct Healthcare Costs   
 The present study estimated all-cause and PD-related healthcare resource utilization 
(HCRU) and direct medical costs. All-cause HCRU was assessed as the number of outpatient 
visits, nursing facility days billed, inpatient visits, and emergency room (ER) visits during the 
12-month follow-up period. All-cause direct healthcare costs include costs corresponding to the 
above healthcare services use and costs of medications (i.e., pharmacy costs). The healthcare 
service use and costs associated with medical claims containing a PD diagnosis (ICD-9-CM 
Code 332.0 as primary or secondary diagnosis) were considered as PD-related HCRU and PD-
related medical costs. The costs of prescription claims for PD-related medications were 
considered as PD-related medication costs. All costs were adjusted to 2010 US dollars using the 
US Consumer Price Index for Medical Care. 
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Table 2.3 Operational definitions of dependent variables  




Adherence Continuous Adherence for AD use in the 12-month follow-up period 
measured by PDC.  
Adherence Categorical  
(Dichotomous) 
Adherence for AD use in the 12-month follow-up period 
measured by PDC.  
0 = Non-adherent (PDC < 0.8) 
1 = Adherent (PDC ≥ 0.8) 
Persistence Continuous The number of days from the first day that a patient initiated 
any AD (index-date) to the discontinuation of all ADs 
without any 30-day gap. Patients who took AD until the end 
of the 12-month follow-up were censored. 
All-cause utilization 
Number of all-cause 
outpatient (OP) visits 
Count Number of all-cause outpatient (OP) visits during the 12-
month follow-up period. It was categorized into OP-office, 
OP-home, and OP-other visits based on place of services— 
 OP-office visit: physician office 
 OP-home visit: location where the patient receives 
care in a private residence 
 OP-other visit: assisted living facility, mobile unit, 
urgent care facility, on campus-outpatient hospital, 
independent clinic, federally qualified health center, 
community mental health center, mass 
immunization center, end-stage renal disease 
treatment facility, public health clinic, rural health 
clinic, and independent laboratory 
Number of all-cause 
nursing facility days 
billed 
Count Number of all-cause nursing facility days billed during the 
12-month follow-up period 
Number of all-cause 
inpatient visits 
Count Number of all-cause inpatient visits during the 12-month 
follow-up period 
Number of all-cause 
emergency room (ER) 
visits 
Count Number of all-cause ER visits during the 12-month follow-
up period 
All-cause direct medical costs 
All-cause outpatient 
(OP) cost 
Continuous All-cause cost of outpatient (OP) visits during the 12-month 
follow-up period. It was categorized into OP-office, OP-
home, and OP-other costs based on place of services— 
 OP-office visit: physician office 
 OP-home visit: location where the patient receives 
care in a private residence 
 OP-other visit: assisted living facility, mobile unit, 
urgent care facility, on campus-outpatient hospital, 
independent clinic, federally qualified health center, 
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community mental health center, mass 
immunization center, end-stage renal disease 
treatment facility, public health clinic, rural health 
clinic, and independent laboratory 
All-cause nursing 
facility cost 
Continuous All-cause cost of nursing facility services during the 12-
month follow-up period 
All-cause inpatient cost Continuous All-cause cost of inpatient visits during the 12-month 
follow-up period 
All-cause emergency 
room (ER) cost 
Continuous All-cause cost of ER visits during the 12-month follow-up 
period 
All-cause pharmacy cost Continuous All-cause prescription costs during the 12-month follow-up 
period 
All-cause total cost Continuous Sum of all-cause OP, nursing facility, inpatient, ER, and 
pharmacy costs during the 12-month follow-up period 
PD-related utilization 
Number of PD-related 
outpatient (OP) visits 
Count Number of PD-related (with ICD-9-CM code: 332.0 as 
primary or secondary diagnosis) outpatient (OP) visits 
during the 12-month follow-up period. It was categorized 
into OP-office, OP-home, and OP-other visits based on place 
of services— 
 OP-office visit: physician office 
 OP-home visit: location where the patient receives 
care in a private residence 
 OP-other visit: assisted living facility, mobile unit, 
urgent care facility, on campus-outpatient hospital, 
independent clinic, federally qualified health center, 
community mental health center, mass 
immunization center, end-stage renal disease 
treatment facility, public health clinic, rural health 
clinic, and independent laboratory 
Number of PD-related 
nursing facility days 
billed 
Count Number of PD-related (with ICD-9-CM code: 332.0 as 
primary or secondary diagnosis) nursing facility days billed 
during the 12-month follow-up period 
Number of PD-related 
inpatient visit 
Count Number of PD-related (with ICD-9-CM code: 332.0 as 
primary or secondary diagnosis) inpatient visits during the 
12-month follow-up period 
Number of PD-related 
emergency room (ER) 
services 
Count Number of PD-related (with ICD-9-CM code: 332.0 as 
primary or secondary diagnosis) ER visits during the 12-
month follow-up period 
PD-related direct medical costs 
PD-related outpatient 
(OP) cost 
Continuous PD-related (with ICD-9-CM code: 332.0 as primary or 
secondary diagnosis) cost of outpatient (OP) visits during 
the 12-month follow-up period. It was categorized into OP-
office, OP-home, and OP-other costs based on place of 
services— 
 OP-office visit: physician office 
 OP-home visit: location where the patient receives 
care in a private residence 
Table 2.3 Operational definitions of dependent variables (continued) 
 (c 
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 OP-other visit: assisted living facility, mobile unit, 
urgent care facility, on campus-outpatient hospital, 
independent clinic, federally qualified health center, 
community mental health center, mass 
immunization center, end-stage renal disease 
treatment facility, public health clinic, rural health 
clinic, and independent laboratory 
PD-related nursing 
facility cost 
Continuous PD-related (with ICD-9-CM code: 332.0 as primary or 
secondary diagnosis) cost of nursing facility services during 
the 12-month follow-up period 
PD-related inpatient cost Continuous PD-related (with ICD-9-CM code: 332.0 as primary or 
secondary diagnosis) cost of inpatient visits during the 12-
month follow-up period 
PD-related emergency 
room (ER) cost 
Continuous PD-related (with ICD-9-CM code: 332.0 as primary or 




Continuous PD-related (with ICD-9-CM code: 332.0 as primary or 
secondary diagnosis) prescription costs during the 12-month 
follow-up period 
PD-related total cost Continuous Sum of PD-related (with ICD-9-CM code: 332.0 as primary 
or secondary diagnosis) OP, nursing facility, inpatient, ER, 
and pharmacy costs during the 12-month follow-up period 





2.5.2 Independent Variable and Covariates 
 The main independent variable was adherence status to the study antidepressant 
(Adherent: PDC ≥ 0.80, non-adherent: PDC < 0.80). Covariates controlled in the present study 
included baseline demographic and clinical characteristics, as well as the pre-index PD-related 
total costs. Covariates for the demographic characteristics include age, gender, and geographic 
region. Covariates for the clinical characteristics include the presence/absence of common 
comorbid neuropsychiatric and cognitive impairment diseases in PD patients (i.e. anxiety, 
psychosis, and dementia), the Charlson Comorbidity Index (CCI),
162,163
 and having regimen 
modification of an antidepressant. In the present study, regimen modification of an 
antidepressant was defined as switching or changing to a combination AD therapy. We did not 
Table 2.3 Operational definitions of dependent variables (continued) 
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include dose escalation as regimen modification for the current study because antidepressant 
treatment involves upward dose titration, thus dose escalation may not be suitable as a predictor 
or a controlled covariate for our study outcomes. Medication switching was defined as starting a 
new study antidepressant that was different from the index antidepressant within 30 days after 
the end of the index medication supply, and without a subsequent refill of the index 
antidepressant.
164,165
 Combination therapy referred to adding a new study antidepressant to the 
index antidepressant while continuing the refills of the index antidepressant without any 30-day 
gap.
164-166
 We only counted the first regimen change (having switching or changing to 
combination therapy) in our study. Pre-index PD-related (with PD diagnosis as the primary or 
secondary diagnosis) total cost (sum of medical services and pharmacy costs) was used as the 
surrogate marker for PD severity. The assigned weights for the CCI, ICD-9-CM codes for 
selected comorbid neuropsychiatric and cognitive diseases, as well as the operational definitions 






Table 2.4 Charlson Comorbidity Index (CCI) 
Comorbid Conditions  Weights ICD-9-CM Codes (Deyo Adaptation)  
Myocardial infarction  1 410.xx, 412  
Congestive heart failure  1 428.x  
Peripheral vascular disease  1 441.x, 443.9, 785.4, V43.4, procedure 38.48  
Cerebrovascular disease  1 430-437.x, 438  
Dementia  1 290.x  
Chronic pulmonary disease  1 490-496, 500-505, 506.4  
Connective tissue disease  1 710.0-710.1, 710.4, 714.0-714.2, 714.81, 725  
Ulcer disease  1 531.4x-531.7x, 532.4x-532.7x, 533.4x-533.7x, 
534.4x-534.7x, 531.0x-531.3x, 532.0x-532.3x, 
533.0x-533.3x, 534.0x-534.3x, 531.9, 532.9, 533.9, 
534.9  
Mild liver disease  1 571.2, 571.4, 571.5, 571.6  
Diabetes  1 250.0x-250.3x, 250.7x  
Diabetes with end organ 
damage  
2 250.4x-250.6x  
Hemiplegia  2 342.x, 344.1  
Moderate or severe renal 
disease  
2 582.x, 583.0-583.7, 585, 586, 588.x  
Any tumor  2 140.x-172.x, 174.x-195.x, 200.xx-208.xx  
Leukemia  2 
Lymphoma  2 
Moderate or severe liver 
disease  
3 572.2-582.8, 456.0-456.2x  
Metastatic solid tumor  6 196.x-199.x  





Table 2.5 Diagnosis codes for the common comorbid neuropsychiatric and cognitive impairment 
diseases  
Comorbid Neuropsychiatric and 
Cognitive Impairment Disease 
ICD-9-CM Code 
Anxiety 300, 309.24, 293.84 
Psychosis 298.0, 298.1, 298.4–298.9 (psychosis), 293.82, 368.16, 780.1 
(hallucinations), 293.81, 297.1 (delusions) 
Dementia 290.0, 290.1, 290.3, 290.4, 290.8, 290.9, 294.1, 294.8, 294.9, 
331.0, 331.1, 331.2, 797 
 
Source: Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in 
longitudinal studies: development and validation. Journal of chronic diseases. 1987;40(5):373-383. Deyo RA, Cherkin 
DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Journal of 








Main independent variable 
Adherence status Categorical 0 = Non-adherent (PDC < 0.80) 
1 = Adherent (PDC ≥ 0.80) 
Covariates   
Demographic characteristics 
Age Continuous Age at index date 
Gender Categorical 0 = Male 
1 = Female 
Geographic region Categorical 1 = Northeast, 2 = Midwest, 3 = South, 4 = 
West 
Clinical characteristics 
Having anxiety Categorical 0 = No, 1 = Yes 
Having psychosis Categorical 0 = No, 1 = Yes 
Having dementia Categorical 0 = No, 1 = Yes 
Charlson Comorbidity Index 
(CCI) score (Deyo adaptation) 
Continuous Sum of the corresponding weight for each 
comorbid disease (See Table 2.4) 
Having regimen modification Categorical Regimen modification refers to switching or 
changing to a combination therapy 
 Switching: starting a new study 
antidepressant that is different from the 
index antidepressant within 30 days 
after the end of the index medication 
supply; and without a subsequent refill 
of the index antidepressant 
 Combination therapy: adding a new 
study antidepressant to the index 
antidepressant while continuing the 
refills of the index antidepressant 
without any 30-day gap 
0 = No, 1 = Yes 
Other covariate 
Pre-index PD-related total 
cost 
Continuous Sum of the medical services and pharmacy costs 
for pre-index healthcare services use with a PD 




2.6 Statistical Analysis 
 Statistical Analysis System (SAS) version 9.4 (SAS Institute, Cary, NC, USA) and STATA 
version 12.1 (StataCorp, College Station, TX, USA) were used to conduct data management and data 
analyses. All statistical analyses used a two-tailed a priori significance level of α=0.05. Histograms 
and Shapiro Wilkes-tests were used to assess the data distribution. For objectives 1 and 2, descriptive 
statistics were provided. The comparisons for the categorical variables were performed using Pearson 
Chi-square tests, while the comparisons for the continuous variables were carried out using Wilcoxon 
rank-sum tests. For objective 2, Kaplan-Meier survival analysis was employed to describe and 
compare persistence among study patients. For objective 3, factors associated with being adherent 
(using 0.80 as the PDC cut-off value) were identified using logistic regression. For objective 4, 
factors associated with persistence were examined using Cox proportional hazards regression 
(sensitivity analyses with 45-, 60-, and 90-day gaps were conducted). Zero-inflated negative binomial 
(ZINB) or GzLM with negative binomial (NB) distributions and log link functions were used to 
address the healthcare resource utilization comparisons as appropriate (objectives 5 and 6). The 
choice of ZINB over NB models was based on the results of Vuong’s tests. Two-part models (part 1: 
logistic regression to predict the likelihood of having observation value greater than zero; part 2: 
GzLM with gamma distribution and log link function to estimate the value greater than zero) and 
GzLM with gamma distributions and log link functions were used to address the healthcare costs 
comparisons as appropriate (objectives 7 and 8). The use of two-part models or GzLMs depended on 
the data distribution. GzLMs were used to account for the positively skewed cost data, while two-part 
models were employed for cost data with both a “spike” of zero values and positively skewed cost 
data. Sensitivity analyses were conducted at PDC cut-off values of 0.70 and 0.90. A summary of the 
objectives, hypotheses, and the corresponding statistical analyses is provided in Table 2.7: 
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Table 2.7 Study objectives, hypotheses, and corresponding statistical analyses 







Objective 1: To describe and compare 
demographic and clinical characteristics 
among PD patients with depression 
Age Continuous Adherence 
status (Yes/No) 
Categorical Descriptive statistics & 
Wilcoxon rank sum test 
 Gender Categorical   Descriptive statistics & 
Pearson Chi-square test 
 Geographic region Categorical   Descriptive statistics & 
Pearson Chi-square test 
 Having anxiety Categorical   Descriptive statistics & 
Pearson Chi-square test 
 Having psychosis Categorical   Descriptive statistics & 
Pearson Chi-square test 
 Having dementia Categorical   Descriptive statistics & 
Pearson Chi-square test 
 Charlson 
Comorbidity Index 
(CCI) score  
Continuous   Descriptive statistics & 
Wilcoxon rank sum test 
 Pre-index PD-
related total cost 
Continuous   Descriptive statistics & 
Wilcoxon rank sum test 
Objective 2: To describe antidepressant use 
patterns (index antidepressant type, 
adherence, persistence, switching, 
combination therapy) among PD patients 
with depression 
Adherence Continuous -- -- Descriptive statistics  
 Adherence Categorical ( 
1 = Adherent 
[PDC ≥ 0.8], 0 
= Non-dherent 
[PDC < 0.8]) 
-- -- Descriptive statistics  
 Persistence Continuous -- -- Kaplan Meier survival 
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analysis 
 Switching Categorical -- -- Descriptive statistics  
 Combination 
therapy 
Categorical -- -- Descriptive statistics  
Objective 3: To identify the factors associated with being adherent among PD patients with depression 
H3a-4i: Age, gender, anxiety, psychosis, 
dementia, CCI score,  regimen modification, 
geographic region, pre-index PD-related 
total cost are not associated with adherence.  
Adherent status (1 = 
Adherent [PDC ≥ 
0.8], 0 = Non-

































Objective 4: To identify the factors associated with persistence among PD patients with depression 
H4a-4i: Age, gender, anxiety, psychosis, 
dementia, CCI score, regimen modification, 
geographical region, pre-index PD-related 










Cox proportional hazards 
regression  























Objective 5: To determine if all-cause healthcare resource utilization differs significantly between adherent and non-adherent antidepressants users 
while controlling for covariates 
H05a: There is no significant difference in 
number of all-cause outpatient visits 
between adherent and non-adherent 
antidepressants users while controlling for 
covariates. 
Number of all-cause 




Yes [PDC ≥ 
0.8] or No 
[PDC < 0.8]) 
Categorical Zero-inflated negative 
binomial (ZINB) model / 
Generalized linear model 
(GzLM) with negative 
binomial (NB) distribution 
and log link function 
H05b: There is no significant difference in 
number of all-cause nursing facility days 
billed between adherent and non-adherent 
antidepressants users while controlling for 
covariates. 
Number of all-cause 





Yes [PDC ≥ 
0.8] or No 
[PDC < 0.8]) 
Categorical Zero-inflated negative 
binomial (ZINB) model 




H05c: There is no significant difference in 
number of all-cause inpatient visits between 
adherent and non-adherent antidepressants 
users while controlling for covariates. 





Yes [PDC ≥ 
0.8] or No 
[PDC < 0.8]) 
Categorical Zero-inflated negative 
binomial (ZINB) model 
H05d: There is no significant difference in 
number of all-cause emergency room (ER) 
visits between adherent and non-adherent 
antidepressants users while controlling for 
covariates. 






Yes [PDC ≥ 
0.8] or No 
[PDC < 0.8]) 
Categorical Zero-inflated negative 
binomial (ZINB) model 
Objective 6: To determine if PD-related healthcare resource utilization differs significantly between adherent and non-adherent antidepressants users 
while controlling for covariates 
H06a: There is no significant difference in 
number of PD-related outpatient visits 
between adherent and non-adherent 
antidepressants users while controlling for 
covariates. 
Number of PD-





Yes [PDC ≥ 
0.8] or No 
[PDC < 0.8]) 
Categorical Zero-inflated negative 
binomial (ZINB) model / 
Generalized linear model 
(GzLM) with negative 
binomial (NB) distribution 
and log link function 
H06b: There is no significant difference in 
number of PD-related nursing facility days 
billed between adherent and non-adherent 








Yes [PDC ≥ 
0.8] or No 
[PDC < 0.8]) 
Categorical Zero-inflated negative 
binomial (ZINB) model 
H06c: There is no significant difference in 
number of PD-related inpatient visits 
between adherent and non-adherent 








Yes [PDC ≥ 
0.8] or No 
[PDC < 0.8]) 
Categorical Zero-inflated negative 
binomial (ZINB) model 
H06d: There is no significant difference in Number of PD- Count Adherence Categorical Zero-inflated negative 




number of PD-related emergency room (ER) 
visits between adherent and non-adherent 
antidepressants users while controlling for 
covariates. 
related emergency 
room (ER) visits 
status 
(Dichotomous: 
Yes [PDC ≥ 
0.8] or No 
[PDC < 0.8]) 
binomial (ZINB) model 
Objective 7: To determine if all-cause healthcare costs differ significantly between adherent and non-adherent antidepressants users while controlling 
for covariates. 
H07a: There is no significant difference in 
all-cause outpatient costs between adherent 
and non-adherent antidepressants users 






Yes [PDC ≥ 
0.8] or No 
[PDC < 0.8]) 
Categorical Two-part model 
H07b: There is no significant difference in 
all-cause nursing facility costs between 
adherent and non-adherent antidepressants 






Yes [PDC ≥ 
0.8] or No 
[PDC < 0.8]) 
Categorical Two-part model 
H07c: There is no significant difference in 
all-cause inpatient costs between adherent 
and non-adherent antidepressants users 






Yes [PDC ≥ 
0.8] or No 
[PDC < 0.8]) 
Categorical Two-part model 
H07d: There is no significant difference in 
all-cause ER costs between adherent and 
non-adherent antidepressants users while 
controlling for covariates. 
All-cause ER costs Continuous Adherence 
status 
(Dichotomous: 
Yes [PDC ≥ 
0.8] or No 
[PDC < 0.8]) 
Categorical Two-part model 
H07e: There is no significant difference in 





Categorical Generalized linear model 
(GzLM) with gamma 




and non-adherent antidepressants users 
while controlling for covariates. 
(Dichotomous: 
Yes [PDC ≥ 
0.8] or No 
[PDC < 0.8]) 
distribution and log link 
function 
H07f: There is no significant difference in 
all-cause total costs between adherent and 
non-adherent antidepressants users while 
controlling for covariates. 
All-cause total costs Continuous Adherence 
status 
(Dichotomous: 
Yes [PDC ≥ 
0.8] or No 
[PDC < 0.8]) 
Categorical Generalized linear model 
(GzLM) with gamma 
distribution and log link 
function 
Objective 8: To determine if PD-related healthcare costs differ significantly between adherent and non-adherent antidepressants users while 
controlling for covariates. 
H08a: There is no significant difference in 
PD-related outpatient costs between 
adherent and non-adherent antidepressants 






Yes [PDC ≥ 
0.8] or No 
[PDC < 0.8]) 
Categorical Two-part model 
H08b: There is no significant difference in 
PD-related nursing facility costs between 
adherent and non-adherent antidepressants 






Yes [PDC ≥ 
0.8] or No 
[PDC < 0.8]) 
Categorical Two-part model 
H08c: There is no significant difference in 
PD-related inpatient costs between adherent 
and non-adherent antidepressants users 






Yes [PDC ≥ 
0.8] or No 
[PDC < 0.8]) 
Categorical Two-part model 
H08d: There is no significant difference in 
PD-related ER costs between adherent and 
non-adherent antidepressants users while 
PD-related ER costs Continuous Adherence 
status 
(Dichotomous: 
Categorical Two-part model 




controlling for covariates.  Yes [PDC ≥ 
0.8] or No 
[PDC < 0.8]) 
H08e: There is no significant difference in 
PD-related pharmacy costs between 
adherent and non-adherent antidepressants 






Yes [PDC ≥ 
0.8] or No 
[PDC < 0.8]) 
Categorical Two-part model 
H08f: There is no significant difference in 
PD-related total costs between adherent and 
non-adherent antidepressants users while 






Yes [PDC ≥ 
0.8] or No 
[PDC < 0.8]) 
Categorical Two-part model 




2.7 Statistical Tests Assumptions and Sample Size Calculations 
This section describes the statistical tests assumptions and the required sample size calculations. 
Objectives that only involve descriptive statistics and baseline characteristics comparisons were 
discussed here. All required sample sizes were calculated using G*Power and PASS 14 software, 
with α set at 0.05 and power at 0.8.  
2.7.1 Logistic Regression 
 Logistic regression is a statistical approach to predict a dichotomous variable value from 
other variables. The key assumptions for logistic regression include: 1) binary outcomes for the 
dependent variable; and 2) each observation is independent. Based on the calculation using 
G*Power, the minimum required sample size was 794 (See Table 2.9). 
2.7.2 Generalized Linear Model (GzLM) 
 The generalized linear model (GzLM) is a large class of statistical models that extend the 
general linear model to allow for response (dependent) variables (Y) with non-normal 
distributions.
172
 A GzLM includes three components: the probability distribution of the response 
variable, the combination of linear predictors, and a link function. The probability distribution of 
the response variable can be any member of the exponential (e.g., normal, binomial, gamma, 
Poisson, inverse-Gaussian distribution), multivariate exponential, (multinomial distribution), 
non-exponential families (e.g., two-parameter negative binomial distribution), or distribution that 
is not specified. A combination of linear predictors (η) refers to the explanatory variables (X) in 
the model (See Figure 2.3). A link function, g(·), specifies the relationship between the expected 
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value of the response variable and the linear predictor (See Figure 2.4).
172,173
 Some commonly 
used exponential families and the link functions are provided in Table 2.8.  
 
Figure 2.3 A combination of linear predictors 
ηi = α + β1Xi1 + β2Xi2 +···+ βkXik      
 
Figure 2.4 A link function 
μi ≡ E(Yi) 
g(μi) = ηi = α + β1Xi1 + β2Xi2 +···+ βkXik      
 
Table 2.8 Canonical link and response range for commonly used exponential families 
Exponential Family  Canonical Link  Range of Yi  
Gaussian  Identity  (-∞,∞)  
Binomial  Logit  (0,1,…ni)/ni  
Poisson  Log  0,1,2,..  
Gamma  Inverse  (0,∞)  
Inverse-Gaussian  Inverse-square  (0,∞)  
 
 
The assumptions of GzLM include: “1) statistical independence of the observations; 2) correct 
specification of the variance function; 3) correct specification of the dispersion parameter; 4) 
correct specification of the link function; 5) correct form for the explanatory variables; and 6) 
lack of undue influence of individual observations on the fit.”172  
 




Generalized Linear Models (GzLMs) with Gamma Distribution and Negative Binomial 
Distribution 
  Little has been reported in the literature regarding the sample size estimation for GzLMs 
with gamma distribution or negative binomial (NB) distribution. However, it has been suggested 
that the required sample size for a multiple regression analysis will be sufficient enough to detect 
statistical significance for GzLMs with gamma distributions.
174
 The sample size for multiple 
regression analysis for our present study was calculated using G*Power and the final estimated 
sample size is 822 (assuming power = 0.8; α = 0.05; small effect size (f
2
) = 0.02; number of 
predictors = 10), which was used as a proxy for sample size requirement for GzLMs with gamma 
distributions. 
  The function of sample size calculation for NB regression is not available in the current 
commonly used sample size estimation software. Because NB regression is an extension of 
Poisson regression,
175
 the required sample size for Poisson regression calculated by G*Power 
was used as a proxy. The healthcare resource utilization was assumed to be 5% higher in non-
adherent patients than the adherent patients at baseline. The detected difference in healthcare 
resource utilization was set at 10% or more. The distribution of the main independent variable 
was assumed to be binomial. The covariates were assumed to have a moderate association with 
the main predictor (X) and yielded an expected squared multiple correlation (R
2
 other X) of 0.3. 
The 12-month follow-up duration (365 days) was used as the mean exposure time. Based on the 
above assumptions and the proportion of non-adherent antidepressant users reported in previous 
studies (44.4 to 76.5%),
176,177
 the required minimum sample size was 261. 
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2.7.3 Cox Proportional Hazards Regression 
 Cox proportional hazards regression, a semi-parametric procedure to estimate the hazard 
of an event over time, identifies the relationship between survival time and explanatory 
variables. Cox proportional hazards regression allows unspecified form or shape of the 
underlying hazard function (h(t)) and assumes a fixed ratio of the hazards for any two individuals 
at any time point.
178,179
 The basic structure of the Cox proportional hazards regression can be 
depicted as shown in Figure 2.5.  




} = X1β1 + ……+ Xnβn   
hi (t): the hazard at time t  
h0 (t): the baseline hazard  
X: the independent variable or the covariates in the model  
β: the regression coefficient for the corresponding independent variable or the covariates  
The required sample size for the Cox proportional hazards regression was estimated using PASS 
14 software (Kaysville, Utah). Based on the reported event rates of discontinuing antidepressants 
(0.42 to 0.63),
176,180
 the minimum required sample size was 650. 
  
 78 


























Required sample size 794 822 261 650 




 other X = 0.3, odds ratio = 1.5,  Pr(Y=1|X=1) HO=0.05, assumed a Poisson distribution 
b
 Because the required sample size for the multiple regression will be sufficient for generalized linear models with a 
gamma distribution, the minimum sample size for multiple regression will be used as a proxy 
c
 Using the required sample size for a Poisson regression as the proxy with R
2
 other X=0.3, base rate Exp(β0)=0.05, 




 other X=0.3, log hazard ratio=1.5, Pr(Y=1|X=1) HO=0.42, SD of X=0.5 
 
Based on the above sample size calculation (Table 2.9), the required minimum sample size for 
the present study was 822.   
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CHAPTER 3: RESULTS 
3.1 Chapter Overview 
 This chapter provides a detailed description of study results. The patient selection 
process, statistical analyses, and hypothesis tests are presented for each objective.   
3.2 Patient Selection 
 There were 1,897,100 patients with at least two study antidepressant prescriptions on 
different dates between 01/01/2007 to 12/31/2010. Among them, 452,992 patients had a 
diagnosis of depression during the study period. After applying the criteria to identify PD 
patients, the sample size reduced to 4,514. Of those, 856 patients met the inclusion criteria for 
age, covered by MAPD plan, and sufficient continuous enrollment. A flowchart depicts study 
inclusion criteria, and the corresponding sample sizes are presented in Figure 3.1. 
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Figure 3.1 Diagram of patient selection process 
 
  
Number of patients with at least two study antidepressant prescriptions on different dates= 
1,897,100 
Number of patients who had at least one depression diagnosis during the study period= 
452,992 
Number of patients who had either 1) at least 2 diagnoses of PD on different dates from the 6-
month pre-index period to 6 months after the index date or ; 2) one PD-related prescription 
plus a diagnosis of PD within 6 months from the 6-month pre-index period to 6 months after 
the index date= 4,514 
Number of patients who had continuous enrollment for at least 6 months before and 12 
months after the index date= 1,002 
Number of patients who were covered by Medicare Advantage plan= 974 
Number of patients who wera ≥ 65 years old at the index date= 856 
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3.3 Study Objectives 
3.3.1 Objective 1: Demographic and Clinical Characteristics 
 Objective 1 was to describe and compare demographic and clinical characteristics among 
adherent and non-adherent antidepressant users. Demographic and clinical characteristics of the 
study sample are shown in  Table 3.1.  
 The mean age for the study patients was 75.4 (±5.5) years old. Slightly less than half of 
them were females (47.1%). The majority of the patients resided in the southern US (59.4%). 
The average CCI was 2.2 (±2.5). More than one-fifth of the patients had anxiety (23.6%) or 
dementia (27.2%). Only 11% of the patients had a regimen modification. The mean pre-index 
PD-related total cost was $4,973 (±$11,462). Among the 856 patients, 58.5% (N = 501) of them 
were non-adherent to their antidepressants (i.e., PDC <0.8). 
 A significant difference in geographic region between adherent and non-adherent 
antidepressant (AD) users was observed (p= 0.032). When compared to patients who were non-
adherent to AD, patients who were adherent to AD had higher proportions of psychosis (10.4% 
vs. 4.8%, p= 0.002) and dementia (31.3% vs. 24.4%, p= 0.025). More adherent AD users had 
regimen modifications than non-adherent AD users (17.2% vs. 6.6%, p <0.001). Additionally, 




 Table 3.1 Demographic and clinical characteristics of adherent versus non-adherent patients 
AD = antidepressant; SD = standard deviation; PD = Parkinson’s disease  
a
 Wilcoxon rank-sum test 
b
 Chi-square test 
*Significant at p < 0.05 
 
 
3.3.2 Objective 2: Antidepressant Use Patterns 
 Objective 2 was to describe antidepressant use patterns (index antidepressant type, 
adherence, persistence, switching, and combination therapy) among PD patients with depression. 
Among the type of antidepressants, most of the patients were prescribed SSRIs at the index date 
(68.1%), followed by other ADs (17.8%), SNRIs (9%), and then TCAs (5.1%). The most 
common antidepressant prescriptions were for citalopram (38.0%) and sertraline (14.1%). The 
mean PDC (±SD) for antidepressant medications was 0.63 (± 0.31). When measuring adherence 
as a dichotomous variable using PDC = 0.8 as the cut-off value, 41.5% of the study sample were 
adherent (PDC ≥0.8). The mean and median time to discontinuation of any antidepressant 




to AD (N=501) 
Adherent to 




 75.4 (5.5) 75.2 (5.4) 75.7 (5.6) 0.124 
Females (%)
 b
 47.1 44.3 51.0 0.054 
Region (%)
 b
    0.032* 
      Midwest 28.7 25.6 33.2  
      Northeast 3.2 2.6 3.9  
      South 59.4 61.9 55.8  
      West 8.8 10.0 7.0  




2.2 (2.5) 2.1 (2.3) 2.5 (2.7) 0.055 
Having anxiety (%)
 b
 23.6 22.8 24.8 0.490 
Having psychosis (%)
 b
 7.1 4.8 10.4 0.002* 
Having dementia (%)
 b
 27.2 24.4 31.3 0.025* 
Having regimen modification (%)
 b
 11.0 6.6 17.2 <0.001* 












taking antidepressants after six months, and 32.0% of the patients continued their antidepressants 
for at least one year. Figure 3.2 is the Kaplan-Meier curve showing the percentage of patients 
who remain persistent on antidepressants during the 1-year follow-up period. Regimen 
modification occurred in 11% of the patients, 2.1% of them switched from their index 
antidepressant to another antidepressant, and 8.9% of them changed to a combination therapy for 
depression treatment. 
Table 3.2 Type of index antidepressant prescribed 
Index Antidepressants Use Frequency % 
Amitriptyline 29 3.39 
Doxepin 3 0.35 
Imipramine 7 0.82 
Nortriptyline 5 0.58 
Any TCAs 44 5.14 
   
Citalopram 325 37.97 
Fluoxetine 80 9.35 
Paroxetine 57 6.66 
Sertraline 121 14.14 
Any SSRIs 583 68.11 
   
Duloxetine 44 5.14 
Venlafaxine 33 3.86 
Any SNRIs 77 9.00 
   
Bupropion 24 2.80 
Mirtazapine 65 7.59 
Trazodone 63 7.36 
Any other antidepressant 152 17.76 
TCAs = tricyclic antidepressants; SSRIs = selective serotonin reuptake inhibitors; SNRIs = serotonin 
norepinephrine reuptake inhibitors   
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Table 3.3 Persistence to antidepressants 
Variable Description Time to Discontinuation 
(Persistence) 
Number of patients with discontinuation, N (%) 582 (68.0%) 
Time to discontinuation, adjusting for censoring, Mean (days) 194.2 
Time to discontinuation, adjusting for censoring, Median (days) 163.5 
Percentage of Patients remaining on antidepressant at time points:  
    3 months, % (95% CI) 62.3 (58.9, 65.4) 
    6 months, % (95% CI) 47.3 (43.9, 50.6) 
    9 months, % (95% CI) 39.4 (36.1, 42.6) 
  12 months, % (95% CI) 32.0 (28.9, 35.1) 
 
 





Figure 3.3 Treatment change patterns 
 
 
3.3.3 Objective 3: Adherence 
 Objective 3 was to identify the factors associated with being adherent to antidepressant 
treatment (dichotomous variable, Yes = ‘PDC ≥ 0.8’, No = ‘PDC < 0.8’) among PD patients with 
depression. Logistic regression showed that CCI score and regimen modification were 
significantly associated with being adherent (Table 3.4). For every one point increase in CCI 
score, patients were 6% more likely to be adherent to their antidepressant (OR =1.063, 95% CI = 
[1.003, 1.126], p = 0.039). Patients who had a regimen modification were almost 3 times more 
likely to be adherent to antidepressant therapy (OR = 2.966, 95% CI = [1.879, 4.682], p < 0.001). 
  






















Age 1.014 0.988 1.041 1.0801 0.299 
Female (ref = Male) 1.324 0.996 1.761 3.7228 0.054 
Region (ref = Northeast)       
      Midwest  0.917 0.402 2.09 0.0427 0.836 
      South    0.634 0.284 1.417 1.2335 0.267 
      West    0.535 0.212 1.348 1.7617 0.184 
Charlson Comorbidity Index (CCI) 1.063 1.003 1.126 4.2461 0.039* 
Having Anxiety 1.117 0.798 1.563 0.4175 0.518 
Having Psychosis 1.712 0.962 3.045 3.344 0.067 
Having Dementia 1.137 0.816 1.585 0.5792 0.447 
Regimen Modification
a 2.966 1.879 4.682 21.8094 <0.001* 
Pre-Index PD-Related Total Cost 1 1 1 1.8395 0.175 
Model Fit Statistics: Likelihood ratio = 53.4925, df = 11, p < 0.001 
*Significant at p < 0.05 
a: AD switch or combination therapy 
 
 
H3a: Age is not associated with being adherent to antidepressants after controlling for other 
covariates. (Not rejected) 
H3b: Being female is not associated with being adherent to antidepressants after controlling for 
other covariates. (Not rejected) 
H3c: Geographic region is not associated with being adherent to antidepressant after controlling 
for other covariates. (Not rejected) 
H3d: Having anxiety is not associated with being adherent to antidepressants after controlling for 
other covariates. (Not rejected) 
H3e: Having psychosis is not associated with being adherent to antidepressants after controlling 
for other covariates. (Not rejected) 
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H3f: Having dementia is not associated with being adherent to antidepressants after controlling 
for other covariates. (Not rejected) 
H3g: The CCI score is not associated with being adherent to antidepressants after controlling for 
other covariates. (Rejected) 
H3h: Having regimen modification of the index antidepressants is not associated with being 
adherent to antidepressants after controlling for other covariates. (Rejected) 
H3i: The pre-index PD-related total cost is not associated with being adherent to 
antidepressants after controlling for other covariates. (Not rejected) 
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3.3.4 Objective 4: Persistence 
 Objective 4 was to identify the factors associated with antidepressant persistence among 
PD patients with depression. A Cox proportional hazards regression model with a 30-day gap 
was used to address this objective (Table 3.5). Sensitivity analyses were conducted using 45-, 
60-, and 90-day gaps. The results showed that patients with regimen modification were more 
persistent to antidepressant (36.9% less likely to discontinue their antidepressant) than those 
without regimen modification (Hazard ratio = 0.631, 95% CI = [0.474, 0.841], p = 0.0016). 
Results of the sensitivity analyses remained robust at 45-, 60-, and 90-day gap periods (Table 
3.6, Table 3.7, and Table 3.8). 
Table 3.5 Cox proportional hazards model results to identify factors associated with persistence 
to antidepressant (with a 30-day gap) 
Covariate Hazard 
Ratio 






Age 0.995 0.98 1.01 0.4878 0.485 
Female (ref = Male) 0.86 0.729 1.015 3.169 0.075 
Region (ref= Northeast)       
      Midwest 0.975 0.582 1.634 0.009 0.924 
      South 1.156 0.699 1.912 0.3194 0.572 
      West 1.184 0.676 2.073 0.3491 0.555 
Charlson Comorbidity Index (CCI) 0.972 0.938 1.007 2.5003 0.114 
Having anxiety 0.951 0.779 1.161 0.2417 0.623 
Having psychosis 0.736 0.507 1.066 2.6303 0.105 
Having dementia 0.938 0.771 1.141 0.4128 0.521 
Regimen modification 0.631 0.474 0.841 9.92 0.0016* 
Preindex PD-related total cost 1 1 1 0.9483 0.330 
Model Fit Statistics: Likelihood ratio = 31.3128, df = 11, p = 0.001 




Table 3.6 Cox proportional hazards model results to identify factors associated with persistence 
to antidepressant (with a 45-day gap) 
Covariate Hazard 
Ratio 






Age 0.998 0.982 1.014 0.0806 0.777 
Female (ref = Male) 0.858 0.72 1.022 2.9459 0.086 
Region (ref= Northeast)      
      Midwest 0.953 0.549 1.656 0.0288 0.865 
      South 1.207 0.706 2.065 0.4733 0.492 
      West 1.201 0.661 2.183 0.36 0.549 
Charlson Comorbidity Index (CCI) 0.972 0.936 1.009 2.2753 0.132 
Having anxiety 0.882 0.714 1.09 1.3491 0.245 
Having psychosis 0.728 0.486 1.089 2.3855 0.123 
Having dementia 0.932 0.757 1.148 0.4398 0.507 
Regimen modification 0.578 0.421 0.794 11.4823 0.001* 
Preindex PD-related total cost 1 1 1 0.6624 0.416 
Model Fit Statistics: Likelihood ratio = 35.2394, df = 11, p = 0.0002 
*Significant at p < 0.05 
 
Table 3.7 Cox proportional hazards model results to identify factors associated with persistence 
to antidepressant (with a 60-day gap) 
Covariate Hazard 
Ratio 






Age 0.994 0.978 1.011 0.4139 0.520 
Female (ref = Male) 0.863 0.717 1.038 2.4488 0.118 
Region (ref= Northeast)      
      Midwest 1.021 0.563 1.852 0.0048 0.945 
      South 1.297 0.727 2.315 0.7756 0.379 
      West 1.288 0.679 2.445 0.6012 0.438 
Charlson Comorbidity Index (CCI) 0.973 0.935 1.012 1.8496 0.174 
Having anxiety 0.891 0.713 1.113 1.0415 0.308 
Having psychosis 0.666 0.431 1.029 3.3462 0.067 
Having dementia 0.961 0.772 1.197 0.1244 0.724 
Regimen modification 0.446 0.308 0.647 18.161 <0.001* 
Preindex PD-related total cost 1 1 1 0.3491 0.555 
Model Fit Statistics: Likelihood ratio = 43.3627, df = 11, p < 0.0001 




Table 3.8 Cox proportional hazards model results to identify factors associated with persistence 
to antidepressant (with a 90-day gap) 
Covariate Hazard 
Ratio 






Age 0.997 0.979 1.015 0.0967 0.756 
Female (ref = Male) 0.849 0.696 1.036 2.5969 0.107 
Region (ref= Northeast)      
      Midwest 1.073 0.56 2.056 0.0446 0.833 
      South 1.284 0.681 2.421 0.5949 0.441 
      West 1.375 0.686 2.757 0.8044 0.370 
Charlson Comorbidity Index (CCI) 0.985 0.945 1.027 0.4977 0.481 
Having anxiety 0.871 0.684 1.108 1.2684 0.260 
Having psychosis 0.699 0.438 1.115 2.2574 0.133 
Having dementia 0.870 0.685 1.105 1.2995 0.254 
Regimen modification 0.411 0.272 0.621 17.7793 <0.001* 
Preindex PD-related total cost 1 1 1 0.0127 0.910 
Model Fit Statistics: Likelihood ratio = 39.1492, df = 11, p < 0.0001 
*Significant at p < 0.05 
 
 
H4a: Age is not associated with persistence after controlling for other covariates. (Not rejected) 
H4b: Being female is not associated with persistence after controlling for other covariates. (Not 
rejected) 
H04c: Geographic region is not associated with persistence after controlling for other covariates. 
(Not rejected) 
H4d: Having anxiety is not associated with persistence after controlling for other covariates. 
(Not rejected) 
H4e: Having psychosis is not associated with persistence after controlling for other covariates. 
(Not rejected) 
 91 
H4f: Having dementia is not associated with persistence after controlling for other covariates. 
(Not rejected) 
H4g: The CCI scores is not associated with persistence after controlling for other covariates. 
(Not rejected) 
H4h: Having regimen modification of the index antidepressants is not associated with 
persistence after controlling for other covariates. (Rejected) 
H4i: The pre-index PD-related total cost is not associated with persistence after controlling for 
other covariates. (Not rejected) 
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3.3.5 Objective 5: All-cause Healthcare Resource Utilization (HCRU) 
 All-cause medical claims for depressed PD patients with AD were examined (A summary 
of number of claims for different utilization was presented in Appendix 1). Objective 5 involved 
the comparisons between adherent and non-adherent antidepressants (AD) users with regard to 
all-cause outpatient visits (OP-office, OP-home, and OP-other), nursing facility days billed, 
inpatient visits, and ER visits.  
 
3.3.5.1 All-cause HCRU comparison (Unadjusted analysis) 
 The unadjusted numbers of all-cause HCRU comparisons were estimated using Wilcoxon 
rank-sum tests. No significant differences were found in all-cause HCRU between adherent and 
non-adherent AD users using the PDC cut-off value of 80% (Table 3.9). For the sensitivity 
analyses: when the cut-off value for was set at “PDC = 0.70”, the unadjusted median numbers of 
all-cause OP-other visits were higher in adherent AD users than those who were non-adherent 
(5.00 vs. 6.00, p = 0.034). Although the median numbers for nursing facility days billed were 
equal, significant difference was found in Wilcoxon rank sum test and adherent AD users had 
more number of nursing facility days billed than those who were non-adherent (median: 0.00 vs. 
0.00, mean rank: 419.94 vs. 442.00, p = 0.029) (Table 3.10). When the cut-off value was set at 
“PDC = 0.90”, the unadjusted median number of all-cause inpatient visits was significantly 




Table 3.9 Unadjusted numbers of all-cause healthcare resource utilization comparisons (Cut-off 
value for being adherent: PDC = 0.80) 










Median IQR Median IQR Median IQR   
# of OP-office visit  14.00 14.00 15.00 16.00 13.00 13.00 -1.395 0.163 
# of OP-home visit 1.00 8.50 1.00 9.00 1.00 8.00 -0.354 0.724 
# of OP-other visit 6.00 8.00 6.00 8.00 6.00 9.00 1.514 0.130 
# of nursing facility days billed  0.00 3.00 0.00 2.00 0.00 4.00 1.645 0.100 
# of inpatient visit 1.00 2.00 1.00 2.00 0.00 2.00 -1.736 0.083 
# of ER visit 0.00 1.00 0.00 1.00 0.00 1.00 0.815 0.415 
Note: Wilcoxon rank-sum tests were used. AD = antidepressant; IQR = interquartile range; OP = 





Table 3.10 Unadjusted numbers of all-cause healthcare resource utilization comparisons (Cut-off 
value for being adherent: PDC = 0.70) 
All-cause Medical Service 
Non-adherent 






Median IQR Median IQR   
# of OP-office visit  15.00 16.00 14.00 13.00 1.5401 0.124 
# of OP-home visit 1.00 8.00 1.00 9.00 0.0259 0.979 
# of OP-other visit 5.00 7.00 6.00 9.00 -2.1259 0.034* 
# of nursing facility days billed  0.00 2.00 0.00 5.00 -2.1798 0.029* 
# of inpatient visit 1.00 2.00 0.00 2.00 1.1619 0.245 
# of ER visit 0.00 1.00 0.00 1.00 -0.4053 0.685 
Note: Wilcoxon rank-sum tests were used. AD = antidepressant; IQR = interquartile range; OP = 
outpatient; ER = emergency room 





Table 3.11 Unadjusted numbers of all-cause healthcare resource utilization comparisons (Cut-off 
value for being adherent: PDC = 0.90) 





Median IQR Median IQR   
# of OP-office visit  15.00 14.00 13.00 12.00 -1.4639 0.143 
# of OP-home visit 1.00 10.00 0.00 7.00 -1.941 0.052 
# of OP-other visit 6.00 9.00 6.00 8.00 0.261 0.794 
# of nursing facility days billed  0.00 3.00 0.00 1.50 -0.3028 0.762 
# of inpatient visit 1.00 2.00 0.00 1.00 -3.4488 0.001* 
# of ER visit 0.00 1.00 0.00 1.00 0.437 0.662 
Note: Wilcoxon rank-sum tests were used. AD = antidepressant; IQR = interquartile range; OP = 
outpatient; ER = emergency room 




3.3.5.2 All-cause HCRU comparison (Adjusted analysis) 
 Based on the results from Vuong tests, zero-inflated negative binomial models were used 
for the comparisons in number of nursing facility days billed, OP-office, OP-home, and inpatient 
visits; GzLMs with negative binomial distribution and log link function were performed for OP-
other and ER visits (Outputs were presented in Appendix 3 to Appendix 8). After adjusting for 
age, gender, geographical region, presence of specific comorbidities (anxiety, psychosis, and 
dementia), Charlson Comorbidity Index (CCI), having regimen modification, and pre-index 
Parkinson’s disease-related total cost, no significant difference was found in number of all-cause 
nursing facility days billed, outpatient (OP-office, OP-home, and OP-other), and ER visits for 
adherent versus non-adherent AD users. However, the results showed that non-adherent AD 
users had more frequent all-cause inpatient visits than adherent AD users during the 1-year 
follow-up period (1.4 vs. 1.0, p = 0.001) (Table 3.12). For the sensitivity analyses when the cut-
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off value for PDC was set at 0.7, no difference was found in the number of all-cause inpatient 
visits. Instead, more number of nursing facility days billed in adherent AD users than non-
adherent AD users was observed (4.20 vs. 6.23, p = 0.020) (Table 3.13). When a PDC cut-off of 




Table 3.12 Zero-inflated negative binomial model or GzLM adjusted all-cause healthcare 
resource utilization comparisons (Cut-off value for being adherent: PDC = 0.80) 
All-cause Medical 
Service 
Non-adherent to AD 
(N=501) 
Adherent to AD  
(N=355) 
p-value 
Mean SE 95% CI Mean SE 95% CI  
# of OP-office visit
a
  18.296 0.593 17.134 19.458 17.099 0.693 15.740 18.457 0.193 
# of OP-home visit
a
 9.796 1.115 7.610 11.982 9.676 1.150 7.422 11.930 0.933 
# of OP-other visit
b
 10.641 0.520 9.622 11.660 9.553 0.513 8.548 10.557 0.137 




4.629 0.569 3.513 5.745 6.062 0.788 4.518 7.606 0.134 
# of inpatient visit
a
 1.439 0.098 1.246 1.631 1.007 0.080 0.849 1.164 0.001* 
# of ER visit
b
 0.637 0.050 0.539 0.734 0.543 0.049 0.447 0.640 0.186 
Note: GzLM = generalized linear model; AD = antidepressant; SE = standard error; CI = confidence 
interval; OP = outpatient; ER = emergency room 
All models adjusted for age, gender, geographical region, presence of specific comorbidities (anxiety, 
psychosis, and dementia), Charlson Comorbidity Index (CCI), having regimen modification, and pre-
index Parkinson’s disease-related total cost. 
a
 Zero-inflated negative binomial model 
b
 GzLM with negative binomial distribution and a log link function 




Table 3.13 Zero-inflated negative binomial model or GzLM adjusted all-cause healthcare 
resource utilization comparisons (Cut-off value for being adherent: PDC = 0.70) 
All-cause Medical 
Service 
Non-adherent to AD (N=413) Adherent to AD (N=443) p-value 
Mean SE 95% CI Mean SE 95% CI  
# of OP-office visit
a
  18.555 0.692 17.200 19.910 17.047 0.626 15.820 18.273 0.108 
# of OP-home visit
a
 9.556 1.167 7.267 11.844 9.903 1.103 7.741 12.065 0.810 
# of OP-other visit
b
 10.159 0.536 9.109 11.210 10.132 0.488 9.177 11.088 0.970 
# of nursing 
facility days billed
a
 4.195 0.561 3.096 5.293 6.229 0.725 4.808 7.650 0.020* 
# of inpatient visit
a
 1.357 0.099 1.163 1.552 1.139 0.081 0.981 1.298 0.089 
# of ER visit
b
 0.648 0.055 0.539 0.757 0.551 0.045 0.463 0.639 0.175 
Note: GzLM = generalized linear model; AD = antidepressant; SE = standard error; CI = confidence 
interval; OP = outpatient; ER = emergency room 
All models adjusted for age, gender, geographical region, presence of specific comorbidities (anxiety, 
psychosis, and dementia), Charlson Comorbidity Index (CCI), having regimen modification, and pre-
index Parkinson’s disease-related total cost. 
a
 Zero-inflated negative binomial model 
b
 GzLM with negative binomial distribution and a log link function 
*Significant at p < 0.05 
 
 
Table 3.14 Zero-inflated negative binomial model or GzLM adjusted all-cause healthcare 
resource utilization comparisons (Cut-off value for being adherent: PDC = 0.90) 
All-cause Medical 
Service 
Non-adherent to AD (N=624) Adherent to AD (N=232) p-value 
Mean SE 95% CI Mean SE 95% CI  
# of OP-office visit
a
  18.153 0.551 17.073 19.232 16.775 0.851 15.106 18.444 0.175 
# of OP-home visit
a
 9.957 1.016 7.967 11.948 9.212 1.351 6.563 11.861 0.632 
# of OP-other visit
b
 10.446 0.445 9.575 11.318 9.412 0.625 8.187 10.637 0.176 
# of nursing 
facility days billed
a
 5.178 0.554 4.092 6.264 6.123 1.114 3.938 8.307 0.425 
# of inpatient visit
a
 1.434 0.084 1.268 1.599 0.791 0.082 0.631 0.951 <0.001* 
# of ER visit
b
 0.615 0.043 0.532 0.699 0.545 0.061 0.425 0.665 0.350 
Note: GzLM = generalized linear model; AD = antidepressant; SE = standard error; CI = confidence 
interval; OP = outpatient; ER = emergency room 
All models adjusted for age, gender, geographical region, presence of specific comorbidities (anxiety, 
psychosis, and dementia), Charlson Comorbidity Index (CCI), having regimen modification, and pre-
index Parkinson’s disease-related total cost. 
a
 Zero-inflated negative binomial model 
b
 GzLM with negative binomial distribution and a log link function 




H05a: There is no significant difference in number of outpatient visits between adherent and 
non-adherent antidepressants users while controlling for covariates. (Not rejected) 
H05b: There is no significant difference in number of nursing facility days billed between 
adherent and non-adherent antidepressants users while controlling for covariates. (Not 
rejected) 
H05c: There is no significant difference in number of inpatient visits between adherent and non-
adherent antidepressants users while controlling for covariates. (Rejected) 
H05d: There is no significant difference in number of emergency room (ER) visits between 




3.3.6 Objective 6: PD-related Healthcare Resource Utilization (HCRU) 
 PD-related medical claims for depressed PD patients with AD were examined (A 
summary of number of claims for different utilization was presented in Appendix 2). Objective 6 
involved the comparisons between adherent and non-adherent antidepressants (AD) users with 
regard to PD-related nursing facility days billed, outpatient visits (OP-office, OP-home, and OP-
other), inpatient visits, and ER visits.  
 
3.3.6.1 PD-related HCRU comparison (Unadjusted analysis) 
 The unadjusted numbers of PD-related HCRUs were compared using Wilcoxon rank-sum 
tests (Table 3.15). No statistically significant differences were found in PD-related HCRUs 
between adherent and non-adherent AD users. When changing the cut-off PDC value to 0.7, 
adherent AD users had significantly higher number of PD-related nursing facility days billed 
than non-adherent AD users even though the medians were equal (median: 0.00 vs. 0.00, mean 
rank: 413.64 vs. 442.35, p = 0.012) (Table 3.16). When cut-off value of 0.9 was applied, same 
median values in non-adherent and adherent AD users were found but non-adherent AD users 
had significantly higher PD-related inpatient visits than adherent AD users (median: 0.00 vs. 
0.00, mean rank: 438.62 vs. 401.29, p = 0.017) (Table 3.17). 
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Table 3.15 Unadjusted numbers of PD-related healthcare resource utilization comparisons (Cut-












Median IQR Median IQR Median IQR   
# of OP-office visit  3.00 5.00 3.00 5.00 3.00 5.00 -1.293 0.196 
# of OP-home visit 0.00 1.00 0.00 1.00 0.00 1.00 -0.571 0.568 
# of OP-other visit 0.00 1.00 0.00 1.00 0.00 1.00 0.474 0.636 
# of nursing facility 
days billed  
0.00 0.00 0.00 0.00 0.00 0.00 1.898 0.058 
# of inpatient visit 0.00 1.00 0.00 1.00 0.00 1.00 -1.381 0.167 
# of ER visit 0.00 0.00 0.00 0.00 0.00 0.00 1.111 0.267 
Note: Wilcoxon rank-sum tests were used. AD = antidepressant; IQR = interquartile range; OP = 





Table 3.16 Unadjusted numbers of PD-related healthcare resource utilization comparisons (Cut-
off value for being adherent: PDC = 0.70) 
PD-related Medical Services 
Non-adherent to AD 
(N=413) 
Adherent to AD 
(N=443) 
Z p-value 
Median IQR Median IQR   
# of OP-office visit  3.00 5.00 3.00 5.00 1.4292 0.153 
# of OP-home visit 0.00 1.00 0.00 1.00 0.5289 0.597 
# of OP-other visit 0.00 1.00 0.00 1.00 -0.2059 0.837 
# of nursing facility days billed  0.00 0.00 0.00 0.00 -2.5027 0.012* 
# of inpatient visit 0.00 1.00 0.00 1.00 0.8119 0.417 
# of ER visit 0.00 0.00 0.00 0.00 -0.8067 0.420 
Note: Wilcoxon rank-sum tests were used. AD = antidepressant; IQR = interquartile range; OP = 
outpatient; ER = emergency room; PD = Parkinson’s disease  




Table 3.17 Unadjusted numbers of PD-related healthcare resource utilization comparisons (Cut-
off value for being adherent: PDC = 0.90) 
PD-related Medical Services Non-adherent to 
AD (N=624) 
Adherent to AD 
(N=232) 
Z p-value 
Median IQR Median IQR   
# of OP-office visit  3.00 5.00 3.00 5.00 -0.8673 0.386 
# of OP-home visit 0.00 1.00 0.00 0.50 -1.3938 0.163 
# of OP-other visit 0.00 1.00 0.00 1.00 -0.3394 0.734 
# of nursing facility days billed  0.00 0.00 0.00 0.00 0.9058 0.365 
# of inpatient visit 0.00 1.00 0.00 1.00 -2.3966 0.017* 
# of ER visit 0.00 0.00 0.00 0.00 1.7338 0.083 
Note: Wilcoxon rank-sum tests were used. AD = antidepressant; IQR = interquartile range; OP = 
outpatient; ER = emergency room; PD = Parkinson’s disease  
*Significant at p < 0.05 
 
3.3.6.2 PD-related HCRU comparison (Adjusted analysis) 
 Based on the results from Vuong tests, zero-inflated negative binomial models were used 
for the comparisons in PD-related nursing facility days billed, OP-office, OP-home, inpatient, 
and ER visits; while GzLM with negative binomial distribution was used for PD-related OP-
other visits (Outputs were presented in Appendix 9 to Appendix 14). After controlling for the 
covariates, no significant differences were found in number of PD-related nursing facility days 
billed, outpatient (OP-office, OP-home, and OP-other), and ER visits. The only difference was 
found in PD-related inpatient visits: non-adherent AD users had more frequent PD-related 
inpatient visits than adherent antidepressant users during the 1-year follow-up period (0.66 vs. 
0.47, p = 0.015) (Table 3.18). For the sensitivity analyses, no significant differences were found 
between the two groups when using a cut-off value of “PDC = 0.70” (Table 3.19). If the cut-off 
value was changed to “PDC = 0.90”, the adjusted PD-related OP-other and inpatient visits for 
non-adherent AD users were higher than those who were adherent to AD (OP-other: 1.44 vs. 
0.99, p = 0.024; inpatient: 0.67 vs. 0.35, p < 0.001) (Table 3.20). 
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Table 3.18 Zero-inflated negative binomial model or GzLM adjusted PD-related healthcare 
resource utilization comparisons (Cut-off value for being adherent: PDC = 0.80) 
PD-related Medical 
Service 
Non-adherent to AD  
(N=501) 
Adherent to AD (N=355) p-value 
Mean SE 95% CI Mean SE 95% CI  
# of OP-office visit
a
  4.535 0.219 4.106 4.963 4.193 0.250 3.702 4.683 0.299 
# of OP-home visit
a
 5.775 1.372 3.085 8.465 4.613 0.933 2.785 6.441 0.371 
# of OP-other visit
b
 1.316 0.151 1.021 1.611 1.294 0.170 0.962 1.627 0.921 




1.225 0.204 0.825 1.626 1.591 0.314 0.977 2.206 0.318 
# of inpatient visit
a
 0.658 0.057 0.547 0.769 0.469 0.051 0.368 0.570 0.015* 
# of ER visit
a
 0.239 0.029 0.182 0.295 0.214 0.029 0.158 0.270 0.548 
Note: GzLM = generalized linear model; AD = antidepressant; SE = standard error; CI = confidence interval; OP = 
outpatient; ER = emergency room. All models adjusted for age, gender, geographical region, presence of specific 
comorbidities (anxiety, psychosis, and dementia), Charlson Comorbidity Index (CCI), having regimen modification, 
and pre-index Parkinson’s disease-related total cost. 
a
 Zero-inflated negative binomial model 
b
 GzLM with negative binomial distribution and a log link function 
*Significant at p < 0.05 
 
 
Table 3.19 Zero-inflated negative binomial model or GzLM adjusted PD-related healthcare 
resource utilization comparisons (Cut-off value for being adherent: PDC = 0.70) 
PD-related Medical 
Service 
Non-adherent to AD  
(N=413) 
Adherent to AD (N=443) p-value 
Mean SE 95% CI Mean SE 95% CI  
# of OP-office visit
a
  4.629 0.244 4.150 5.108 4.177 0.223 3.741 4.614 0.169 
# of OP-home visit
a
 5.012 1.119 2.819 7.206 4.999 0.969 3.100 6.899 0.992 
# of OP-other visit
b
 1.209 0.148 0.920 1.499 1.394 0.161 1.078 1.710 0.365 




1.063 0.201 0.669 1.458 1.660 0.281 1.110 2.211 0.080 
# of inpatient visit
a
 0.586 0.055 0.479 0.693 0.566 0.055 0.459 0.674 0.803 
# of ER visit
a
 0.244 0.033 0.179 0.309 0.216 0.028 0.162 0.270 0.505 
Note: GzLM = generalized linear model; AD = antidepressant; SE = standard error; CI = confidence interval; OP = 
outpatient; ER = emergency room. All models adjusted for age, gender, geographical region, presence of specific 
comorbidities (anxiety, psychosis, and dementia), Charlson Comorbidity Index (CCI), having regimen modification, 
and pre-index Parkinson’s disease-related total cost. 
a
 Zero-inflated negative binomial model 
b
 GzLM with negative binomial distribution and a log link function 
*Significant at p < 0.05 
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Table 3.20 Zero-inflated negative binomial model or GzLM adjusted PD-related healthcare 
resource utilization comparisons (Cut-off value for being adherent: PDC = 0.90) 
PD-related Medical 
Service 
Non-adherent to AD  
(N=624) 
Adherent to AD (N=232) p-value 
Mean SE 95% CI Mean SE 95% CI  
# of OP-office visit
a
  4.482 0.196 4.098 4.867 4.140 0.300 3.552 4.727 0.334 
# of OP-home visit
a
 5.409 1.035 3.381 7.437 4.279 1.028 2.264 6.293 0.358 
# of OP-other visit
b
 1.443 0.151 1.147 1.739 0.986 0.154 0.685 1.287 0.024* 
# of nursing facility 
days billed
a
 1.336 0.197 0.950 1.721 1.649 0.424 0.819 2.480 0.491 
# of inpatient visit
a
 0.672 0.052 0.571 0.773 0.354 0.050 0.256 0.453 <0.001* 
# of ER visit
a
 0.223 0.024 0.175 0.271 0.242 0.039 0.166 0.319 0.668 
GzLM = generalized linear model; AD = antidepressant; SE = standard error; CI = confidence interval; OP = 
outpatient; ER = emergency room. All models adjusted for age, gender, geographical region, presence of specific 
comorbidities (anxiety, psychosis, and dementia), Charlson Comorbidity Index (CCI), having regimen modification, 
and pre-index Parkinson’s disease-related total cost. 
a
 Zero-inflated negative binomial model 
b
 GzLM with negative binomial distribution and a log link function 
*Significant at p < 0.05 
 
 
H06a: There is no significant difference in number of PD-related outpatient visits between 
adherent and non-adherent antidepressants users while controlling for covariates. (Not 
rejected) 
H06b: There is no significant difference in number of PD-related nursing facility days billed 
between adherent and non-adherent antidepressants users while controlling for covariates. 
(Not rejected) 
H06c: There is no significant difference in number of PD-related inpatient visits between 
adherent and non-adherent antidepressants users while controlling for covariates. 
(Rejected) 
H06d: There is no significant difference in number of PD-related ER visits between adherent and 
non-adherent antidepressants users while controlling for covariates. (Not rejected) 
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3.3.7 Objective 7: All-cause Healthcare Cost  
 Objective 7 involved the comparisons between adherent and non-adherent AD users with 
regard to all-cause outpatient costs (OP-office, OP-home, and OP-other), nursing facility service 
costs, inpatient costs, ER costs, pharmacy costs, and total costs.  
 
3.3.7.1 All-cause Healthcare Cost Comparison (Unadjusted analysis) 
 The unadjusted costs for all-cause healthcare services for adherent and non-adherent AD 
users were compared using Wilcoxon rank-sum tests. The detailed results are presented in Table 
3.21. There were no significant differences in all-cause outpatient (OP-office, OP-home, and OP-
other), inpatient, ER, and total costs between the two groups. Patients who were adherent to 
antidepressant medications had higher all-cause pharmacy costs than those who were non-
adherent to antidepressants ($2,765 vs. $4,260, p < 0.001). Sensitivity analyses with different 
levels as PDC cut-off values were carried out (Table 3.22 and Table 3.23). When a PDC cut-off 
value of 0.70 was specified, higher all-cause pharmacy cost ($2,673 vs. $3,994, p < 0.001) and 
total cost ($12,654 vs. $ 15,457, p = 0.034) were observed in adherent AD users than non-
adherent AD users. If the PDC cut-off value was set at 0.90, non-adherent AD users had higher 
all-cause inpatient costs ($144 vs. $ 0, p < 0.001) and lower all-cause pharmacy costs ($3,069 vs. 
$4,340, p < 0.001) compared to adherent AD users. 
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Table 3.21 Unadjusted all-cause healthcare costs comparisons (Cut-off value for being adherent: 





Overall (N=856) Non-adherent to 
AD (N=501) 
Adherent to AD 
(N=355) 
Z p-value 
Median IQR Median IQR Median IQR   
OP-office  $1,579 $2,038 $1,610 $1,857 $1,501 $2,187 -0.6759 0.499 
OP-home $95 $2,674 $115 $2,677 $68 $2,651 -0.2188 0.827 
OP-other $699 $2,258 $746 $2,326 $666 $2,103 -0.1535 0.878 
Nursing 
facilities 
$0 $1,119 $0 $875 $0 $1,208 0.392 0.695 
Inpatient $11 $10,498 $85 $11,451 $0 $9,040 -1.9285 0.054 
ER $177 $939 $176 $1,030 $178 $860 -0.6773 0.498 
Pharmacy  $3,361 $3,408 $2,765 $3,081 $4,260 $3,745 8.1157 <0.001* 
Total $14,225 $26,401 $13,623 $30,255 $14,401 $23,777 1.0275 0.304 
Note: Wilcoxon rank-sum tests were used. AD = antidepressant; IQR = interquartile range; OP = 
outpatient; ER = emergency room 




Table 3.22 Unadjusted all-cause healthcare costs comparisons (Cut-off value for being adherent: 




Non-adherent to AD 
(N=413) 
Adherent to AD 
(N=443) 
Z p-value 
Median IQR Median IQR   
OP-office  $1,639 $2,020 $1,467 $2,002 1.3398 0.180 
OP-home $103 $2,658 $92 $2,866 -0.1045 0.917 
OP-other $669 $2,122 $716 $2,410 -0.9518 0.341 
Nursing facilities $0 $386 $0 $1,482 -1.191 0.234 
Inpatient $84 $11,315 $0 $9,849 1.2668 0.205 
ER $177 $1,010 $178 $905 0.563 0.573 
Pharmacy  $2,673 $2,944 $3,994 $3,942 -8.4878 <0.001* 
Total $12,654 $24,870 $15,457 $27,791 -2.1155 0.034* 
Note: Wilcoxon rank-sum tests were used. AD = antidepressant; IQR = interquartile range; OP = 
outpatient; ER = emergency room 





Table 3.23 Unadjusted all-cause healthcare costs comparisons (Cut-off value for being adherent: 




Non-adherent to AD 
(N=624) 
Adherent to AD 
(N=232) 
Z p-value 
Median IQR Median IQR   
OP-office  $1,613 $2,069 $1,436 $1,934 -1.3378 0.181 
OP-home $128 $3,228 $0 $1,624 -1.8817 0.060 
OP-other $771 $2,279 $535 $2,214 -1.3095 0.190 
Nursing facilities $0 $2,072 $0 $542 -1.7109 0.087 
Inpatient $144 $12,546 $0 $5,498 -4.3478 <0.001* 
ER $179 $1,008 $171 $768 -0.9721 0.331 
Pharmacy  $3,069 $3,244 $4,340 $3,606 5.8271 <0.001* 
Total $14,827 $31,902 $12,737 $18,386 -1.6102 0.107 
Note: Wilcoxon rank-sum tests were used. AD = antidepressant; IQR = interquartile range; OP = 
outpatient; ER = emergency room 
*Significant at p < 0.05 
 
 
3.3.7.2 All-cause Healthcare Cost Comparison (Adjusted analysis) 
 GzLMs with gamma distribution and log link function were used for the comparisons in 
all-cause pharmacy and total costs to account for the right skewed cost data. Two-part models 
were performed for the comparisons in all-cause OP-office, OP-home, OP-other, nursing facility, 
inpatient, and ER costs because these cost data were right skewed and many of them were zero 
(Outputs were presented in Appendix 15 to Appendix 22). The adjusted mean all-cause nursing 
facility costs ($5,179 vs. $2,351, p < 0.001) and inpatient costs ($10,503 vs. $6,254, p < 0.001) 
for non-adherent AD users were approximately two times higher than adherent AD users (Table 
3.24.). The all-cause ER cost ($859 vs. $644, p =0.027) and total cost ($28,813 vs. $23,290, p 
=0.008) were also significantly higher in non-adherent AD users than adherent AD users.  
However, the all-cause mean pharmacy cost was higher in adherent AD users than non-adherent 
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AD users ($3,596 vs. $4,889, p <0.001). The results for all-cause inpatient and pharmacy cost 
were robust in sensitivity analyses (Table 3.25 and Table 3.26). But all-cause nursing facility, 
ER, and total costs were no longer significantly different between adherent and non-adherent AD 
users when cut-off value was 0.70. The adjusted all-cause ER costs did not differ significantly 
when a cut-off value of 0.90 was applied. 
 
 
Table 3.24 Two-part model or GzLM adjusted all-cause healthcare cost comparisons (Cut-off 
value for being adherent: PDC = 0.80) 
All-cause Cost 
Category 
Non-adherent to AD (N=501) Adherent to AD (N=355) p-value 
Mean SE 95% CI Mean SE 95% CI  
OP-office
a
  $2,061 $104 $1,857 $2,265 $2,266 $141 $1,990 $2,542 0.239 
OP-home
a
 $3,455 $410 $2,652 $4,258 $3,827 $507 $2,832 $4,821 0.536 
OP-other
a





$5,179 $625 $3,954 $6,405 $2,351 $300 $1,763 $2,939 <0.001* 
Inpatient
a
 $10,503 $951 $8,639 $12,366 $6,254 $727 $4,829 $7,678 <0.001* 
ER
a
 $859 $72 $718 $1,000 $644 $65 $517 $771 0.027* 
Pharmacy
b
 $3,596 $137 $3,327 $3,865 $4,889 $213 $4,471 $5,306 <0.001* 
Total
b
 $28,813 $1,669 $25,542 $32,084 $23,290 $1,474 $20,401 $26,178 0.008* 
Note: GzLM = generalized linear model; AD = antidepressant; SE = standard error; CI = confidence interval; OP = 
outpatient; ER = emergency room. All models adjusted for age, gender, geographical region, presence of specific 
comorbidities (anxiety, psychosis, and dementia), Charlson Comorbidity Index (CCI), having regimen modification, 
and pre-index Parkinson’s disease-related total cost. 
a
 Two-part model with logistic regression as the first part and GzLM with a gamma regression and a log link as the 
second part 
b
 GzLM with a gamma regression and a log link 





Table 3.25 Two-part model or GzLM adjusted all-cause healthcare cost comparisons (Cut-off 
value for being adherent: PDC = 0.70) 
All-cause Cost 
Category 
Non-adherent to AD (N=413) Adherent to AD (N=443) p-value 




   $2,105  $118   $1,874   $2,336   $2,183   $124   $1,941   $2,425  0.643 
OP-home
a
  $3,369  $436   $2,514   $4,224   $3,861   $475   $2,929   $4,793  0.406 
OP-other
a





 $4,482   $590   $3,326   $5,638   $3,216   $373   $2,484   $3,947  0.069 
Inpatient
a
 $10,115  $1,012   $8,133  $12,098   $7,335   $761   $5,844   $8,826  0.028* 
ER
a
 $ 831  $ 76   $681  $ 980   $705   $63   $581   $829  0.205 
Pharmacy
b
  $3,437   $145   $3,153   $3,722   $4,786   $189   $4,415   $5,157  <0.001* 
Total
b
 $27,080  $1,705  $23,737  $30,422  $25,692  $1,509  $22,734  $28,649  0.514 
GzLM = generalized linear model; AD = antidepressant; SE = standard error; CI = confidence interval; OP = 
outpatient; ER = emergency room. All models adjusted for age, gender, geographical region, presence of specific 
comorbidities (anxiety, psychosis, and dementia), Charlson Comorbidity Index (CCI), having regimen modification, 
and pre-index Parkinson’s disease-related total cost. 
a
 Two-part model with logistic regression as the first part and GzLM with a gamma regression and a log link as the 
second part 
b
 GzLM with a gamma regression and a log link 
*Significant at p < 0.05 
 
 
Table 3.26 Two-part model or GzLM adjusted all-cause healthcare cost comparisons (Cut-off 




Non-adherent to AD (N=624) Adherent to AD (N=232) p-value 
Mean SE 95% CI Mean SE 95% CI  
OP-office
a
  $2,139 $100 $1,944 $2,335 $2,156 $170 $1,823 $2,489 0.933 
OP-home
a
 $3,489 $355 $2,792 $4,185 $3,977 $658 $2,687 $5,268 0.489 
OP-other
a




 $4,871 $481 $3,928 $5,813 $1,296 $223 $859 $1,732 <0.001 
Inpatient
a
 $10,573 $873 $8,862 $12,284 $4,049 $629 $2,816 $5,281 <0.001 
ER
a
 $817 $62 $696 $938 $635 $80 $479 $792 0.074 
Pharmacy
b
 $3,863 $130 $3,607 $4,119 $4,911 $264 $4,393 $5,428 <0.001 
Total
b
 $28,980 $1,509 $26,022 $31,939 $19,906 $1,541 $16,886 $22,927 <0.001 
GzLM = generalized linear model; AD = antidepressant; SE = standard error; CI = confidence interval; OP = 
outpatient; ER = emergency room. All models adjusted for age, gender, geographical region, presence of specific 
comorbidities (anxiety, psychosis, and dementia), Charlson Comorbidity Index (CCI), having regimen modification, 
and pre-index Parkinson’s disease-related total cost. 
a
 Two-part model with logistic regression as the first part and GzLM with a gamma regression and a log link as the 
second part 
b
 GzLM with a gamma regression and a log link 
*Significant at p < 0.05 
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H07a: There is no significant difference in all-cause outpatient costs between adherent and non-
adherent antidepressants users while controlling for covariates. (Not rejected) 
H07b: There is no significant difference in all-cause nursing facility costs between adherent and 
non-adherent antidepressants users while controlling for covariates. (Rejected) 
H07c: There is no significant difference in all-cause inpatient costs between adherent and non-
adherent antidepressants users while controlling for covariates. (Rejected) 
H07d: There is no significant difference in all-cause ER costs between adherent and non-adherent 
antidepressants users while controlling for covariates. (Rejected) 
H07e: There is no significant difference in all-cause pharmacy costs between adherent and non-
adherent antidepressants users while controlling for covariates. (Rejected) 
H07f: There is no significant difference in all-cause total costs between adherent and non-
adherent antidepressants users while controlling for covariates. (Rejected) 
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3.3.8 Objective 8: PD-related Healthcare Cost  
 Objective 8 involved the comparisons between adherent and non-adherent antidepressant 
(AD) users with regard to PD-related outpatient costs (OP-office, OP-home, and OP-other), 
nursing facility service costs, inpatient costs, ER costs, pharmacy costs, and total costs.  
 
3.3.8.1 PD-related Healthcare Cost Comparison (Unadjusted analysis) 
 Wilcoxon rank-sum tests were used to assess the PD-related healthcare costs for adherent 
and non-adherent AD users. The detailed results are shown in Table 3.27. The PD-related 
outpatient (OP-office, OP-home, and OP-other), nursing facility, inpatient, ER, and total costs of 
adherent AD users did not significantly differ from non-adherent AD users (all p > 0.05). 
Compared to non-adherent antidepressant users, the pharmacy costs for adherent AD users was 
$125 higher ($340 vs. $465, p < 0.001). The results for PD-related pharmacy costs were robust 
after conducting sensitivity analyses with PDC cut-off values of 0.70 and 0.90. However, when 
cut-off value was set at 0.70, adherent AD users had significantly higher PD-related nursing 
facility costs than non-adherent AD users even though the medians were equal (median: $0 vs. 
$0, mean rank: 414.65 vs. 441.41, p = 0.019). If cut-off value equaled to 0.90, non-adherent AD 
users had significantly higher PD-related inpatient costs than non-adherent AD users despite 
same median values were observed (median: $0 vs. $0, mean rank: 439.95 vs. 397.71, p = 
0.006). Results for sensitivity analyses are presented in Table 3.28 and Table 3.29. 
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Table 3.27 Unadjusted PD-related healthcare costs comparisons (Cut-off value for being 







Adherent to AD 
(N=355) 
Z p-value 
Median IQR Median IQR Median IQR   
OP-Office  $252 $486 $244 $488 $262 $481 -0.7289 0.466 
OP-Home  $0 $117 $0 $118 $0 $102 -0.3032 0.762 
OP-Other  $0 $115 $0 $123 $0 $108 -0.0155 0.988 
Nursing facility  $0 $0 $0 $0 $0 $0 1.6663 0.096 
Inpatient  $0 $506 $0 $1,299 $0 $217 -1.6822 0.093 
ER  $0 $0 $0 $0 $0 $0 1.0952 0.273 
Pharmacy  $393 $983 $340 $843 $465 $1,052 3.8814 <0.001* 
Total  $2,500 $9,769 $2,410 $9,781 $2,741 $9,767 1.0562 0.291 
Note: Wilcoxon rank-sum tests were used. AD = antidepressant; IQR = interquartile range; OP = 
outpatient; ER = emergency room; PD = Parkinson’s disease 
*Significant at p < 0.05 
 
Table 3.28 Unadjusted PD-related healthcare costs comparisons (Cut-off value for being 





Adherent to AD 
(N=443) 
Z p-value 
Median IQR Median IQR   
OP-Office  $246 $486 $255 $454 1.0226 0.307 
OP-Home  $0 $121 $0 $102 0.2527 0.801 
OP-Other  $0 $130 $0 $105 0.1807 0.857 
Nursing facility  $0 $0 $0 $0 -2.3439 0.019* 
Inpatient  $0 $1,021 $0 $309 1.0435 0.297 
ER  $0 $0 $0 $0 -0.9938 0.320 
Pharmacy  $344 $844 $434 $1,020 -3.0085 0.003* 
Total  $2,290 $8,972 $2,750 $10,346 -1.5556 0.120 
Note: Wilcoxon rank-sum tests were used. AD = antidepressant; IQR = interquartile range; OP = 
outpatient; ER = emergency room; PD = Parkinson’s disease 




Table 3.29 Unadjusted PD-related healthcare costs comparisons (Cut-off value for being 





Adherent to AD 
(N=232) 
Z p-value 
Median IQR Median IQR   
OP-Office  $252 $497 $251 $462 -0.5756 0.565 
OP-Home  $0 $183 $0 $0 -1.3803 0.168 
OP-Other  $0 $126 $0 $99 -0.8785 0.380 
Nursing facility  $0 $0 $0 $0 0.7343 0.463 
Inpatient  $0 $1,533 $0 $0 -2.7261 0.006* 
ER  $0 $0 $0 $0 1.3271 0.185 
Pharmacy  $366 $890 $465 $1,205 2.8813 0.004* 
Total  $2,687 $10,714 $2,290 $6,925 -1.2302 0.219 
Note: Wilcoxon rank-sum tests were used. AD = antidepressant; IQR = interquartile range; OP = 
outpatient; ER = emergency room; PD = Parkinson’s disease 
*Significant at p < 0.05 
 
3.3.8.2 PD-related Healthcare Cost Comparison (Adjusted analysis) 
 The adjusted mean cost for PD-related healthcare services were estimated using two-part 
models to account for right skewed distribution and many zero values (Outputs were presented in 
Appendix 23 to Appendix 30). Table 3.30 shows the results after adjusting for demographic, 
clinical, and other covariates. There were no significant differences in adjusted PD-related mean 
outpatient (OP-office, OP-home, and OP-other), nursing facility, inpatient, ER, and total costs 
between adherent and non-adherent antidepressant users. But the results indicated that adherent 
antidepressant users had $400 more in PD-related pharmacy costs than non-adherent 
antidepressant users ($803 vs. $1,203, p < 0.001). Sensitivity analyses using different PDC cut-
off values were performed and result for PD-related pharmacy costs were robust when the cut-off 
value was set at 0.70 or 0.90 (Table 3.31 and Table 3.32). However, when cut-off value of 0.90 
was used, differences in PD-related OP-other, nursing facility, inpatient, and total mean costs 
between adherent and non-adherent AD users were found (all p < 0.05). The adjusted PD-related 
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OP-other, nursing facility, and inpatient costs for patients who were not adherent to 
antidepressant were more than two times higher than those who were adherent (OP-other: $542 
vs. $255, p = 0.006; Nursing facility: $1,734 vs. $630, p = 0.001; Inpatient: $3,851 vs. $1,625, p 
< 0.001). In addition, the PD-related total cost for non-adherent AD users was $3,415 higher than 
non-adherent AD users when a cut-off value of 0.90 was specified ($11,000 vs. $7,585, p = 
0.007) (Table 3.31and Table 3.32). 
 
 
Table 3.30 Two-part models adjusted PD-related healthcare cost comparisons (Cut-off value for 
being adherent: PDC = 0.80) 
PD-related Cost 
Category 
Non-adherent to AD (N=501) Adherent to AD (N=355) p-value 
Mean SE 95% CI Mean SE 95% CI  
OP-Office  $474 $35 $406 $543 $475 $39 $399 $551 0.995 
OP-Home  $1,939 $294 $1,363 $2,514 $2,042 $354 $1,349 $2,735 0.814 
OP-Other  $518 $88 $345 $691 $369 $71 $230 $507 0.168 
Nursing facility  $1,683 $318 $1,059 $2,307 $1,066 $227 $621 $1,510 0.112 
Inpatient  $3,709 $511 $2,707 $4,711 $2,499 $456 $1,604 $3,393 0.084 
ER  $206 $27 $153 $259 $173 $25 $124 $223 0.38 
Pharmacy  $803 $69 $667 $939 $1,203 $113 $982 $1,424 <0.001* 
Total  $10,523 $1,505 $7,574 $13,472 $9,010 $1,319 $6,424 $11,596 0.209 
Note: Two-part models were used (1
st
 part: Logistic regression, 2
nd
 part: GzLM with a gamma distribution 
and a log link). AD = antidepressant; SE = standard error; CI = confidence interval; OP = outpatient; ER 
= emergency room. All models adjusted for age, gender, geographical region, presence of specific 
comorbidities (anxiety, psychosis, and dementia), Charlson Comorbidity Index (CCI), having regimen 
modification, and pre-index Parkinson’s disease-related total cost. 




Table 3.31 Two-part model adjusted PD-related healthcare cost comparisons (Cut-off value for 
being adherent: PDC = 0.70) 
PD-related Cost 
Category 
Non-adherent to AD (N=413) Adherent to AD (N=443) p-
value 
Mean SE 95% CI Mean SE 95% CI  
OP-Office  $487 $38 $412 $563 $464 $35 $396 $532 0.611 
OP-Home  $1,897 $313 $1,285 $2,510 $2,069 $331 $1,422 $2,717 0.693 
OP-Other  $465 $83 $301 $628 $443 $80 $287 $599 0.837 
Nursing facility  $1,434 $321 $804 $2,063 $1,376 $279 $829 $1,922 0.892 
Inpatient  $3,387 $523 $2,362 $4,412 $3,015 $489 $2,055 $3,974 0.613 
ER  $198 $29 $141 $256 $186 $25 $137 $235 0.750 
Pharmacy  $807 $76 $659 $955 $1,125 $101 $927 $1,322 0.002* 
Total  $9,819 $1,423 $7,030 $12,607 $9,840 $1,409 $7,079 $12,601 0.986 
Note: Two-part models were used (1
st
 part: Logistic regression, 2
nd
 part: GzLM with a gamma distribution 
and a log link). AD = antidepressant; SE = standard error; CI = confidence interval; OP = outpatient; ER 
= emergency room. All models adjusted for age, gender, geographical region, presence of specific 
comorbidities (anxiety, psychosis, and dementia), Charlson Comorbidity Index (CCI), having regimen 
modification, and pre-index Parkinson’s disease-related total cost. 
*Significant at p < 0.05 
 
Table 3.32 Two-part model adjusted PD-related healthcare cost comparisons (Cut-off value for 
being adherent: PDC = 0.90) 
PD-related Cost 
Category 
Non-adherent to AD (N=624) Adherent to AD (N=232) p-
value 
Mean SE 95% CI Mean SE 95% CI  
OP-Office  $483 $33 $418 $547 $456 $44 $370 $542 0.596 
OP-Home  $1,912 $243 $1,435 $2,388 $2,195 $479 $1,256 $3,134 0.584 
OP-Other  $542 $88 $369 $714 $255 $63 $131 $378 0.006 
Nursing facility  $1,734 $285 $1,175 $2,294 $630 $160 $317 $943 0.001 
Inpatient  $3,851 $482 $2,908 $4,795 $1,625 $388 $865 $2,386 <0.001 
ER  $197 $23 $151 $243 $179 $32 $117 $241 0.657 
Pharmacy  $843 $66 $714 $973 $1,299 $139 $1,026 $1,572 0.001 
Total  $11,000 $1,605 $7,855 $14,145 $7,585 $1,242 $5,151 $10,020 0.007 
Note: Two-part models were used (1
st
 part: Logistic regression, 2
nd
 part: GzLM with a gamma distribution 
and a log link). AD = antidepressant; SE = standard error; CI = confidence interval; OP = outpatient; ER 
= emergency room. All models adjusted for age, gender, geographical region, presence of specific 
comorbidities (anxiety, psychosis, and dementia), Charlson Comorbidity Index (CCI), having regimen 
modification, and pre-index Parkinson’s disease-related total cost. 
*Significant at p < 0.05 
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H08a: There is no significant difference in PD-related outpatient costs between adherent and 
non-adherent antidepressants users while controlling for covariates. (Not rejected) 
H08b: There is no significant difference in PD-related nursing facility costs between adherent 
and non-adherent antidepressants users while controlling for covariates. (Not rejected) 
H08c: There is no significant difference in PD-related inpatient costs between adherent and non-
adherent antidepressants users while controlling for covariates. (Not rejected) 
H08d: There is no significant difference in PD-related ER costs between adherent and non-
adherent antidepressants users while controlling for covariates. (Not rejected) 
H08e: There is no significant difference in PD-related pharmacy costs between adherent and 
non-adherent antidepressants users while controlling for covariates. (Rejected) 
H08f: There is no significant difference in PD-related total costs between adherent and non-
adherent antidepressants users while controlling for covariates. (Not rejected) 
 
3.3.9 Summary of Hypotheses Testing 
 A summary of hypotheses testing is presented in Table 3.33.
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Table 3.33 Results of hypotheses testing 
Objectives/Hypotheses Statistical Analysis Result 
Objective 1: To describe and compare demographic and clinical characteristics among PD patients with 
depression 
Descriptive statistics -- 
Objective 2: To describe antidepressants use patterns (index antidepressant type, adherence, 
persistence, switching, combination therapy) among PD patients with depression 
Descriptive statistics -- 
Objective 3: To identify the factors associated with being adherent among PD patients with depression 
H03a: Age is not associated with being adherent to antidepressants after controlling for other covariates. Logistic regression Not rejected 
H03b: Being female is not associated with being adherent to antidepressants after controlling for other 
covariates. 
Logistic regression Not rejected 
H03c: Geographic region is not associated with being adherent to antidepressants after controlling for 
other covariates.  
Logistic regression Not rejected 
H03d: Having anxiety is not associated with being adherent to antidepressants after controlling for other 
covariates.  
Logistic regression Not rejected 
H03e: Having psychosis is not associated with being adherent to antidepressants after controlling for 
other covariates.  
Logistic regression Not rejected 
H03f: Having dementia is not associated with being adherent to antidepressants after controlling for 
other covariates  
Logistic regression Not rejected 
H03g: The CCI score is not associated with being adherent to antidepressants after controlling for other 
covariates.  
Logistic regression Rejected 
H03h: Having regimen modification of the index antidepressants is not associated with being adherent to 
antidepressants after controlling for other covariates.  
Logistic regression Rejected 
H03i: The pre-index PD-related total cost is not associated with being adherent to antidepressants after 
controlling for other covariates. 
Logistic regression Not rejected 
Objective 4: To identify the factors associated with persistence among PD patients with depression 
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H04a: Age is not associated with persistence after controlling for other covariates.  Cox proportional hazards 
model 
Not rejected 
H04b: Being female is not associated with persistence after controlling for other covariates.  Cox proportional hazards 
model 
Rejected 
H04c: Geographic region is not associated with persistence after controlling for other covariates. Cox proportional hazards 
model 
Not rejected 
H04d: Having anxiety is not associated with persistence after controlling for other covariates.  Cox proportional hazards 
model 
Not rejected 
H04e: Having psychosis is not associated with persistence after controlling for other covariates. Cox proportional hazards 
model 
Not rejected 
H04f: Having dementia is not associated with persistence after controlling for other covariates.  Cox proportional hazards 
model 
Not rejected 
H04g: The CCI score is not associated with persistence after controlling for other covariates.  Cox proportional hazards 
model 
Not rejected 
H04h: Having regimen modification of the index antidepressants is not associated with persistence 
after controlling for other covariates.  
Cox proportional hazards 
model 
Rejected 
H04i: The pre-index PD-related total cost is not associated with persistence after controlling for other 
covariates.  
Cox proportional hazards 
model 
Not rejected 
Objective 5: To determine if all-cause healthcare resource utilization differs significantly between adherent and non-adherent antidepressants users 
while controlling for covariates 
H05a: There is no significant difference in number of outpatient visits between adherent and non-
adherent antidepressants users while controlling for covariates.  
ZINB model or GzLM Not rejected 
H05b: There is no significant difference in number of nursing facility days billed between adherent and 
non-adherent antidepressants users while controlling for covariates.  
ZINB model Not rejected 
H05c: There is no significant difference in number of inpatient visits between adherent and non-adherent 
antidepressants users while controlling for covariates.  
ZINB model Rejected 
H05d: There is no significant difference in number of emergency room (ER) visits between adherent and 
non-adherent antidepressants users while controlling for covariates. 
ZINB model Not rejected 
Objective 6: To determine if PD-related healthcare resource utilization differs significantly between adherent and non-adherent antidepressants users 
while controlling for covariates 
Table 3.33 Results of hypotheses testing (continued) 
 (con 
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H06a: There is no significant difference in number of PD-related outpatient visits between adherent and 
non-adherent antidepressants users while controlling for covariates.  
ZINB model or GzLM Not rejected 
H06b: There is no significant difference in number of PD-related nursing facility days billed between 
adherent and non-adherent antidepressants users while controlling for covariates.  
ZINB model Not rejected 
H06c: There is no significant difference in number of PD-related inpatient visits between adherent and 
non-adherent antidepressants users while controlling for covariates.  
ZINB model Rejected 
H06d: There is no significant difference in number of PD-related ER visits between adherent and non-
adherent antidepressants users while controlling for covariates.  
ZINB model Not rejected 
Objective 7: To determine if all-cause healthcare costs differ significantly between adherent and non-adherent antidepressants users while 
controlling for covariates. 
H07a: There is no significant difference in all-cause outpatient costs between adherent and non-adherent 
antidepressants users while controlling for covariates.  
Two-part model Not rejected 
H07b: There is no significant difference in all-cause nursing facility costs between adherent and non-
adherent antidepressants users while controlling for covariates.  
Two-part model Rejected 
H07c: There is no significant difference in all-cause inpatient costs between adherent and non-adherent 
antidepressants users while controlling for covariates.  
Two-part model Rejected 
H07d: There is no significant difference in all-cause ER costs between adherent and non-adherent 
antidepressants users while controlling for covariates.  
Two-part model Rejected 
H07e: There is no significant difference in all-cause pharmacy costs between adherent and non-adherent 
antidepressants users while controlling for covariates.  
GzLM Rejected 
H07f: There is no significant difference in all-cause total costs between adherent and non-adherent 
antidepressants users while controlling for covariates.  
GzLM Rejected 
Objective 8: To determine if PD-related healthcare costs differ significantly between adherent and non-adherent antidepressants users while 
controlling for covariates. 
H08a: There is no significant difference in PD-related outpatient costs between adherent and non-
adherent antidepressants users while controlling for covariates.  
Two-part model Not rejected 
H08b: There is no significant difference in PD-related nursing facility costs between adherent and non-
adherent antidepressants users while controlling for covariates.  
Two-part model Not rejected 
H08c: There is no significant difference in PD-related inpatient costs between adherent and non-
adherent antidepressants users while controlling for covariates.  
Two-part model Not rejected 
H08d: There is no significant difference in PD-related ER costs between adherent and non-adherent Two-part model Not rejected 
Table 3.33 Results of hypotheses testing (continued) 
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antidepressants users while controlling for covariates.  
H08e: There is no significant difference in PD-related pharmacy costs between adherent and non-
adherent antidepressants users while controlling for covariates.  
Two-part model Rejected 
H08f: There is no significant difference in PD-related total costs between adherent and non-adherent 
antidepressants users while controlling for covariates.  
Two-part model Not rejected 
GzLM = generalized linear model; ZINB = zero-inflated negative binomial; ER = emergency room 
Covariates include age, gender, geographical region, presence of specific comorbidities (anxiety, psychosis, and dementia), Charlson 




Table 3.33 Results of hypotheses testing (continued) 
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CHAPTER 4: DISCUSSION AND CONCLUSIONS 
4.1 Chapter Overview 
 This chapter provides a summary of the main findings of our study. Results are compared 
with previous studies and possible explanations are discussed. Study strengths and limitations, 
conclusions, and suggestions for future research are covered at the end of this chapter. 
4.2 Review of Study Purpose 
 As discussed in the literature review section, depression is a prevalent comorbidity in PD 
patients and often starts in the early phase of PD. Previous studies have found that the use of 
antidepressant may delay the progression of PD and improve motor and cognitive functions of 
PD patients. However, little has been reported regarding antidepressant use and the related 
outcomes among depressed PD patients. Therefore, the aims of the present study were to 
examine antidepressant use patterns and evaluate the associated healthcare resource utilization 
and costs for depressed PD patients using the Humana database from January 2007 to December 
2010. 
4.3 Study Objectives 
4.3.1 Objective 1: Demographic and Clinical Characteristics 
 Objective 1 was to describe and compare demographic and clinical characteristics among 
adherent and non-adherent antidepressant (AD) users. Mean age and gender distribution for our 
entire study cohort were within the range of the values reported by previous studies for PD 
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patients (Mean age: 68.9 – 78.4 years old; Female percentage: 39.7% - 60.5%).
23,27,28,79,83,85
 As 
expected, more patients resided in the Southern US in our study than other studies because the 
Humana database covers a greater proportion of members in the South. The mean CCI for our  
study cohort (2.2) was higher than the mean CCIs reported for general PD patients in other 
studies (1.0 – 1.76) .This may indicate that depressed PD patients with antidepressant use had a 
higher level of overall comorbidity burden than general PD patients.
23,27,79
 Compared to non-
adherent AD users, adherent AD users had higher pre-index PD-related total costs and greater 
proportions of the presence of psychosis and dementia. This may suggest that adherent AD users 
had greater PD severity and more comorbid neuropsychiatric and cognitive impairment diseases 
than non-adherent AD users at baseline. A greater proportion of adherent AD users had regimen 
modifications (switching or combination therapy) than non-adherent AD users during the 1-year 
follow-up. A detailed discussion about the relationship between regimen modification and 
adherence to AD is presented later in Objective 3 discussion section.  
 
4.3.2 Objective 2: Antidepressant Use Patterns 
 Objective 2 was to describe antidepressant use patterns (index antidepressant type, 
adherence, persistence, switching, and combination therapy). In our study, most of the patients 
were prescribed SSRIs at the index date (68.1%). This was in line with previous findings that the 
majority of depressed PD patients received SSRIs for their depression treatment.
118,148
 Based on 
the VA data, Chen and his colleagues reported that 62.9% of the patients used SSRIs. Weintraub 
et al. used a convenience sample from a PD center and found that 69.6% of the patients received 
SSRIs. This observation also revealed that although some evidence indicated that TCAs may 
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have greater efficacy for treating depression in PD, SSRIs are still most commonly prescribed in 
practice.
116
 The most commonly prescribed antidepressants in the present study were citalopram 
(37.97%) and sertraline (14.14%). The proportions of patients using citalopram and sertraline 
were both 26.1% in the Weintraub study.
148
 One previous study also reported that citalopram was 
more commonly prescribed for depression than sertraline in Medicare beneficiaries with 
depression.
181
 However, the Chen study using VA data and found sertraline use (25.90%) was 
more common than citalopram (19.76%) use for depressed PD patients with antidepressants.
118
 
One possible explanation for the proportional differences may be due to the difference in 
prescription drug coverage under Medicare and the VA system.  
 Adherence (measured as PDC) to antidepressants among depressed PD patients in our 
study differed from some of the estimates of adherence to antidepressants for depressed patients 
in previous studies.
182
 In the present study, the mean PDC was 0.63, and 41.5% of the depressed 
PD patients were considered adherent using a cut-off of PDC=0.8 during the 1-year follow-up. 
Cantrell et al. used the Impact National Managed Care Benchmark Database to assess the 
adherence to antidepressant among non-PD patients with depression and/or anxiety and found a 
mean MPR of 0.43 along with an adherence rate of 43% (MPR ≥0.8) during the 6-month follow-
up.
182
 Using VA data, Zivin et al. followed depressed patients for six months and reported a 
mean MPR of 0.66, with 40% being adherent (MPR ≥0.8).
183
 Another recent study using the 
MarketScan Database measured adherence to antidepressants for six months among depressed 
patients and found a PDC of 0.71.
159
 Lin et al. used the Medical Expenditure Panel Survey and 
observed that 23.5% of the patients were adherent (PDC ≥0.8) during the 1-year follow-up.
177
 
The differences in adherence may be partially explained by different follow-up periods, different 
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study population and demographic characteristics in varied databases, and the presence of PD. 
Rather than using a shorter 6- month follow-up period, we used a 1-year follow-up period to 
capture adherence, persistence, and annual utilization/costs. For the demographical differences, 
the samples in the Zivin study were predominantly male (94-95%) while nearly half of the 
patients in our study were female (47.1%). Previous studies have found that women tend to have 
lower adherence rate to medications for chronic disease treatment than men, which may partially 
explain the different adherence results.
184-186
 In addition, the study cohorts in the above studies 
(Zivin study: mean age=52 years; Cantrell study: mean age=37.6 years; Wu study: mean age=41 
years; Lin study: less than 10% of the patients older than 65 years) were much younger than our 
study cohort (mean age=75.4 years). In previous studies, older age and presence of PD were 
associated with more frequent follow-up medical visits, which may be positively related to better 
adherence.
187-189
 In fact, elderly patients, on average, had better adherence rates than younger 
patients.
190-192
 A published report from the Centers for Medicare & Medicaid Services (CMS) 
estimated MPR for medications used to treat several chronic diseases and found that most of the 
patients with chronic conditions had an MPR ≥ 0.70 during a 1-year follow-up among those who 
enrolled in a Medicare prescription drug plan (PDP). The reported MPRs to medications for 
depression ranged from 0.59 to 0.73.
193
 Although we used a relatively conservative approach — 
PDC instead of MPR- to measure adherence and set our original cut-off at PDC = 0.8 (instead of 
MPR of .70), our population is similar and our results are comparable to the findings for 
adherence to depression treatment among depressed Medicare PDP enrollees. 
 If there is no or minimal response to antidepressants after initial treatment, guidelines 
recommend 1) increasing the dose, 2) switching ADs, or 3) adding another AD agent. Only a 
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small proportion of our study cohort experienced regimen modification (11.0%, without 
examining dose escalation). The proportion of patients with regimen modification in our study 
(11.0%) was smaller than the result from the Milea study (23.2%) but similar to the proportion 
for the older patient group from the Sanglier study (10.8%) (Milea et al. and Sanglier et al. did 
not include dose escalation as one of regimen modification categories either).
194,195
 The 
discrepancy may be due to the age differences. The mean age for our study cohort was 75.4 
years, while the mean age among patients in the Milea study was 39.1 years. Sanglier et al. 
compared the treatment patterns of antidepressants between older (≥65) and younger (25-64 
years) patients. The authors reported a mean age of 78.1 for the older patient group. Khandker et 
al. used the PharMetrics Patient-Centric Database and also found that patients younger than 40 
years old were more likely to make an antidepressant switch.
196
 It could be possible that 
physicians may adopt longer antidepressant trials for older patients before they change 
treatment,
197,198
 and thus these patients may be less likely to have regimen modifications during 
the follow-up period.  
 In our study patients had higher rates of combination therapy than switching (8.9% vs. 
2.1%). However, Milea et al. reported that the proportion of patients with combination therapy 
was similar to those with antidepressant switching (9.1% vs. 9.5%);
194
 and Sanglier et al. 
observed nearly reversed results of our study (2.8% combination vs. 8.0% switching).
195
 The 
proportional differences of combination therapy and switching among our study and previous 
studies might indicate that the main reasons for regimen modification were different. Instead of 
switching to another antidepressant because of intolerable side effects of the initial therapy, the 
majority of depressed PD patients with regimen modification might have tolerated initial therapy 
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but had inadequate response to monotherapy. In addition, there may be fewer antidepressant 
switching options for depressed PD patients. For example, TCAs are not recommended to 
depressed PD patients because their antimuscarinic side effects (such as constipation and urinary 
retention) may exacerbate the pre-existing non-motor symptoms of PD.
99
 Other antidepressants 
such as phenelzine and tranylcypromine should also be used with caution because of their 
potential for causing a hypertensive crisis among PD patients using levodopa.
99
  
 The persistence to antidepressants of depressed PD patients in our study differed from the 
persistence results from other studies. Cantrell et al. found that only 44.6% of those patients with 
depression were still on their antidepressants after six months.
182
 Milea et al. reported the median 
treatment duration was 111 days, and 37.5% of the depressed patients were still using 
antidepressants at the 6-month follow-up.
194
 Milea et al. also reported that at the end of the 1-
year follow-up period, the proportion of patients who remained on antidepressant treatment was 
22.8%. Compared to the Cantrell study and the Milea study, the study cohort in our analysis had 
better persistence (median treatment duration: 163.5 days; percentages of patients with 
antidepressant after six months: 47.3%, after one year: 32.0%). However, patients in our study 
were less persistent than those patients from the Bao study and the Sanglier study. Bao et al. 
found the rate of antidepressant disruption among Medicare beneficiaries ranged from 29.3 to 
39.3% after six months.
199
 Sanglier et al. also investigated the rate of antidepressant disruption 
using the IMS LifeLink Health Plan Database.
195
 The non-persistence rate for the older patient 
group (aged ≥65 years) from their study was 51%. Age may partially contribute to the varying 
persistence results. The mean age for our study cohort was 75.4 years, which was greater than 
the observations in the first two studies described (the Cantrell study: 43 years; the Milea study: 
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39.1 years), but slightly younger than the observations in the last two studies above (the Bao 
study: 78.9 and 77.9 years depending on whether they were receiving low-income subsidy; the 
Sanglier study: 78.1 years). As mentioned above, clinicians tend to extend the antidepressant 
titration period for elderly patients to evaluate whether patients have adequate response.
197,198
 
Therefore, older patients may have longer initial antidepressant trial periods and show better 
persistence results. 
 A great proportion of patients discontinued antidepressant treatment after the 6-month 
follow-up (52.7%). However, we do not know the reasons behind early discontinuation. Possible 
factors associated with suboptimal persistence in this population such as unpleasant side effects 
of AD, complexity of treatment, and lack of understanding of the disease may be explored in the 
future. Another possible explanation is that lacked follow-up pharmacologic management to 
optimize antidepressants treatment effect, which in turn caused early discontinuation due to the 
poor response to antidepressants. We observed a small proportion of patients with regimen 
modification (11%). Weintraub et al. used a convenience sample at a PD center and also 
observed nearly all patients did not receive regimen modification to optimize treatment during 
the follow-up.
148
 One possible explanation for this is the difficulty in understanding whether the 
clinical presentations were related to “inadequate antidepressant treatment” or PD because 





4.3.3 Objectives 3 & 4: Factors Associated with Adherence and Persistence 
 Objectives 3 and 4 were to identify factors associated with adherence and persistence to 
antidepressants among depressed PD patients. Our results revealed that depressed PD patients 
with a greater comorbidity score were more likely to be adherent to antidepressants. Mixed 
results have been found in the literature for the relationship between comorbidities and 
adherence to antidepressants. Rivero-Santana et al. conducted a systematic review to analyze the 
predictors of compliance with antidepressants in depressed patients.
200
 In this systematic review, 
three studies reported that higher levels of comorbidity were significantly associated with better 
adherence to antidepressants, whereas another three studies observed a negative association 
between the level of comorbidity and adherence. The authors concluded that the inconsistency 
might be explained as follows: while the experience of coping with a variety of diseases may 
positively affect patients’ medication management, this relationship may be shifted to a reverse 
direction after the interaction with other factors such as sociodemographics, health beliefs, and 
access to follow-up pharmacologic management. This assumption may also be applied to our 
findings given that PD patients are often older and may live with other chronic diseases. In 
addition, as commented above, higher levels of comorbidity may also be associated with more 
frequent physician visits for follow-up care, which may be linked to better adherence.
188
 
 In the present study, depressed PD patients with regimen modification had better 
adherence and persistence to antidepressants than those without. A similar trend was also 
observed in the Milea study.
194
 After controlling for demographic and clinical characteristics, 
Milea et al. found that patients with combination therapy or augmentation were less likely to 
discontinue their antidepressant than those without (combination, HR = 0.83 [95% CI, 0.81–
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0.86]; augmentation, HR = 0.75 [95% CI, 0.73–0.77]). One possible explanation is that regimen 
modification reflects whether physicians optimize antidepressant treatment and adjust treatment 
strategy for partially responsive depression or resistant depression.
111
 Therefore, patients may 
benefit from regimen modification and have a better response, which in turn may improve 
adherence and persistence to antidepressants. 
 
4.3.4 Objectives 5 to 8: Utilization and Costs 
  All-cause and PD-related utilization and costs were calculated for the entire study cohort, 
and then differences were compared between adherent and non-adherent AD users. For all-cause 
utilization, we found that the patients in the current study had a higher number of all-cause ER 
visits (0.59) than other studies that investigated utilization in PD patients (0.16 and 0.37).
23,25
 
However, it is difficult to compare other healthcare services use from our findings with previous 
results because the definitions of many healthcare services vary from study to study.
23-25,79
 When 
comparing our cost results to the costs of PD patients, overall, our study cohort had higher all-
cause inpatient ($8,646), outpatient (OP-office: $2,232, OP-home: $3,603, OP-other: $2,637), 
ER ($763), and total costs ($25,746) than the majority of the different service costs in other 
studies.
22-25,79
 Huse et al. analyzed the MarketScan database and reported the following costs for 
PD patients: inpatient acute plus non-acute care ($11,155), ER ($29), outpatient ($8,557 - which 
was similar to the sum of our outpatient costs), pharmacy ($3,366), and total cost ($23,101). 
Another study used survey data from Medicare beneficiaries to estimate costs for PD patients: 
inpatient ($4,119), outpatient ($4,082), long-term care ($4,926), short-term facility ($855), home 
health care ($1,111), and total cost ($18,528). O’Brien et al. also calculated costs for PD patients 
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under different service categories: physician visits ($571), nursing home ($5,126, which was 
higher than our nursing facility costs), hospitalization ($1,382), other ($2,645), and total cost 
($12,491). Davis et al. only categorized the costs into three categories and observed $8,762 for 
medical cost, $3,504 for pharmacy cost, and $12,266 for the total cost. The reason why our 
findings are higher than previous studies may be explained by the fact that patients in our study 
had comorbid depression and received antidepressants for their depression treatment, while other 
studies included all PD patients, whether or not they had comorbid depression. Given that 
depression has been reported as a factor associated with worse outcomes in PD,
135-138
 it is 
understandable that we found higher costs in our study.  
 Objectives 5 and 6 were to compare all-cause and PD-related utilization between 
adherent and non-adherent AD users among depressed PD patients. We found that adherent AD 
users had fewer all-cause and PD-related inpatient visits than non-adherent AD users. If we 
applied a more restrictive criterion for “being adherent” and used PDC=0.90 as the cut-off value, 
results for inpatient visits remained the same but adherent AD users also had less PD-related OP-
other visits than non-adherent AD users. Objectives 7 and 8 were to compare all-cause and PD-
related costs between adherent and non-adherent AD users. We found that there were significant 
differences in all-cause cost categories between adherent and non-adherent users except for all-
cause outpatient costs. Overall, adherent AD users had less all-cause nursing facility, inpatient, 
and ER costs. Although adherent AD users had a higher all-cause pharmacy cost than non-
adherent AD users, the extra cost in pharmacy was offset by reduced costs in other cost 
categories and generated lower all-cause total cost in adherent AD users. However, although we 
observed this trend in PD-related costs, the results were no longer significant. But if we applied a 
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more restrictive cut-off value (PDC=0.90) for being adherent to antidepressants, significant 
differences were found: adherent AD users had higher PD-related pharmacy costs but lower PD-
related OP-other, nursing facility, inpatient, and total costs than non-adherent AD users. The 
reason why applying a higher PDC cut-off value was associated with more significant 
differences in outcomes may be that using a higher cut-off value may better reflect the 
effectiveness of antidepressant treatment in our study cohort. This is supported by the Fortney 
study.
201
 Fortney and his colleagues assessed the correlation between adherence to antidepressant 
and changes in self-reported depression symptoms. Although the traditional recommended cut-
off value for MPR is 0.80, they found that MPR ≥ 0.90 could better predict treatment response to 
antidepressants. 
 Overall, these findings showed that for this cohort of older depressed PD patients, those 
who were adherent to antidepressant treatment had fewer all-cause and PD-related healthcare 
utilization and lower costs for some services than those who were non-adherent. Because of the 
shared etiologic factors, it has been suggested that depression can be a potential risk factor for 
developing PD or depression could be an early manifestation of PD.
7,87
 Several studies have also 
reported that use of antidepressants to manage depression in PD may not only control depression 
but also delay the need for dopaminergic therapy, ameliorate motor function, and improve 
certain domains of cognitive dysfunction for PD patients.
90,91,93
 Our results may give credence to 
these previous findings: Depressed PD patients who were adherent to antidepressants had less 
all-cause and PD-related inpatient visits. It could be possible that well-controlled depression may 
slow the progression of PD, and thus prevent falls in PD patients and reduce inpatient visits. The 
effects of slowing PD progression and improving cognitive function may result in lower all-
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cause and PD-related costs among patients who were adherent to antidepressant than those who 
were not. Moreover, as discussed in the demographic characteristics comparisons above, these 
adherent patients in our study had higher pre-index PD-related total costs and higher CCI at 
baseline. This may suggest that better control of depression may decrease all-cause and PD-
related utilization and costs despite the greater PD severity and comorbid disease burden at 
baseline. In addition to the above potential neurobiological link between depression and PD, 
depression has also been identified as a determinant associated with non-adherence to 
antiparkinson medications and higher healthcare costs in PD patients. Taken together, 
improvement of depression care may be associated with better outcomes and reduced healthcare 
costs among depressed PD patients. Besides these, previous studies have also reported that 
depression is a determinant of lower HRQoL among PD patients.
4
 Therefore, improvement in 
control of depression and the potential decrease in inpatient visits may translate into a higher 
HRQoL for depressed PD patients. 
 
4.4 Study Strengths and Limitations 
 Although previous studies have examined antidepressant use in depressed PD patients, no 
study has assessed treatment patterns such as adherence, persistence, and regimen modification 
among this population. Our study provides the first evidence of compliance and treatment 
changes, as well as the factors associated with these treatment patterns of antidepressant use in 
this population. Moreover, the Chen study used VA data with predominantly male elderly 




Therefore, our study may have a better generalizability, especially for the population enrolled in 
a Medicare Advantage Prescription Drug (MAPD) plan 
 Previous studies have suggested that depression may negatively affect PD, but no study 
has investigated whether better adherence with antidepressants, and thus expected better control 
of depression, can improve outcomes in PD patients. Based on our knowledge, our study is the 
first to address the association between adherence to antidepressant treatment and healthcare 
outcomes among depressed PD patients.  
 There are several study limitations. First, because this is an observational study, causal 
relationships cannot be established. This means it cannot be concluded that better adherence to 
antidepressants caused reduced utilization and costs among depressed PD patients, just that there 
is an association. Second, due to the lack of clinical data, we were unable to control for disease 
severity of PD in our present study. Healthcare resource utilization and costs are closely related 
to the severity of PD. In addition, patients with  a PD diagnosis may not receive antiparkinson 
medication until the motor symptoms affect their daily function.
202
 Since depression can occur 
before or after the onset of motor symptoms,
87,203,204
 patients with different PD severity levels 
were included, which in turn may lead to bias in the outcomes. In addition, although it was 
expected that pre-index adherence to PD-related medications would be correlated with AD 
adherence, over 100 patients did not have any PD-related medications before the index AD. 
Clinically, this occurs because practitioners may wait until symptoms of PD are intensified 
before prescribing PD-related medications.
202
 Third, due to the lack of data, we were not able to 
examine those factors (e.g., race, laboratory values, education level, marital status, income, and 
health behavior) that may be relevant to our outcomes. Fourth, the original purpose of 
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administrative claims databases are for reimbursement rather than research. Therefore, the 
potential errors of disease misclassification or miscoding could be possible. Fifth, by using a 
prescription claims database, the outcomes we observed were specifically based on “prescription 
fill patterns” rather than actual “medication taking patterns”. Although high concordance 
between using prescription fill data and pill count were reported in a previous study,
205
 the 
prescription fill data may not exactly reflect true medication use behavior. Sixth, although all of 
our AD users were with depression diagnoses, it could still be possible that some of them also 
used ADs to treat other comorbidities. Lastly, because this study was conducted in patients with 
Medicare Advantage Prescription Drug (MAPD) Plan, and a majority resided in the southern US 
regions, this study may have limited generalizability beyond this population. 
 Although we identified factors associated with adherence and persistence to 
antidepressants, the reasons for discontinuation or non-adherence are not known. Future research 
could conduct interviews with focus groups to understand the reasons behind treatment 
interruption and suboptimal adherence. It would also be interesting to know the association 
between antidepressant dosing escalation and the corresponding adherence changes. Because we 
found our results changed with different PDC cut-off values, future studies may also explore the 





 In conclusion, regimen modifications of antidepressants (switching or combination 
therapy) were associated with better adherence and persistence among depressed PD patients. 
Less frequent all-cause and PD-related inpatient visits as well as lower all-cause and PD-related 
direct medical costs were found in adherent AD users compared to non-adherent AD users 
among depressed PD patients. Our results also have clinical implications. Depression has a 
negative impact on PD and improved adherence to antidepressant may partially reverse this 
impact. Given the fact that depression is often under-diagnosed and untreated,
206
 it is important 
to screen for depression in PD and prescribe and monitor antidepressant treatment for those who 
are identified as depressed PD patients.   
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Appendix 1 Number of claims for different all-cause healthcare utilization 
Category Place of Service Frequency Percent 
OP-office Office      29,196  22.89 
OP-home Home      17,807  13.96 
OP-other Assisted Living Facility             28  0.02 
Urgent Care Facility             17  0.01 
On Campus-Outpatient Hospital      15,062  11.81 
Ambulatory Surgical Center           566  0.44 
Mass Immunization Center               4  0 
End-Stage Renal Disease Treatment Facility        1,509  1.18 
Rural Health Clinic             17  0.01 
Independent Laboratory      11,799  9.25 
Inpatient Inpatient Hospital        24,805  19.45 
Inpatient Psychiatric Facility                  2  0 
Psychiatric Facility-Partial Hospitalization             268  0.21 
Comprehensive Inpatient Rehabilitation Facility             143  0.11 
ER Emergency Room – Hospital          9,966  7.82 
Nursing facility Skilled Nursing Facility          5,666  4.44 
Nursing Facility          8,299  6.51 
Custodial Care Facility                12  0.01 
Others Ambulance - Land          2,324  1.82 
Other Place of Service                32  0.03 
Note: OP=outpatient; ER=emergency room  
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Appendix 2 Number of claims for different PD-related healthcare utilization 
Category Place of Service Frequency Percent 
OP-office Office          5,401  17.08 
OP-home Home          8,793  27.81 
OP-other Assisted Living Facility                  1  0 
Urgent Care Facility                  2  0.01 
On Campus-Outpatient Hospital          2,280  7.21 
Ambulatory Surgical Center                17  0.05 
Independent Laboratory             859  2.72 
Inpatient Inpatient Hospital          6,818  21.56 
Psychiatric Facility-Partial Hospitalization                  7  0.02 
Comprehensive Inpatient Rehabilitation 
Facility 
               24  0.08 
ER Emergency Room – Hospital          2,726  8.62 
Nursing 
facility 
Skilled Nursing Facility          1,857  5.87 
Nursing Facility          2,723  8.61 
Custodial Care Facility                  2  0.01 
Others Ambulance - Land             106  0.34 
 Other Place of Service                  1  0 
Note: OP=outpatient; ER=emergency room   
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Appendix 3 Zero-inflated negative binomial model for number of all-cause outpatient office 
(OP-office) visits  
Variable Coefficient SE z p-value 95% CI 
Being adherent to AD  -0.045 0.052 -0.87 0.386 -0.147 0.057 
Age 0.001 0.005 0.13 0.895 -0.008 0.010 
Female (Ref=Male) 0.043 0.050 0.85 0.394 -0.056 0.141 
Region (Ref=Northeast)       
Midwest -0.465 0.143 -3.25 0.001 -0.745 -0.184 
South -0.292 0.139 -2.11 0.035 -0.564 -0.020 
West -0.418 0.159 -2.62 0.009 -0.730 -0.105 
Having anxiety 0.043 0.059 0.74 0.460 -0.072 0.158 
Having psychosis -0.341 0.107 -3.19 0.001 -0.551 -0.132 
Having dementia -0.174 0.059 -2.93 0.003 -0.290 -0.057 
CCI 0.049 0.010 4.86 <0.001 0.029 0.069 
Having regimen modification -0.118 0.081 -1.46 0.146 -0.278 0.041 
Pre-index PD-related cost 2.8E-06 <0.001 1.27 0.203 -1.5E-06 7.2E-06 
Intercept 3.116 0.376 8.29 <0.001 2.379 3.853 
Inflate       
Being adherent to AD 1.995 1.148 1.74 0.082 -0.255 4.244 
Age 0.071 0.063 1.14 0.256 -0.052 0.194 
Female (Ref=Male) -0.002 0.638 0 0.997 -1.253 1.249 
Region (Ref=Northeast)       
Midwest 16.793 4921.002 0 0.997 -9628.193 9661.780 
South 15.786 4921.002 0 0.997 -9629.200 9660.773 
West 16.658 4921.002 0 0.997 -9628.328 9661.645 
Having anxiety -1.547 1.751 -0.88 0.377 -4.979 1.886 
Having psychosis 1.303 0.712 1.83 0.067 -0.091 2.698 
Having dementia 1.238 0.707 1.75 0.080 -0.147 2.624 
CCI -0.266 0.159 -1.67 0.095 -0.578 0.047 
Having regimen modification 0.187 0.914 0.2 0.838 -1.604 1.978 
Pre-index PD-related cost 1.26E-05 2.12E-05 0.59 0.553 -2.9E-05 5.4E-05 
Intercept -27.249 4921.004 -0.01 0.996 -9672.240 9617.743 
ln alpha -0.809 0.058 -13.95 <0.001 -0.922 -0.695 
Alpha 0.445 0.026 -- -- 0.398 0.499 
Note: Inflation model = logit; LR chi2 = 72.23; Log likelihood = -3225.927; Vuong test: z = 2.34, p = 0.010; AD=antidepressant; 
SE=standard error; CI=confidence interval; CCI=Charlson comorbidity index  
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Appendix 4 Zero-inflated negative binomial model for number of all-cause outpatient home (OP-
home) visits 
Variable Coefficient SE z p-value 95% CI 
Being adherent to AD 0.001 0.152 0 0.996 -0.297 0.298 
Age 0.020 0.014 1.41 0.159 -0.008 0.048 
Female (Ref=Male) 0.054 0.150 0.36 0.717 -0.240 0.348 
Region (Ref=Northeast)       
Midwest 0.781 0.489 1.6 0.11 -0.177 1.740 
South 1.352 0.470 2.88 0.004 0.431 2.274 
West 1.077 0.523 2.06 0.039 0.052 2.102 
Having anxiety -0.088 0.191 -0.46 0.643 -0.463 0.286 
Having psychosis 0.083 0.301 0.28 0.783 -0.508 0.674 
Having dementia 0.112 0.177 0.63 0.527 -0.234 0.458 
CCI 0.110 0.031 3.54 <0.001 0.049 0.170 
Having regimen modification 0.355 0.235 1.51 0.131 -0.106 0.815 
Pre-index PD-related cost 2.5E-05 7.8E-06 3.21 0.001 9.7E-06 4.0E-05 
Intercept -0.856 1.258 -0.68 0.496 -3.322 1.611 
Inflate       
Being adherent to AD 0.161 0.406 0.4 0.691 -0.635 0.958 
Age -0.122 0.049 -2.49 0.013 -0.218 -0.026 
Female (Ref=Male) 0.153 0.403 0.38 0.704 -0.637 0.944 
Region (Ref=Northeast)       
Midwest -0.512 1.430 -0.36 0.721 -3.315 2.292 
South 0.023 1.281 0.02 0.985 -2.488 2.535 
West 0.277 1.336 0.21 0.836 -2.341 2.894 
Having anxiety 0.863 0.526 1.64 0.101 -0.168 1.894 
Having psychosis 0.425 1.050 0.4 0.686 -1.633 2.483 
Having dementia 0.168 0.654 0.26 0.798 -1.114 1.450 
CCI -0.848 0.404 -2.1 0.036 -1.639 -0.057 
Having regimen modification -0.457 0.704 -0.65 0.517 -1.836 0.923 
Pre-index PD-related cost -2.8E-04 1.0E-04 -2.29 0.022 -5.2E-04 -4.1E-05 
Intercept 8.816 3.906 2.26 0.024 1.160 16.471 
ln alpha 1.196 0.102 11.75 <0.001 0.996 1.395 
Alpha 3.306 0.336 -- -- 2.708 4.035 
Note: Inflation model = logit; LR chi2 = 56.54; Log likelihood = -2194.553; Vuong test: z = 4.12, p < 0.001; AD=antidepressant; 
SE=standard error; CI=confidence interval; CCI=Charlson comorbidity index  
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Appendix 5 GzLM with negative binomial distribution and log link for number of all-cause 
outpatient other (OP-other) visits 
Variable Coefficient SE z p-value 95% CI 
Being adherent to AD -0.108 0.073 -1.48 0.138 -0.250 0.035 
Age 0.005 0.006 0.88 0.379 -0.007 0.017 
Female (Ref=Male) 0.114 0.068 1.67 0.095 -0.020 0.247 
Region (Ref=Northeast)       
Midwest 0.135 0.199 0.68 0.497 -0.254 0.524 
South   -0.195 0.194 -1 0.315 -0.575 0.185 
West 0.063 0.219 0.29 0.774 -0.367 0.493 
Having anxiety -0.219 0.081 -2.71 0.007 -0.378 -0.061 
Having psychosis -0.083 0.134 -0.62 0.538 -0.345 0.180 
Having dementia 0.047 0.080 0.59 0.557 -0.110 0.204 
CCI 0.098 0.014 6.91 <0.001 0.070 0.125 
Having regimen modification 0.301 0.111 2.7 0.007 0.083 0.519 
Pre-index PD-related cost 9.7E-06 3.0E-06 3.28 0.001 3.9E-06 1.2E-05 
Intercept 1.652 0.501 3.29 0.001 0.669 2.634 
ln alpha -0.163 0.052 -- -- -0.265 -0.062 
Alpha 0.849 0.044 -- -- 0.767 0.940 
Note: LR chi2 = 99.47; Log likelihood = -2824.5443; p < 0.001; GzLM=generalized linear model; AD=antidepressant; 
SE=standard error; CI=confidence interval; CCI=Charlson comorbidity index  
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Appendix 6 Zero-inflated negative binomial model for number of all-cause nursing facility days 
billed 
Variable Coefficient SE z p-value 95% CI 
Being adherent to AD  0.427 0.171 2.5 0.012 0.092 0.761 
Age 0.006 0.015 0.39 0.698 -0.023 0.034 
Female (Ref=Male) -0.048 0.166 -0.29 0.772 -0.373 0.277 
Region (Ref=Northeast)       
Midwest 0.815 0.394 2.07 0.039 0.043 1.587 
South 0.367 0.398 0.92 0.357 -0.414 1.148 
West 0.662 0.473 1.4 0.161 -0.265 1.590 
Having anxiety -0.143 0.191 -0.75 0.452 -0.517 0.230 
Having psychosis 0.172 0.243 0.71 0.479 -0.304 0.647 
Having dementia 0.274 0.173 1.58 0.113 -0.065 0.613 
CCI -0.011 0.031 -0.35 0.729 -0.072 0.051 
Having regimen modification 0.373 0.236 1.58 0.114 -0.089 0.836 
Pre-index PD-related cost 1.2E-05 6.7E-06 1.77 0.077 -1.3E-06 2.5E-05 
Intercept 1.238 1.195 1.04 0.301 -1.105 3.581 
Inflate       
Being adherent to AD 0.346 0.202 1.71 0.087 -0.050 0.741 
Age -0.092 0.018 -5.1 <0.001 -0.128 -0.057 
Female (Ref=Male) -0.043 0.189 -0.23 0.820 -0.414 0.328 
Region (Ref=Northeast)       
Midwest -0.086 0.572 -0.15 0.880 -1.207 1.035 
South 0.842 0.563 1.5 0.135 -0.261 1.944 
West 0.929 0.636 1.46 0.144 -0.318 2.177 
Having anxiety -0.042 0.226 -0.19 0.851 -0.485 0.400 
Having psychosis -0.612 0.396 -1.54 0.122 -1.389 0.165 
Having dementia -0.974 0.213 -4.57 <0.001 -1.391 -0.556 
CCI -0.176 0.046 -3.84 <0.001 -0.265 -0.086 
Having regimen modification -0.493 0.300 -1.65 0.100 -1.080 0.094 
Pre-index PD-related cost -1.9E-05 9.0E-06 -2.11 0.034 -3.7E-05 -1.4E-06 
Intercept 7.833 1.476 5.31 <0.001 4.939 10.727 
ln alpha 0.418 0.161 2.59 0.010 0.101 0.735 
alpha 1.519 0.245 -- -- 1.107 2.085 
Note: Inflation model = logit; LR chi2 = 30.40; Log likelihood = -1430.849; Vuong test: z = 6.32, p = 0.010; AD=antidepressant; 
SE=standard error; CI=confidence interval; CCI=Charlson comorbidity index 
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Appendix 7 Zero-inflated negative binomial model for number of all-cause inpatient visits 
Variable Coefficient SE z p-value 95% CI 
Being adherent to AD  -0.332 0.123 -2.7 0.007 -0.573 -0.091 
Age -0.008 0.010 -0.79 0.427 -0.028 0.012 
Female (Ref=Male) -0.013 0.113 -0.11 0.909 -0.234 0.208 
Region (Ref=Northeast)       
Midwest 0.165 0.347 0.48 0.634 -0.515 0.846 
South 0.181 0.343 0.53 0.598 -0.491 0.852 
West 0.210 0.387 0.54 0.587 -0.549 0.969 
Having anxiety -0.055 0.143 -0.39 0.7 -0.335 0.225 
Having psychosis 0.416 0.192 2.16 0.031 0.039 0.793 
Having dementia -0.003 0.130 -0.02 0.981 -0.259 0.253 
CCI 0.085 0.021 4.16 <0.001 0.045 0.125 
Having regimen modification 0.426 0.191 2.23 0.026 0.051 0.800 
Pre-index PD-related cost 6.7E-06 4.3E-06 1.57 0.117 -1.7E-06 1.5E-05 
Intercept 0.618 0.876 0.71 0.48 -1.098 2.335 
Inflate       
Being adherent to AD  0.242 0.593 0.41 0.683 -0.920 1.404 
Age -0.137 0.046 -3.01 0.003 -0.226 -0.048 
Female (Ref=Male) -0.573 0.572 -1.00 0.316 -1.695 0.549 
Region (Ref=Northeast)       
Midwest -1.668 1.291 -1.29 0.196 -4.198 0.863 
South -0.605 1.049 -0.58 0.564 -2.661 1.452 
West -0.452 1.209 -0.37 0.708 -2.822 1.918 
Having anxiety 0.955 0.632 1.51 0.131 -0.284 2.195 
Having psychosis -0.069 1.390 -0.05 0.960 -2.794 2.656 
Having dementia -0.437 0.878 -0.50 0.619 -2.159 1.284 
CCI -0.497 0.210 -2.37 0.018 -0.908 -0.086 
Having regimen modification 0.509 0.827 0.62 0.538 -1.111 2.130 
Pre-index PD-related cost -4.5E-04 2.0E-04 -2.29 0.022 -0.001 -6E-04 
Intercept 10.622 3.605 2.95 0.003 3.556 17.688 
ln alpha -0.100 0.137 -0.73 0.463 -0.369 0.168 
alpha 0.904 0.124 -- -- 0.691 1.183 
Note: Inflation model = logit; LR chi2 = 36.74; Log likelihood = -1251.198; Vuong test: z = 2.95, p = 0.002; AD=antidepressant; 
SE=standard error; CI=confidence interval; CCI=Charlson comorbidity index 
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Appendix 8 GzLM with negative binomial distribution and log link for number of all-cause ER 
visits 
Variable Coefficient SE z p-value 95% CI 
Being adherent to AD -0.158 0.120 -1.32 0.188 -0.395 0.078 
Age 0.004 0.011 0.37 0.713 -0.017 0.025 
Female (Ref=Male) 0.289 0.118 2.46 0.014 0.058 0.520 
Region (Ref=Northeast)       
Midwest 0.244 0.343 0.71 0.478 -0.429 0.917 
South   -0.034 0.336 -0.1 0.919 -0.694 0.625 
West -0.116 0.387 -0.3 0.764 -0.875 0.643 
Having anxiety -0.049 0.140 -0.35 0.726 -0.324 0.226 
Having psychosis 0.028 0.220 0.13 0.898 -0.403 0.460 
Having dementia 0.153 0.132 1.16 0.246 -0.106 0.413 
CCI 0.042 0.024 1.78 0.076 -0.004 0.089 
Having regimen modification 0.294 0.176 1.67 0.095 -0.051 0.639 
Pre-index PD-related cost 1.2E-05 5.0E-06 2.4 0.016 2.2E-06 2.2E-05 
Intercept -1.190 0.880 -1.35 0.177 -2.915 0.536 
ln alpha 0.088 0.157 -- -- -0.220 0.397 
Alpha 1.093 0.172 -- -- 0.803 1.487 
Note: LR chi2 =26.45; Log likelihood = -885.48097; p =0.009; GzLM=generalized linear model; AD=antidepressant; 
SE=standard error; CI=confidence interval; CCI=Charlson comorbidity index; ER=emergency room  
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Appendix 9 Zero-inflated negative binomial model for number of PD-related outpatient office 
(OP-office) visits 
Variable Coefficient SE z p-value 95% CI 
Being adherent to AD -0.060 0.080 -0.75 0.453 -0.216 0.096 
Age -0.001 0.007 -0.18 0.857 -0.016 0.013 
Female (Ref=Male) 0.086 0.079 1.09 0.276 -0.068 0.240 
Region (Ref=Northeast)       
Midwest -0.976 0.207 -4.73 <0.001 -1.381 -0.571 
South -0.862 0.194 -4.44 <0.001 -1.242 -0.481 
West -0.907 0.233 -3.9 <0.001 -1.363 -0.452 
Having anxiety -0.005 0.091 -0.05 0.958 -0.184 0.174 
Having psychosis -0.465 0.188 -2.47 0.013 -0.833 -0.097 
Having dementia -0.233 0.096 -2.43 0.015 -0.421 -0.045 
CCI -0.029 0.018 -1.64 0.101 -0.063 0.006 
Having regimen 
modification 
0.013 0.118 0.11 0.915 -0.219 0.244 
Pre-index PD-related cost 1.8E-5 3.6E-6 4.97 <0.001 1.1E-5 2.5E-5 
Intercept 2.535 0.591 4.29 <0.001 1.376 3.693 
Inflate       
Being adherent to AD  0.269 0.481 0.56 0.577 -0.675 1.212 
Age 0.045 0.051 0.89 0.375 -0.054 0.144 
Female (Ref=Male) 0.208 0.497 0.42 0.676 -0.766 1.181 
Region (Ref=Northeast)       
Midwest 1.491 1.526 0.98 0.328 -1.499 4.481 
South 0.420 1.439 0.29 0.770 -2.401 3.242 
West 0.750 1.726 0.43 0.664 -2.633 4.133 
Having anxiety -0.401 0.698 -0.57 0.565 -1.769 0.966 
Having psychosis -0.556 1.066 -0.52 0.602 -2.645 1.534 
Having dementia 0.920 0.476 1.93 0.053 -0.012 1.853 
CCI 0.212 0.074 2.88 0.004 0.068 0.357 
Having regimen 
modification 
-0.362 0.754 -0.48 0.631 -1.840 1.115 
Pre-index PD-related cost 1.7E-05 1.2E-05 1.41 0.158 -6.5E-06 4.0E-05 
Intercept -7.812 4.450 -1.76 0.079 -16.534 0.911 
ln alpha -0.317 0.093 -3.4 0.001 -0.500 -0.134 
alpha 0.728 0.068 -- -- 0.606 0.874 
Note: Inflation model = logit; LR chi2 = 79.03; Log likelihood = -2156.948; Vuong test: z = 2.20, p = 0.014; PD=Parkinson’s 
disease; AD=antidepressant; SE=standard error; CI=confidence interval; CCI=Charlson comorbidity index 
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Appendix 10 Zero-inflated negative binomial model for number of PD-related outpatient home 
(OP-home) visits 
Variables Coefficient SE z p-value 95% CI 
Being adherent to AD  -0.249 0.253 -0.98 0.325 -0.744 0.247 
Age 0.064 0.023 2.81 0.005 0.019 0.109 
Female -0.494 0.248 -2 0.046 -0.979 -0.009 
Region       
Midwest 1.797 0.675 2.66 0.008 0.475 3.120 
South 2.075 0.629 3.3 0.001 0.842 3.308 
West 1.428 0.741 1.93 0.054 -0.025 2.881 
Having anxiety 0.450 0.326 1.38 0.168 -0.190 1.089 
Having psychosis 0.392 0.501 0.78 0.434 -0.590 1.374 
Having dementia -0.481 0.297 -1.62 0.106 -1.064 0.102 
CCI 0.130 0.057 2.29 0.022 0.018 0.241 
Having regimen modification 0.509 0.369 1.38 0.168 -0.215 1.233 
Pre-index PD-related cost 2.7E-05 1.1E-05 2.38 0.017 4.7E-06 4.8E-05 
Intercept -5.174 1.934 -2.68 0.007 -8.964 -1.384 
Inflate       
Being adherent to AD -0.163 0.471 -0.35 0.729 -1.087 0.760 
Age -0.038 0.038 -1.01 0.314 -0.112 0.036 
Female -1.205 0.690 -1.75 0.081 -2.557 0.148 
Region       
Midwest 2.269 2.402 0.94 0.345 -2.439 6.976 
South 2.243 2.372 0.95 0.344 -2.406 6.893 
West 2.738 2.486 1.1 0.271 -2.134 7.610 
Having anxiety 1.774 0.740 2.4 0.017 0.323 3.225 
Having psychosis 3.745 1.553 2.41 0.016 0.701 6.789 
Having dementia 0.040 0.620 0.06 0.949 -1.176 1.256 
CCI 0.056 0.085 0.66 0.507 -0.110 0.222 
Having regimen modification -0.002 0.668 0 0.997 -1.312 1.307 
Pre-index PD-related cost -0.001 0.001 -2.05 0.040 -0.003 -6.5E-05 
Intercept 1.043 3.778 0.28 0.783 -6.361 8.447 
ln alpha 1.833 0.131 14.03 <0.001 1.577 2.089 
alpha 6.251 0.816 -- -- 4.839 8.074 
Note: Inflation model = logit; LR chi2 = 34.58; Log likelihood = -1300.138; Vuong test: z = 4.96, p < 0.001; PD=Parkinson’s 
disease; AD=antidepressant; SE=standard error; CI=confidence interval; CCI=Charlson comorbidity index 
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Appendix 11 GzLM with negative binomial distribution and log link for number of PD-related 
outpatient other (OP-other) visits 
Variable Coefficient SE z p-value 95% CI 
Being adherent to AD -0.016 0.166 -0.1 0.921 -0.342 0.309 
Age -0.042 0.014 -2.96 0.003 -0.070 -0.014 
Female (Ref=Male) -0.331 0.153 -2.17 0.030 -0.631 -0.032 
Region (Ref=Northeast)       
Midwest -0.747 0.418 -1.79 0.074 -1.566 0.073 
South -1.179 0.407 -2.9 0.004 -1.978 -0.381 
West -0.288 0.465 -0.62 0.535 -1.199 0.623 
Having anxiety -0.233 0.186 -1.25 0.210 -0.597 0.131 
Having psychosis -0.038 0.322 -0.12 0.905 -0.670 0.594 
Having dementia -0.413 0.193 -2.14 0.033 -0.791 -0.034 
CCI -0.116 0.031 -3.72 <0.001 -0.177 -0.055 
Having regimen modification 0.478 0.256 1.87 0.062 -0.023 0.979 
Pre-index PD-related cost 1.9E-05 7.1E-06 2.66 0.008 5.0E-06 3.3E-05 
Intercept 4.592 1.118 4.11 <0.001 2.400 6.784 
ln alpha 1.309 0.085 -- -- 1.143 1.475 
alpha 3.702 0.314 -- -- 3.135 4.371 
Note: LR chi2 = 69.80; Log likelihood = -1129.661; p < 0.001; GzLM=generalized linear model; PD=Parkinson’s disease; 
AD=antidepressant; SE=standard error; CI=confidence interval; CCI=Charlson comorbidity index   
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Appendix 12 Zero-inflated negative binomial model for number of PD-related nursing facility 
days billed 
Variable Coefficient SE z p-value 95% CI 
Being adherent to AD 0.509 0.267 1.9 0.057 -0.015 1.033 
Age -0.036 0.027 -1.3 0.195 -0.089 0.018 
Female -0.149 0.297 -0.5 0.614 -0.731 0.432 
Region       
Midwest 0.138 0.779 0.18 0.859 -1.388 1.665 
South 0.393 0.811 0.49 0.627 -1.195 1.982 
West -0.282 0.925 -0.3 0.760 -2.095 1.531 
Having anxiety 0.005 0.326 0.02 0.987 -0.634 0.645 
Having psychosis -0.361 0.419 -0.86 0.388 -1.183 0.460 
Having dementia 0.411 0.305 1.35 0.178 -0.187 1.010 
CCI -0.085 0.065 -1.31 0.191 -0.213 0.043 
Having regimen modification 0.131 0.362 0.36 0.718 -0.579 0.840 
Pre-index PD-related cost 1.2E-05 8.4E-06 1.38 0.166 -4.8E-06 2.8E-05 
Intercept 3.529 2.294 1.54 0.124 -0.968 8.025 
Inflate       
Being adherent to AD  0.667 0.380 1.76 0.079 -0.078 1.412 
Age -0.137 0.032 -4.22 <0.001 -0.200 -0.073 
Female 0.110 0.356 0.31 0.758 -0.588 0.808 
Region       
Midwest -1.300 0.979 -1.33 0.184 -3.219 0.618 
South 0.483 0.923 0.52 0.600 -1.325 2.291 
West 0.681 1.132 0.6 0.548 -1.538 2.899 
Having anxiety 0.300 0.408 0.73 0.463 -0.501 1.100 
Having psychosis -1.651 0.995 -1.66 0.097 -3.601 0.298 
Having dementia -1.098 0.415 -2.65 0.008 -1.911 -0.285 
CCI -0.092 0.101 -0.91 0.362 -0.291 0.106 
Having regimen modification -1.104 0.544 -2.03 0.042 -2.170 -0.037 
Pre-index PD-related cost -1.1E-04 5.1E-05 -2.15 0.031 -2.1E-04 -9.9E-06 
Intercept 11.729 2.580 4.55 0 6.672 16.785 
Ln alpha 1.362 0.227 6.01 0 0.918 1.807 
Alpha 3.905 0.886 -- -- 2.503 6.091 
Note: Inflation model = logit; LR chi2 = 16.44; Log likelihood = -803.994; Vuong test: z = 5.26, p < 0.001; PD=Parkinson’s 
disease; AD=antidepressant; SE=standard error; CI=confidence interval; CCI=Charlson comorbidity index 
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Appendix 13 Zero-inflated negative binomial model for number of PD-related inpatient visits 
Variable Coefficient SE z p-value 95% CI 
Being adherent to AD -0.221 0.176 -1.26 0.209 -0.566 0.124 
Age -0.005 0.015 -0.34 0.735 -0.034 0.024 
Female -0.017 0.171 -0.1 0.922 -0.352 0.318 
Region       
Midwest 0.505 0.546 0.92 0.355 -0.565 1.575 
South 0.281 0.538 0.52 0.601 -0.773 1.336 
West 0.573 0.583 0.98 0.326 -0.570 1.715 
Having anxiety -0.180 0.203 -0.88 0.377 -0.578 0.219 
Having psychosis 0.016 0.287 0.05 0.956 -0.547 0.578 
Having dementia 0.186 0.192 0.97 0.331 -0.189 0.562 
CCI -0.008 0.028 -0.27 0.788 -0.063 0.048 
Having regimen modification 0.261 0.277 0.94 0.347 -0.282 0.805 
Pre-index PD-related cost 7.1E-06 5.5E-06 1.29 0.197 -3.7E-06 1.8E-05 
Intercept -0.197 1.281 -0.15 0.878 -2.708 2.314 
Inflate       
Being adherent to AD  0.558 0.533 1.05 0.295 -0.487 1.603 
Age -0.070 0.043 -1.61 0.107 -0.155 0.015 
Female -0.066 0.534 -0.12 0.902 -1.113 0.981 
Region       
Midwest -0.468 1.561 -0.3 0.764 -3.528 2.592 
South 0.042 1.509 0.03 0.978 -2.916 2.999 
West 0.488 1.597 0.31 0.76 -2.642 3.618 
Having anxiety 0.086 0.602 0.14 0.887 -1.094 1.265 
Having psychosis -0.182 1.082 -0.17 0.867 -2.302 1.939 
Having dementia 0.798 0.561 1.42 0.155 -0.301 1.897 
CCI -0.208 0.129 -1.61 0.108 -0.462 0.046 
Having regimen modification 0.516 0.687 0.75 0.452 -0.830 1.862 
Pre-index PD-related cost -0.001 3.9E-04 -2.18 0.029 -0.002 -8.6E-05 
Intercept 5.174 3.668 1.41 0.158 -2.016 12.364 
ln alpha 0.131 0.200 0.66 0.511 -0.260 0.522 
Alpha 1.140 0.228 -- -- 0.771 1.686 
Note: Inflation model = logit; LR chi2 = 9.74; Log likelihood = -840.1256; Vuong test: z = 2.95, p = 0.002; PD=Parkinson’s 
disease; AD=antidepressant; SE=standard error; CI=confidence interval; CCI=Charlson comorbidity index 
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Appendix 14 Zero-inflated negative binomial model for number of PD-related ER visits 
Variable Coefficient SE z p-value 95% CI 
Being adherent to AD -0.348 0.249 -1.4 0.161 -0.836 0.139 
Age 0.004 0.020 0.2 0.843 -0.036 0.044 
Female -0.023 0.241 -0.1 0.923 -0.495 0.449 
Region       
Midwest 0.893 0.533 1.67 0.094 -0.153 1.938 
South 0.637 0.532 1.2 0.231 -0.405 1.679 
West 1.029 0.599 1.72 0.086 -0.145 2.202 
Having anxiety -0.047 0.329 -0.14 0.885 -0.692 0.597 
Having psychosis -0.005 0.376 -0.01 0.990 -0.742 0.733 
Having dementia -0.217 0.286 -0.76 0.449 -0.777 0.344 
CCI -0.072 0.061 -1.19 0.235 -0.191 0.047 
Having regimen modification 0.151 0.349 0.43 0.665 -0.533 0.835 
Pre-index PD-related cost 1.3E-07 8.2E-06 0.02 0.987 -1.6E-05 1.6E-05 
Intercept -1.560 1.635 -0.95 0.340 -4.764 1.645 
Inflate       
Being adherent to AD -0.753 0.618 -1.22 0.223 -1.964 0.458 
Age -0.022 0.045 -0.49 0.626 -0.109 0.066 
Female -0.290 0.547 -0.53 0.596 -1.363 0.782 
Region       
Midwest 13.171 682.152 0.02 0.985 -1323.823 1350.165 
South 13.486 682.152 0.02 0.984 -1323.507 1350.478 
West 13.569 682.152 0.02 0.984 -1323.424 1350.563 
Having anxiety 0.433 0.770 0.56 0.574 -1.076 1.941 
Having psychosis -0.148 1.268 -0.12 0.907 -2.633 2.337 
Having dementia -0.032 0.737 -0.04 0.966 -1.476 1.412 
CCI -0.166 0.237 -0.7 0.484 -0.631 0.299 
Having regimen modification -1.224 1.178 -1.04 0.299 -3.534 1.085 
Pre-index PD-related cost -5.0E-04 3.2E-04 -1.57 0.116 -0.001 1.2E-04 
Intercept -10.303 682.164 -0.02 0.988 -1347.319 1326.714 
ln alpha -0.309 0.459 -0.67 0.501 -1.210 0.591 
Alpha 0.734 0.337 -- -- 0.298 1.806 
Note: Inflation model = logit; LR chi2 =8.65; Log likelihood = -469.7431; Vuong test: z = 2.63, p = 0.004; PD=Parkinson’s 
disease; ER=emergency room; AD=antidepressant; SE=standard error; CI=confidence interval; CCI=Charlson comorbidity index 
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Appendix 15 Two part model for all-cause outpatient office (OP-office) cost 
Variable Coefficient SE z p-value 95% CI 
Logit       
Being adherent to AD -1.530 0.528 -2.9 0.004 -2.565 -0.496 
Age -0.048 0.043 -1.12 0.262 -0.133 0.036 
Female (Ref=Male) 0.156 0.457 0.34 0.733 -0.739 1.051 
Region (Ref=Northeast)       
Midwest -0.221 0.810 -0.27 0.784 -1.808 1.365 
South 0.481 0.820 0.59 0.557 -1.125 2.087 
Having anxiety 0.687 0.654 1.05 0.294 -0.595 1.969 
Having psychosis -0.874 0.551 -1.59 0.113 -1.953 0.206 
Having dementia -1.198 0.479 -2.5 0.012 -2.136 -0.259 
CCI 0.254 0.123 2.06 0.039 0.013 0.496 
Having regimen modification 0.082 0.657 0.12 0.901 -1.207 1.370 
Pre-index PD-related cost -1.9E-05 1.3E-05 -1.52 0.129 -4.4E-05 5.5E-06 
Intercept 8.116 3.309 2.45 0.014 1.630 14.602 
GzLM       
Being adherent to antidepressant 0.125 0.079 1.59 0.111 -0.029 0.280 
Age 4.5E-04 0.007 0.06 0.949 -0.013 0.014 
Female (Ref=Male) -0.036 0.076 -0.47 0.637 -0.184 0.113 
Region (Ref=Northeast)       
Midwest -0.742 0.224 -3.31 0.001 -1.181 -0.303 
South -0.612 0.219 -2.79 0.005 -1.042 -0.183 
West -0.706 0.247 -2.86 0.004 -1.190 -0.222 
Having anxiety 0.084 0.089 0.94 0.345 -0.090 0.259 
Having psychosis -0.275 0.158 -1.75 0.081 -0.584 0.034 
Having dementia -0.280 0.089 -3.14 0.002 -0.454 -0.105 
CCI 0.065 0.016 4.05 <0.001 0.034 0.097 
Having regimen modification -0.150 0.122 -1.23 0.218 -0.388 0.088 
Pre-index PD-related cost 5.6E-06 3.4E-06 1.68 0.093 -9.4E-07 1.2E-05 
Intercept 8.170 0.578 14.14 <0.001 7.037 9.302 
Note: Log pseudolikelihood = -7321.945; Region category—West was omitted in logit model because of collinearity; 
AD=antidepressant; SE=standard error; CI=confidence interval; CCI=Charlson comorbidity index; GzLM=generalized linear 
model  
 149 
Appendix 16 Two part model for all-cause outpatient home (OP-home) cost 
Variable Coefficient SE z p-value 95% CI 
Logit       
Being adherent to AD -0.240 0.150 -1.59 0.111 -0.534 0.055 
Age 0.038 0.013 2.84 0.005 0.012 0.064 
Female (Ref=Male) 0.101 0.145 0.7 0.487 -0.184 0.386 
Region (Ref=Northeast)       
Midwest 0.071 0.431 0.16 0.87 -0.775 0.916 
South 0.150 0.421 0.36 0.722 -0.675 0.975 
West 0.074 0.477 0.16 0.876 -0.861 1.010 
       
Having anxiety -0.278 0.172 -1.62 0.105 -0.614 0.058 
Having psychosis -0.425 0.300 -1.42 0.157 -1.014 0.163 
Having dementia 0.252 0.172 1.47 0.143 -0.085 0.589 
CCI 0.158 0.032 4.85 <0.001 0.094 0.221 
Having regimen modification 0.268 0.236 1.14 0.255 -0.193 0.730 
Pre-index PD-related cost 3.3E-05 8.2E-06 4.03 <0.001 1.7E-05 4.9E-05 
Intercept -3.305 1.105 -2.99 0.003 -5.470 -1.140 
GzLM       
Being adherent to AD 0.190 0.155 1.23 0.221 -0.114 0.493 
Age 0.014 0.014 0.96 0.337 -0.014 0.041 
Female (Ref=Male) 0.196 0.148 1.32 0.188 -0.095 0.487 
Region (Ref=Northeast)       
Midwest 0.307 0.443 0.69 0.488 -0.561 1.175 
South 0.366 0.429 0.85 0.393 -0.474 1.206 
West 0.489 0.491 1 0.319 -0.473 1.451 
Having anxiety -0.045 0.191 -0.24 0.813 -0.419 0.329 
Having psychosis 0.082 0.296 0.28 0.781 -0.498 0.663 
Having dementia 0.183 0.167 1.09 0.275 -0.145 0.511 
CCI 0.071 0.032 2.24 0.025 0.009 0.133 
Having regimen modification 0.093 0.228 0.41 0.684 -0.354 0.540 
Pre-index PD-related cost 2.2E-05 7.4E-06 3.03 0.002 7.9E-06 3.7E-05 
Intercept 6.762 1.166 5.8 <0.001 4.477 9.046 
Note: Log pseudolikelihood = -4955.016; AD=antidepressant; SE=standard error; CI=confidence interval; CCI=Charlson 
comorbidity index; GzLM=generalized linear model  
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Appendix 17 Two part model for all-cause outpatient other (OP-other) cost 
Variable Coefficient SE z p-value 95% CI 
logit       
Being adherent to AD  0.064 0.367 0.17 0.861 -0.655 0.783 
Age -0.014 0.033 -0.41 0.681 -0.078 0.051 
Female (Ref=Male) 0.360 0.362 0.99 0.320 -0.350 1.069 
Region (Ref=Northeast)       
Midwest 0.393 0.630 0.62 0.533 -0.843 1.628 
South -0.058 0.573 -0.1 0.919 -1.182 1.065 
Having anxiety 0.062 0.426 0.15 0.884 -0.772 0.897 
Having psychosis -0.418 0.609 -0.69 0.493 -1.611 0.776 
Having dementia -0.611 0.394 -1.55 0.121 -1.383 0.161 
CCI 0.412 0.130 3.16 0.002 0.157 0.668 
Having regimen modification 0.052 0.561 0.09 0.926 -1.046 1.151 
Pre-index PD-related cost -1.6E-05 1.2E-05 -1.4 0.162 -3.9E-05 6.5E-06 
Intercept 3.555 2.491 1.43 0.153 -1.327 8.437 
GzLM       
Being adherent to AD -0.315 0.181 -1.74 0.081 -0.670 0.039 
Age -0.027 0.015 -1.79 0.074 -0.056 0.003 
Female (Ref=Male) 0.011 0.167 0.07 0.947 -0.317 0.339 
Region (Ref=Northeast)       
Midwest 0.251 0.521 0.48 0.630 -0.771 1.273 
South -0.212 0.514 -0.41 0.681 -1.219 0.796 
West -0.192 0.574 -0.34 0.738 -1.318 0.933 
Having anxiety -0.206 0.203 -1.02 0.310 -0.603 0.192 
Having psychosis -0.244 0.356 -0.69 0.493 -0.942 0.454 
Having dementia -0.208 0.199 -1.05 0.294 -0.598 0.181 
CCI 0.126 0.037 3.39 0.001 0.053 0.198 
Having regimen modification 0.240 0.284 0.84 0.399 -0.318 0.797 
Pre-index PD-related cost 4.4E-06 6.5E-06 0.67 0.500 -8.4E-06 1.7E-05 
Intercept 9.805 1.247 7.87 <0.001 7.362 12.248 
Note: Log pseudolikelihood = -7377.381; Region category—West was omitted in logit model because of collinearity; 
AD=antidepressant; SE=standard error; CI=confidence interval; CCI=Charlson comorbidity index; GzLM=generalized linear 
model  
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Appendix 18 Two part model for all-cause nursing facility cost 
Variable Coefficient SE z p-value 95% CI 
Logit       
Being adherent to AD -0.194 0.171 -1.13 0.258 -0.530 0.142 
Age 0.084 0.016 5.3 0 0.053 0.115 
Female (Ref=Male) 0.026 0.167 0.15 0.877 -0.301 0.352 
Region (Ref=Northeast)       
Midwest 0.194 0.454 0.43 0.67 -0.696 1.084 
South -0.681 0.445 -1.53 0.126 -1.553 0.190 
West -0.773 0.524 -1.48 0.14 -1.801 0.254 
Having anxiety 0.016 0.198 0.08 0.936 -0.372 0.404 
Having psychosis 0.480 0.308 1.56 0.119 -0.124 1.084 
Having dementia 0.902 0.179 5.05 <0.001 0.552 1.253 
CCI 0.137 0.033 4.16 <0.001 0.073 0.202 
Having regimen modification 0.402 0.255 1.57 0.115 -0.098 0.903 
Pre-index PD-related cost 1.9E-05 7.0E-06 2.75 0.006 5.5E-06 3.3E-05 
Intercept -7.553 1.300 -5.81 <0.001 -10.101 -5.005 
GzLM       
Being adherent to AD -0.685 0.149 -4.6 <0.001 -0.977 -0.393 
Age -0.002 0.013 -0.14 0.887 -0.028 0.024 
Female (Ref=Male) 0.081 0.147 0.55 0.584 -0.208 0.369 
Region (Ref=Northeast)       
Midwest 0.246 0.349 0.71 0.480 -0.438 0.930 
South -0.114 0.348 -0.33 0.744 -0.796 0.569 
West -0.218 0.431 -0.51 0.612 -1.063 0.626 
Having anxiety -0.190 0.170 -1.12 0.263 -0.524 0.143 
Having psychosis -0.024 0.226 -0.11 0.914 -0.467 0.418 
Having dementia 0.230 0.154 1.5 0.135 -0.071 0.531 
CCI -0.030 0.025 -1.19 0.233 -0.079 0.019 
Having regimen modification 0.127 0.211 0.6 0.547 -0.286 0.540 
Pre-index PD-related cost 1.1E-05 5.8E-06 1.83 0.067 -7.5E-07 2.2E-05 
Intercept 9.663 1.080 8.94 <0.001 7.545 11.780 
Note: Log pseudolikelihood = -3143.230; AD=antidepressant; SE=standard error; CI=confidence interval; CCI=Charlson 
comorbidity index; GzLM=generalized linear model  
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Appendix 19 Two part model for all-cause inpatient cost 
Variable Coefficient SE z p-value 95% CI 
Logit       
Being adherent to AD -0.473 0.151 -3.13 0.002 -0.770 -0.177 
Age 0.028 0.013 2.12 0.034 0.002 0.055 
Female (Ref=Male) 0.076 0.145 0.52 0.602 -0.209 0.360 
Region (Ref=Northeast)       
Midwest 0.298 0.432 0.69 0.490 -0.549 1.144 
South 0.150 0.421 0.36 0.722 -0.675 0.976 
West 0.195 0.477 0.41 0.683 -0.740 1.130 
Having anxiety -0.222 0.171 -1.29 0.196 -0.558 0.114 
Having psychosis 0.448 0.309 1.45 0.148 -0.159 1.054 
Having dementia 0.159 0.171 0.93 0.351 -0.175 0.494 
CCI 0.165 0.033 5.07 <0.001 0.101 0.229 
Having regimen modification 0.327 0.235 1.39 0.163 -0.133 0.788 
Pre-index PD-related cost 2.6E-05 7.7E-06 3.42 0.001 1.1E-05 4.1E-05 
Intercept -2.694 1.105 -2.44 0.015 -4.861 -0.528 
GzLM       
Being adherent to AD  -0.310 0.132 -2.34 0.019 -0.570 -0.051 
Age -0.007 0.011 -0.65 0.517 -0.030 0.015 
Female (Ref=Male) 0.004 0.128 0.03 0.974 -0.247 0.255 
Region (Ref=Northeast)       
Midwest 0.714 0.379 1.89 0.059 -0.028 1.457 
South 0.577 0.370 1.56 0.119 -0.148 1.302 
West 0.733 0.419 1.75 0.080 -0.088 1.555 
Having anxiety 0.190 0.155 1.23 0.218 -0.113 0.493 
Having psychosis 0.193 0.222 0.87 0.384 -0.241 0.628 
Having dementia -0.044 0.142 -0.31 0.759 -0.323 0.235 
CCI 0.063 0.024 2.59 0.010 0.015 0.110 
Having regimen modification -0.155 0.200 -0.78 0.437 -0.546 0.236 
Pre-index PD-related cost 2.0E-06 5.4E-06 0.36 0.716 -8.6E-06 1.3E-05 
Intercept 9.561 0.980 9.75 <0.001 7.639 11.482 
Note: Log pseudolikelihood = -5193.728; AD=antidepressant; SE=standard error; CI=confidence interval; CCI=Charlson 
comorbidity index; GzLM=generalized linear model   
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Appendix 20 Two part model for all-cause ER cost 
Variable Coefficient SE z p-value 95% CI 
Logit       
Being adherent to AD -0.283 0.150 -1.89 0.059 -0.578 0.011 
Age 0.042 0.013 3.14 0.002 0.016 0.068 
Female (Ref=Male) 0.359 0.145 2.47 0.014 0.074 0.644 
Region (Ref=Northeast)       
Midwest -0.145 0.446 -0.32 0.745 -1.018 0.729 
South -0.540 0.435 -1.24 0.214 -1.392 0.312 
West -0.401 0.489 -0.82 0.413 -1.360 0.558 
Having anxiety -0.034 0.171 -0.2 0.843 -0.369 0.302 
Having psychosis 0.119 0.308 0.39 0.699 -0.485 0.723 
Having dementia 0.219 0.172 1.27 0.204 -0.119 0.556 
CCI 0.140 0.032 4.32 <0.001 0.077 0.204 
Having regimen modification 0.438 0.237 1.85 0.064 -0.026 0.903 
Pre-index PD-related cost 1.5E-05 7.1E-06 2.13 0.033 1.2E-06 2.9E-05 
Intercept -3.085 1.107 -2.79 0.005 -5.255 -0.915 
GzLM       
Being adherent to AD -0.172 0.116 -1.48 0.140 -0.399 0.056 
Age -0.009 0.010 -0.87 0.383 -0.029 0.011 
Female (Ref=Male) -0.190 0.113 -1.69 0.091 -0.411 0.030 
Region (Ref=Northeast)       
Midwest 0.527 0.302 1.75 0.081 -0.064 1.119 
South 0.437 0.296 1.48 0.139 -0.142 1.016 
West 0.133 0.341 0.39 0.697 -0.536 0.802 
Having anxiety 0.312 0.134 2.33 0.020 0.049 0.575 
Having psychosis 0.165 0.206 0.8 0.422 -0.238 0.568 
Having dementia -0.125 0.123 -1.02 0.308 -0.367 0.116 
CCI 0.041 0.023 1.8 0.072 -0.004 0.086 
Having regimen modification 0.160 0.170 0.94 0.346 -0.173 0.493 
Pre-index PD-related cost 2.7E-06 5.4E-06 0.5 0.618 -7.9E-06 1.3E-05 
Intercept 7.419 0.842 8.81 <0.001 5.768 9.070 
Note: Log pseudolikelihood = -4442.048; ER=emergency room; AD=antidepressant; SE=standard error; CI=confidence interval; 
CCI=Charlson comorbidity index; GzLM=generalized linear model   
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Appendix 21 GzLM for all-cause pharmacy cost 
Variable Coefficient SE z p-value 95% CI 
Being adherent to AD 0.307 0.058 5.33 <0.001 0.194 0.420 
Age -0.010 0.005 -1.95 0.052 -0.020 0.000 
Female (Ref=Male) 0.022 0.057 0.39 0.696 -0.089 0.133 
Region (Ref=Northeast)       
Midwest 0.104 0.166 0.63 0.531 -0.221 0.429 
South 0.042 0.161 0.26 0.796 -0.274 0.358 
West 0.148 0.183 0.81 0.419 -0.211 0.507 
Having anxiety -0.084 0.067 -1.25 0.211 -0.216 0.048 
Having psychosis 0.068 0.114 0.6 0.549 -0.155 0.291 
Having dementia 0.240 0.066 3.62 <0.001 0.110 0.370 
CCI 0.054 0.012 4.5 <0.001 0.030 0.077 
Having regimen modification 0.181 0.090 2.01 0.045 0.004 0.358 
Pre-index PD-related cost 9.0E-06 2.8E-06 3.24 0.001 3.6E-06 1.4E-05 
Intercept 8.604 0.424 20.28 <0.001 7.772 9.436 
Note: Log likelihood   = -7946.961; GzLM=generalized linear model; AD=antidepressant; SE=standard error; CI=confidence 
interval; CCI=Charlson comorbidity index   
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Appendix 22 GzLM for all-cause total cost 
Variable Coefficient SE z p-value 95% CI 
Being adherent to AD -0.213 0.080 -2.65 0.008 -0.370 -0.055 
Age 0.010 0.007 1.42 0.157 -0.004 0.024 
Female (Ref=Male) 0.049 0.079 0.63 0.530 -0.105 0.203 
Region (Ref=Northeast)       
Midwest 0.368 0.229 1.6 0.109 -0.082 0.818 
South 0.099 0.224 0.44 0.658 -0.339 0.537 
West 0.149 0.254 0.59 0.557 -0.348 0.646 
Having anxiety -0.035 0.093 -0.38 0.707 -0.217 0.147 
Having psychosis 0.183 0.156 1.17 0.242 -0.123 0.488 
Having dementia 0.134 0.091 1.48 0.140 -0.044 0.313 
CCI 0.115 0.017 6.66 <0.001 0.081 0.148 
Having regimen modification 0.104 0.125 0.83 0.406 -0.141 0.349 
Pre-index PD-related cost 1.5E-05 4.0E-06 3.77 <0.001 7.2E-06 2.3E-05 
Intercept 8.831 0.584 15.13 <0.001 7.687 9.975 
Note: Log likelihood   = -9483.912; GzLM=generalized linear model; AD=antidepressant; SE=standard error; CI=confidence 
interval; CCI=Charlson comorbidity index   
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Appendix 23 Two-part model for PD-related outpatient office (OP-office) cost 
Variable Coefficient SE z p-value 95% CI 
Logit       
Being adherent to AD -0.147 0.182 -0.81 0.420 -0.503 0.210 
Age -0.011 0.016 -0.68 0.495 -0.044 0.021 
Female (Ref=Male) -0.105 0.179 -0.59 0.558 -0.456 0.246 
Region (Ref=Northeast)       
Midwest -1.331 0.653 -2.04 0.042 -2.611 -0.050 
South -0.858 0.647 -1.33 0.185 -2.127 0.411 
West -1.026 0.704 -1.46 0.145 -2.405 0.354 
Having anxiety 0.142 0.216 0.66 0.511 -0.281 0.566 
Having psychosis -0.238 0.313 -0.76 0.447 -0.851 0.375 
Having dementia -0.743 0.192 -3.87 <0.001 -1.119 -0.367 
CCI -0.132 0.033 -3.98 <0.001 -0.197 -0.067 
Having regimen modification 0.337 0.301 1.12 0.263 -0.253 0.926 
Pre-index PD-related cost -2.7E-06 7.3E-06 -0.37 0.712 -1.7E-05 1.2E-05 
Intercept 3.858 1.424 2.71 0.007 1.067 6.648 
GzLM       
Being adherent to AD 0.028 0.093 0.3 0.767 -0.155 0.210 
Age -0.008 0.008 -0.9 0.368 -0.024 0.009 
Female (Ref=Male) 0.131 0.090 1.45 0.148 -0.046 0.308 
Region (Ref=Northeast)       
Midwest -1.474 0.264 -5.59 <0.001 -1.991 -0.957 
South -1.519 0.256 -5.94 <0.001 -2.021 -1.018 
West -1.470 0.286 -5.14 <0.001 -2.030 -0.910 
Having anxiety -0.035 0.105 -0.33 0.742 -0.241 0.171 
Having psychosis -0.071 0.202 -0.35 0.725 -0.466 0.325 
Having dementia -0.256 0.107 -2.39 0.017 -0.467 -0.046 
CCI -3.3E-04 0.021 -0.02 0.987 -0.041 0.040 
Having regimen modification -0.063 0.139 -0.45 0.652 -0.336 0.210 
Pre-index PD-related cost 2.6E-05 4.6E-06 5.72 <0.001 1.7E-05 3.5E-05 
Intercept 8.162 0.695 11.75 <0.001 6.800 9.524 
Note: Log pseudolikelihood = -5345.004; PD=Parkinson’s disease; AD=antidepressant; SE=standard error; CI=confidence 
interval; CCI=Charlson comorbidity index; GzLM=generalized linear model  
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Appendix 24 Two-part model for PD-related outpatient home (OP-home) cost 
Variable Coefficient SE z p-value 95% CI 
Logit       
Being adherent to AD -0.158 0.166 -0.95 0.343 -0.484 0.168 
Age 0.038 0.015 2.56 0.010 0.009 0.068 
Female (Ref=Male) 0.090 0.160 0.56 0.575 -0.224 0.405 
Region (Ref=Northeast)       
Midwest 0.155 0.480 0.32 0.747 -0.787 1.096 
South 0.175 0.469 0.37 0.710 -0.745 1.094 
West -0.255 0.543 -0.47 0.638 -1.319 0.809 
Having anxiety -0.160 0.193 -0.83 0.408 -0.538 0.218 
Having psychosis -0.441 0.347 -1.27 0.204 -1.121 0.240 
Having dementia -0.103 0.189 -0.55 0.583 -0.473 0.266 
CCI -0.004 0.033 -0.11 0.915 -0.068 0.061 
Having regimen modification 0.064 0.256 0.25 0.802 -0.438 0.566 
Pre-index PD-related cost 3.9E-05 7.2E-06 5.45 <0.001 2.5E-05 5.3E-05 
Intercept -4.125 1.243 -3.32 0.001 -6.561 -1.689 
GzLM       
Being adherent to AD 0.151 0.195 0.78 0.438 -0.230 0.532 
Age 0.021 0.018 1.16 0.245 -0.014 0.055 
Female (Ref=Male) 0.098 0.185 0.53 0.596 -0.265 0.462 
Region (Ref=Northeast)       
Midwest 0.965 0.549 1.76 0.079 -0.112 2.042 
South 0.730 0.530 1.38 0.168 -0.308 1.768 
West 1.031 0.619 1.67 0.095 -0.181 2.244 
Having anxiety 0.116 0.236 0.49 0.621 -0.345 0.578 
Having psychosis -0.059 0.379 -0.16 0.875 -0.802 0.683 
Having dementia -0.012 0.219 -0.06 0.955 -0.441 0.416 
CCI 0.054 0.044 1.25 0.212 -0.031 0.140 
Having regimen modification 0.266 0.279 0.95 0.340 -0.281 0.814 
Pre-index PD-related cost 1.8E-05 7.6E-06 2.33 0.020 2.8E-06 3.3E-05 
Intercept 5.985 1.478 4.05 <0.001 3.089 8.881 
Note: Log pseudolikelihood = -2760.934; PD=Parkinson’s disease; AD=antidepressant; SE=standard error; CI=confidence 
interval; CCI=Charlson comorbidity index; GzLM=generalized linear model   
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Appendix 25 Two-part model for PD-related outpatient other (OP-other) cost 
Variable Coefficient SE z p-value 95% CI 
Logit       
Being adherent to AD 0.081 0.152 0.53 0.593 -0.217 0.380 
Age -0.030 0.014 -2.18 0.029 -0.056 -0.003 
Female (Ref=Male) -0.281 0.148 -1.89 0.058 -0.571 0.010 
Region (Ref=Northeast)       
Midwest 0.330 0.435 0.76 0.448 -0.522 1.182 
South -0.093 0.426 -0.22 0.826 -0.929 0.742 
West 0.362 0.479 0.76 0.450 -0.577 1.300 
Having anxiety 0.142 0.173 0.82 0.413 -0.198 0.482 
Having psychosis 0.316 0.296 1.07 0.286 -0.265 0.897 
Having dementia -0.347 0.178 -1.95 0.051 -0.696 0.002 
CCI -0.070 0.031 -2.22 0.027 -0.131 -0.008 
Having regimen modification -0.139 0.239 -0.58 0.561 -0.607 0.329 
Pre-index PD-related cost 1.2E-05 6.5E-06 1.86 0.063 -6.5E-07 2.5E-05 
Intercept 1.813 1.113 1.63 0.103 -0.369 3.994 
GzLM       
Being adherent to AD -0.387 0.229 -1.69 0.091 -0.837 0.062 
Age -0.055 0.020 -2.81 0.005 -0.094 -0.017 
Female (Ref=Male) -0.301 0.209 -1.44 0.151 -0.711 0.110 
Region (Ref=Northeast)       
Midwest -0.673 0.748 -0.9 0.368 -2.139 0.793 
South -1.653 0.744 -2.22 0.026 -3.112 -0.194 
West -1.129 0.775 -1.46 0.145 -2.649 0.390 
Having anxiety -0.218 0.250 -0.87 0.383 -0.708 0.272 
Having psychosis -0.056 0.455 -0.12 0.901 -0.949 0.836 
Having dementia -0.594 0.292 -2.03 0.042 -1.167 -0.021 
CCI 0.050 0.040 1.25 0.212 -0.028 0.128 
Having regimen modification 0.727 0.378 1.92 0.054 -0.013 1.467 
Pre-index PD-related cost -9.4E-07 8.7E-06 -0.11 0.914 -1.8E-05 1.6E-05 
Intercept 12.544 1.538 8.16 <0.001 9.530 15.558 
Note: Log pseudolikelihood = -2978.204; PD=Parkinson’s disease; AD=antidepressant; SE=standard error; CI=confidence 
interval; CCI=Charlson comorbidity index; GzLM=generalized linear model   
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Appendix 26 Two-part model for PD-related nursing facility cost 
Variable Coefficient SE z p-value 95% CI 
Logit       
Being adherent to AD -0.041 0.198 -0.21 0.837 -0.428 0.347 
Age 0.077 0.019 4.15 <0.001 0.041 0.113 
Female (Ref=Male) -0.138 0.195 -0.71 0.478 -0.519 0.243 
Region (Ref=Northeast)       
Midwest 0.620 0.522 1.19 0.235 -0.404 1.644 
South -0.249 0.518 -0.48 0.630 -1.264 0.765 
West -0.437 0.621 -0.7 0.482 -1.654 0.780 
Having anxiety 0.098 0.229 0.43 0.669 -0.351 0.548 
Having psychosis 0.441 0.319 1.38 0.167 -0.184 1.065 
Having dementia 0.771 0.203 3.79 <0.001 0.372 1.169 
CCI 0.036 0.037 0.98 0.328 -0.036 0.108 
Having regimen modification 0.688 0.272 2.53 0.012 0.154 1.221 
Pre-index PD-related cost 2.9E-05 7.3E-06 4 <0.001 1.5E-05 4.4E-05 
Intercept -8.003 1.532 -5.23 <0.001 -11.005 -5.001 
GzLM       
Being adherent to AD -0.429 0.248 -1.73 0.083 -0.914 0.057 
Age -0.022 0.024 -0.92 0.359 -0.069 0.025 
Female (Ref=Male) 0.117 0.249 0.47 0.637 -0.370 0.605 
Region (Ref=Northeast)       
Midwest 0.165 0.623 0.26 0.792 -1.056 1.385 
South -0.015 0.617 -0.02 0.981 -1.224 1.194 
West -0.059 0.766 -0.08 0.938 -1.561 1.443 
Having anxiety -0.191 0.287 -0.67 0.504 -0.754 0.371 
Having psychosis -0.555 0.393 -1.41 0.158 -1.326 0.216 
Having dementia -0.148 0.250 -0.59 0.555 -0.639 0.343 
CCI -0.024 0.042 -0.56 0.573 -0.106 0.059 
Having regimen modification -0.004 0.324 -0.01 0.990 -0.640 0.631 
Pre-index PD-related cost 1.3E-05 7.9E-06 1.64 0.101 -2.5E-06 2.9E-05 
Intercept 10.766 1.930 5.58 <0.001 6.983 14.550 
Note: Log pseudolikelihood = -1901.472; PD=Parkinson’s disease; AD=antidepressant; SE=standard error; CI=confidence 
interval; CCI=Charlson comorbidity index; GzLM=generalized linear model   
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Appendix 27 Two-part model for PD-related inpatient cost 
Variable Coefficient SE z p-value 95% CI 
Logit       
Being adherent to AD -0.374 0.162 -2.3 0.021 -0.692 -0.055 
Age 0.014 0.014 1.01 0.312 -0.014 0.042 
Female (Ref=Male) -0.029 0.155 -0.19 0.852 -0.332 0.275 
Region (Ref=Northeast)       
Midwest 0.768 0.500 1.54 0.125 -0.212 1.749 
South 0.405 0.492 0.82 0.411 -0.560 1.370 
West 0.562 0.545 1.03 0.303 -0.507 1.630 
Having anxiety 0.045 0.183 0.25 0.806 -0.313 0.403 
Having psychosis 0.010 0.311 0.03 0.975 -0.600 0.619 
Having dementia -0.104 0.182 -0.57 0.566 -0.461 0.252 
CCI 0.051 0.031 1.67 0.096 -0.009 0.111 
Having regimen modification -0.114 0.256 -0.44 0.657 -0.615 0.388 
Pre-index PD-related cost 3.3E-05 7.1E-06 4.65 <0.001 1.9E-05 4.7E-05 
Intercept -2.532 1.196 -2.12 0.034 -4.877 -0.187 
GzLM       
Being adherent to AD -0.148 0.208 -0.71 0.477 -0.556 0.260 
Age 1.4E-04 0.018 0.01 0.994 -0.036 0.036 
Female (Ref=Male) 0.002 0.202 0.01 0.993 -0.395 0.398 
Region (Ref=Northeast)       
Midwest 0.363 0.647 0.56 0.575 -0.906 1.632 
South -0.023 0.631 -0.04 0.971 -1.260 1.214 
West 0.312 0.698 0.45 0.655 -1.056 1.680 
Having anxiety -0.095 0.233 -0.41 0.685 -0.551 0.362 
Having psychosis -0.553 0.366 -1.51 0.131 -1.271 0.164 
Having dementia -0.045 0.233 -0.19 0.846 -0.502 0.411 
CCI 0.027 0.038 0.7 0.485 -0.049 0.102 
Having regimen modification 0.065 0.327 0.2 0.844 -0.577 0.706 
Pre-index PD-related cost 2.1E-07 7.0E-06 0.03 0.976 -1.4E-05 1.4E-05 
Intercept 9.136 1.609 5.68 <0.001 5.982 12.290 
Note: Log pseudolikelihood = -3175.4793; PD=Parkinson’s disease; AD=antidepressant; SE=standard error; CI=confidence 
interval; CCI=Charlson comorbidity index; GzLM=generalized linear model   
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Appendix 28 Two-part model for PD-related ER cost 
Variable Coefficient SE z p-value 95% CI 
Logit       
Being adherent to AD 0.061 0.181 0.34 0.736 -0.293 0.415 
Age 0.032 0.016 1.95 0.051 0.000 0.064 
Female (Ref=Male) 0.022 0.176 0.13 0.899 -0.323 0.368 
Region (Ref=Northeast)       
Midwest -0.019 0.471 -0.04 0.967 -0.942 0.904 
South -0.520 0.464 -1.12 0.262 -1.429 0.389 
West 0.032 0.524 0.06 0.951 -0.994 1.058 
Having anxiety -0.092 0.212 -0.43 0.666 -0.508 0.324 
Having psychosis 0.160 0.335 0.48 0.633 -0.497 0.818 
Having dementia -0.219 0.208 -1.05 0.293 -0.628 0.189 
CCI -0.025 0.037 -0.7 0.487 -0.097 0.046 
Having regimen modification 0.593 0.253 2.34 0.019 0.097 1.089 
Pre-index PD-related cost 2.1E-05 6.8E-06 3.1 0.002 7.7E-06 3.4E-05 
Intercept -3.609 1.336 -2.7 0.007 -6.228 -0.990 
GzLM       
Being adherent to AD -0.221 0.142 -1.56 0.120 -0.499 0.057 
Age 0.004 0.012 0.35 0.727 -0.020 0.028 
Female (Ref=Male) -0.018 0.138 -0.13 0.895 -0.289 0.253 
Region (Ref=Northeast)       
Midwest 0.813 0.363 2.24 0.025 0.102 1.524 
South 0.786 0.358 2.19 0.028 0.084 1.488 
West 0.759 0.403 1.88 0.060 -0.031 1.549 
Having anxiety -0.182 0.181 -1.01 0.314 -0.537 0.172 
Having psychosis 0.036 0.251 0.14 0.886 -0.456 0.529 
Having dementia -0.402 0.170 -2.37 0.018 -0.736 -0.069 
CCI 0.016 0.033 0.5 0.614 -0.047 0.080 
Having regimen modification 0.006 0.188 0.03 0.973 -0.363 0.375 
Pre-index PD-related cost -1.8E-06 6.4E-06 -0.28 0.777 -1.4E-05 1.1E-05 
Intercept 5.961 0.987 6.04 <0.001 4.027 7.895 
Note: Log pseudolikelihood = -1776.685; PD=Parkinson’s disease; ER=emergency room; AD=antidepressant; SE=standard 
error; CI=confidence interval; CCI=Charlson comorbidity index; GzLM=generalized linear model 
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Appendix 29 Two-part model for PD-related pharmacy cost 
Variable Coefficient SE z p-value 95% CI 
Logit       
Being adherent to AD 0.398 0.197 2.02 0.044 0.011 0.785 
Age 0.019 0.017 1.09 0.274 -0.015 0.052 
Female (Ref=Male) 0.028 0.187 0.15 0.879 -0.337 0.394 
Region (Ref=Northeast)       
Midwest 0.036 0.536 0.07 0.947 -1.015 1.087 
South -0.042 0.522 -0.08 0.935 -1.066 0.981 
West 0.130 0.602 0.22 0.830 -1.051 1.310 
Having anxiety 0.016 0.220 0.07 0.941 -0.415 0.447 
Having psychosis -0.510 0.330 -1.55 0.121 -1.156 0.135 
Having dementia -0.567 0.206 -2.75 0.006 -0.971 -0.163 
CCI -0.088 0.035 -2.53 0.011 -0.157 -0.020 
Having regimen modification 0.584 0.356 1.64 0.101 -0.113 1.281 
Pre-index PD-related cost 8.9E-06 9.0E-06 0.99 0.323 -8.8E-06 2.7E-05 
Intercept 0.311 1.400 0.22 0.824 -2.433 3.054 
GzLM       
Being adherent to AD 0.345 0.101 3.41 0.001 0.147 0.544 
Age -0.034 0.009 -3.75 <0.001 -0.052 -0.016 
Female (Ref=Male) -0.034 0.099 -0.34 0.732 -0.229 0.161 
Region (Ref=Northeast)       
Midwest -0.117 0.297 -0.39 0.693 -0.700 0.465 
South -0.047 0.291 -0.16 0.870 -0.617 0.522 
West -0.102 0.325 -0.31 0.755 -0.739 0.536 
Having anxiety -0.085 0.120 -0.71 0.480 -0.320 0.150 
Having psychosis -0.199 0.215 -0.93 0.353 -0.620 0.221 
Having dementia -0.189 0.120 -1.57 0.116 -0.425 0.047 
CCI -0.097 0.021 -4.59 <0.001 -0.138 -0.056 
Having regimen modification 0.121 0.153 0.79 0.430 -0.179 0.421 
Pre-index PD-related cost 3.0E-05 5.6E-06 5.29 <0.001 1.9E-05 4.1E-05 
Intercept 9.562 0.733 13.05 <0.001 8.126 10.998 
Note: Log pseudolikelihood = -5969.268; PD=Parkinson’s disease; AD=antidepressant; SE=standard error; CI=confidence 
interval; CCI=Charlson comorbidity index; GzLM=generalized linear model 
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Appendix 30 Two-part model for PD-related total cost 
Variable Coefficient SE z p-value 95% CI 
Logit       
Being adherent to AD 0.464 0.403 1.15 0.249 -0.325 1.253 
Age -0.002 0.035 -0.06 0.951 -0.072 0.067 
Female -0.441 0.384 -1.15 0.250 -1.193 0.311 
Region       
Midwest 0.404 0.836 0.48 0.629 -1.235 2.043 
South 0.489 0.812 0.6 0.547 -1.103 2.081 
West 0.854 1.062 0.8 0.421 -1.227 2.934 
Having anxiety -0.073 0.436 -0.17 0.867 -0.927 0.781 
Having psychosis -0.721 0.533 -1.35 0.176 -1.765 0.323 
Having dementia -1.082 0.402 -2.69 0.007 -1.871 -0.294 
CCI -0.090 0.062 -1.45 0.147 -0.212 0.032 
Having regimen modification 1.335 1.034 1.29 0.196 -0.691 3.361 
Pre-index PD-related cost 2.8E-06 1.7E-05 0.17 0.866 -3.0E-05 3.6E-05 
Intercept 3.700 2.835 1.31 0.192 -1.856 9.255 
GzLM       
Being adherent to AD -0.171 0.122 -1.41 0.160 -0.409 0.067 
Age 0.016 0.011 1.44 0.149 -0.006 0.037 
Female -0.026 0.118 -0.22 0.826 -0.258 0.206 
Region       
Midwest 0.272 0.353 0.77 0.440 -0.419 0.964 
South -0.285 0.343 -0.83 0.406 -0.957 0.387 
West -0.111 0.388 -0.29 0.775 -0.872 0.650 
Having anxiety -0.115 0.141 -0.82 0.414 -0.392 0.162 
Having psychosis -0.313 0.243 -1.29 0.198 -0.790 0.164 
Having dementia -0.067 0.140 -0.48 0.632 -0.342 0.208 
CCI 0.026 0.025 1.02 0.308 -0.024 0.075 
Having regimen modification 0.195 0.185 1.05 0.292 -0.168 0.558 
Pre-index PD-related cost 3.8E-05 7.0E-06 5.38 <0.001 2.4E-05 5.1E-05 
Intercept 7.784 0.899 8.65 <0.001 6.021 9.547 
Note: Log pseudolikelihood = -8356.364; PD=Parkinson’s disease; AD=antidepressant; SE=standard error; CI=confidence 
interval; CCI=Charlson comorbidity index; GzLM=generalized linear model   
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